Abstract
Background
The mainstay treatment for hypoxaemia is oxygen therapy, which is given to the vast majority of adults admitted to the intensive care unit (ICU). The practice of oxygen administration has been liberal, which may result in hyperoxaemia. Some studies have indicated an association between hyperoxaemia and mortality, whilst other studies have not. The ideal target for supplemental oxygen for adults admitted to the ICU is uncertain. Despite a lack of robust evidence of effectiveness, oxygen administration is widely recommended in international clinical practice guidelines. The potential benefit of supplemental oxygen must be weighed against the potentially harmful effects of hyperoxaemia.
Objectives
To assess the benefits and harms of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the ICU.
Search methods
We identified trials through electronic searches of CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, BIOSIS Previews, CINAHL, and LILACS. We searched for ongoing or unpublished trials in clinical trials registers. We also scanned the reference lists of included studies. We ran the searches in December 2018.
Selection criteria
We included randomized controlled trials (RCTs) that compared higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the ICU. We included trials irrespective of publication type, publication status, and language.
We included trials with a difference between the intervention and control groups of a minimum 1 kPa in partial pressure of arterial oxygen (PaO2), minimum 10% in fraction of inspired oxygen (FiO2), or minimum 2% in arterial oxygen saturation of haemoglobin/non‐invasive peripheral oxygen saturation (SaO2/SpO2).
We excluded trials randomizing participants to hypoxaemia (FiO2 below 0.21, SaO2/SpO2 below 80%, and PaO2 below 6 kPa) and to hyperbaric oxygen.
Data collection and analysis
Three review authors independently, and in pairs, screened the references retrieved in the literature searches and extracted data. Our primary outcomes were all‐cause mortality, the proportion of participants with one or more serious adverse events, and quality of life. None of the trials reported the proportion of participants with one or more serious adverse events according to the International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) criteria. Nonetheless, most trials reported several serious adverse events. We therefore included an analysis of the effect of higher versus lower fraction of inspired oxygen, or targets using the highest reported proportion of participants with a serious adverse event in each trial. Our secondary outcomes were lung injury, acute myocardial infarction, stroke, and sepsis.
None of the trials reported on lung injury as a composite outcome, however some trials reported on acute respiratory distress syndrome (ARDS) and pneumonia. We included an analysis of the effect of higher versus lower fraction of inspired oxygen or targets using the highest reported proportion of participants with ARDS or pneumonia in each trial. To assess the risk of systematic errors, we evaluated the risk of bias of the included trials. We used GRADE to assess the overall certainty of the evidence.
Main results
We included 10 RCTs (1458 participants), seven of which reported relevant outcomes for this review (1285 participants). All included trials had an overall high risk of bias, whilst two trials had a low risk of bias for all domains except blinding of participants and personnel.
Meta‐analysis indicated harm from higher fraction of inspired oxygen or targets as compared with lower fraction or targets of arterial oxygenation regarding mortality at the time point closest to three months (risk ratio (RR) 1.18, 95% confidence interval (CI) 1.01 to 1.37; I2 = 0%; 4 trials; 1135 participants; very low‐certainty evidence). Meta‐analysis indicated harm from higher fraction of inspired oxygen or targets as compared with lower fraction or targets of arterial oxygenation regarding serious adverse events at the time point closest to three months (estimated highest proportion of specific serious adverse events in each trial RR 1.13, 95% CI 1.04 to 1.23; I2 = 0%; 1234 participants; 6 trials; very low‐certainty evidence). These findings should be interpreted with caution given that they are based on very low‐certainty evidence.
None of the included trials reported any data on quality of life at any time point.
Meta‐analysis indicated no evidence of a difference between higher fraction of inspired oxygen or targets as compared with lower fraction or targets of arterial oxygenation on lung injury at the time point closest to three months (estimated highest reported proportion of lung injury RR 1.03, 95% CI 0.78 to 1.36; I2 = 0%; 1167 participants; 5 trials; very low‐certainty evidence).
None of the included trials reported any data on acute myocardial infarction or stroke, and only one trial reported data on the effects on sepsis.
Authors' conclusions
We are very uncertain about the effects of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the ICU on all‐cause mortality, serious adverse events, and lung injuries at the time point closest to three months due to very low‐certainty evidence. Our results indicate that oxygen supplementation with higher versus lower fractions or oxygenation targets may increase mortality. None of the trials reported the proportion of participants with one or more serious adverse events according to the ICH‐GCP criteria, however we found that the trials reported an increase in the number of serious adverse events with higher fractions or oxygenation targets. The effects on quality of life, acute myocardial infarction, stroke, and sepsis are unknown due to insufficient data.
Plain language summary
Supplemental oxygen for adults admitted to the intensive care unit
Review question
We set out to assess whether more supplemental oxygen is better than less supplemental oxygen for adults admitted to the intensive care unit (ICU).
Background
Adults admitted to the ICU are critically ill and are at high risk of dying. Oxygen supplementation, or therapy, is given to most adults admitted to ICU, and many are mechanically ventilated. Severe illness can result in a lack of oxygen in the blood, known as hypoxaemia, which puts patients at risk of low tissue levels of oxygen (hypoxia) and organ failure. The use of sedatives and strong pain relief medications can also depress breathing and therefore oxygen levels.
The practice of supplemental oxygen administration has been liberal, possibly resulting in too much oxygen, known as hyperoxia. Despite a lack of robust evidence of effectiveness, supplemental oxygen administration has been widely recommended in international clinical practice guidelines. However, a new guideline recommends against high oxygen levels as some, but not all, clinical studies have indicated a link between hyperoxaemia and an increased risk of dying. The potential benefit of supplemental oxygen must be weighed against the potentially harmful effects of hyperoxaemia.
Study characteristics
We identified 10 randomized controlled trials (studies where participants are randomly allocated to either an experimental or a control group) involving 1458 participants up to December 2018. Seven of the trials (1285 participants) provided findings on the number of deaths, serious adverse events, and lung injuries in the three months following oxygen therapy in the ICU. Lung injury was measured according to participants developing acute respiratory distress syndrome or pneumonia. Five trials included adults admitted to an ICU caring for patients with a range of serious health conditions and one to a surgical ICU. Two trials involved adults with traumatic brain injury; one trial adults after cardiac arrest and resuscitation; and one trial adults with stroke. All participants in six trials received invasive mechanical ventilation directly through a tube into the main airway. In one trial some of the participants were on mechanical ventilation, whilst others received non‐invasive oxygen administration. Three trials involved adults receiving non‐invasive oxygen. All trials compared more with less oxygen, however using very different levels of oxygen supplementation. Oxygen therapy was given for timeframes ranging from one hour to the length of hospital admission.
Key results
We are uncertain about the effects of higher levels of oxygen as our findings are based on very low‐certainty evidence. We found no evidence for a beneficial effect of higher compared with lower supplemental oxygen levels for adults admitted to ICU. Higher levels of oxygen may have increased the risk of death (4 trials; 1135 participants) and serious adverse events (6 trials; 1234 participants). There was no evidence of a difference in lung injuries with the use of higher supplemental oxygen compared with lower supplemental oxygen, but the evidence is very uncertain (5 trials; 1167 participants). None of the included trials reported on quality of life at any time point, acute myocardial infarction, and stroke. Only one trial reported on sepsis.
Certainty of the evidence
The numbers of participants enrolled in the trials were too small to permit a definitive judgement about the review findings. The trials varied in the types of illness of the participants, their associated clinical care, disease severity, the targets for how much oxygen was given, and for how long. Two of the trials had a low risk of bias other than for lack of blinding of participants and personnel. Overall all included trials had a high risk of bias.
Summary of findings
Summary of findings for the main comparison. Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the ICU.
Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the ICU | ||||||
Patient or population: adults admitted to the ICU Setting: trials were conducted in ICU departments in Europe (n = 5); Iran (n = 2); New Zealand (n = 1); Australia, New Zealand, France (n = 1); and Japan (n = 1) Intervention: higher fraction of inspired oxygen or targets of arterial oxygenation Comparison: lower fraction of inspired oxygen or targets of arterial oxygenation | ||||||
Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
Risk with lower FiO2 or targets of arterial oxygenation | Risk with higher FiO2 or targets of arterial oxygenation | |||||
All‐cause mortality follow‐up: range 1 month to 3 months | Study population | RR 1.18 (1.01 to 1.37) | 1135 (4 RCTs) | ⊕⊝⊝⊝ Very low1 | ‐ | |
331 per 1000 | 391 per 1000 (334 to 453) | |||||
Proportion of participants with 1 or more serious adverse events according to International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) follow‐up: range 3 to 90 days |
Study population | RR 1.13 (1.04 to 1.23) | 1234 (6 RCTs) | ⊕⊝⊝⊝ Very low2 | Reported results are derived by taking the highest proportion reported in each trial which addresses the lowest possible proportion of participants with 1 or more serious adverse events. The following outcomes and numbers of trials and participants have been included: mortality: 3 trials, 701 participants; pneumonia: 1 trial, 65 participants; proportion of participants with 1 or more serious adverse events: 1 trial, 434 participants; mechanical ventilation (reported as a poor outcome): 1 trial, 34 participants. Meta‐analysis from the analysis cumulating all reported serious adverse events which address the highest possible reported proportion of participants with 1 or more serious adverse events showed RR 1.08, 95% CI 0.99 to 1.18. |
|
430 per 1000 | 486 per 1000 (447 to 529) | |||||
Quality of life (any valid scale such as the 36‐item Short Form Health Survey (SF‐36)) | Study population | Not estimable | (0 studies) | ‐ | No studies reported this outcome. | |
‐ | ‐ | |||||
Lung injury diagnosed after randomization (composite outcome) follow‐up: range 4 to 23 days | Study population | RR 1.03 (0.78 to 1.36) | 1167 (5 RCTs) | ⊕⊝⊝⊝ Very low3 | Reported results are derived by taking the highest proportion reported in each trial which addresses the lowest possible proportion of participants with 1 or more lung injuries. The following outcomes and numbers of trials and participants have been included: ARDS: 2 trials, 223 participants; pneumonia: 3 trials, 944 participants. Meta‐analysis from the analysis cumulating all reported lung injuries which address the highest possible reported proportion of participants with 1 or more lung injuries showed RR 0.99, 95% CI 0.75 to 1.30. |
|
128 per 1000 | 132 per 1000 (100 to 174) | |||||
Acute myocardial infarction diagnosed after randomization | Study population | Not estimable | (0 studies) | ‐ | No studies reported this outcome. | |
‐ | ‐ | |||||
Stroke diagnosed after randomization | Study population | Not estimable | (0 studies) | ‐ | No studies reported this outcome. | |
‐ | ‐ | |||||
Severe sepsis diagnosed after randomization follow‐up: 3 days | Study population | RR 1.87 (0.93 to 3.87) | 445 (1 study) |
⊕⊝⊝⊝ Very low4 | Meta‐analysis was not conducted, as only 1 trial reported on sepsis. | |
50 per 1000 | 94 per 1000 (46 to 189) | |||||
*The risk in the intervention (higher) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The risk in the control (lower) group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ARDS: acute respiratory distress syndrome; CI: confidence interval; FiO2: fraction of inspired oxygen; ICU: intensive care unit; RCT: randomised controlled trial; RR: risk ratio | ||||||
GRADE Working Group grades of evidence High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. |
1Downgraded three levels: one level because of risk of bias, as only one trial was overall low risk of bias except for blinding of participants and personnel (performance bias); one level because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups between trials; and one level because the optimal information size (OIS) was not reached. Required information size (RIS) is 2623 participants. RIS = OIS when I2 = 0 and alpha is adjusted for multiple outcomes. 2Downgraded three levels: one level because of risk of bias, as only one trial was overall low risk of bias except for blinding of participants and personnel (performance bias); one level because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups between trials; and one level because the optimal information size (OIS) was not reached. Required information size (RIS) is 1577 participants. RIS = OIS when I2 = 0 and alpha is adjusted for multiple outcomes. 3Downgraded three levels: one level because of risk of bias, as only one trial was overall low risk of bias except for blinding of participants and personnel (performance bias); one level because of differences in inspiratory oxygen fraction and target of arterial oxygenation in the experimental and control groups between trials; and one level because the optimal information size (OIS) was not reached. Required information size (RIS) is 7656 participants. RIS = OIS when I2 = 0 and alpha is adjusted for multiple outcomes. 4Downgraded three levels: one level because of risk of bias; one level because we cannot reject inconsistency due to the inclusion of only one trial; and one level because the optimal information size was not reached.
Background
Description of the condition
Hypoxaemia refers to lack of oxygen in the blood and is usually defined in terms of partial pressure of arterial oxygen (PaO2) or arterial oxygen saturation of haemoglobin (SaO2) (O'Driscoll 2017). Additionally, the non‐invasive peripheral oxygen saturation (SpO2) measured by pulse oximetry is routinely used. Hypoxaemia refers directly to the levels of oxygen in the blood, whilst the term hypoxia is defined as the lack of oxygen at a cellular level, for example tissues, organs, alveoli, or the body as a whole (O'Driscoll 2017).
In healthy individuals, the normal range for PaO2 at sea level is 80 mmHg to 100 mmHg (Kratz 2004), with a general decrease with age (Crapo 1999). There is no clear definition of hypoxaemia; the most widely used definitions are a PaO2 below 60 mmHg or a SaO2 below 90% (O'Driscoll 2017). However, oxygenation targets below the normal range, and even defined as hypoxaemic, are recommended in adults who are mechanically ventilated with acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) targeting PaO2 of 55 mmHg to 80 mmHg or SpO2 of 88% to 95% (ARDS Network 2000; Brower 2004).
In adults admitted to the ICU, hypoxaemia is a common clinical manifestation of inadequate gas exchange in the lungs (Petersson 2014). The condition can arise primarily from four different mechanisms: hypoventilation, ventilation or perfusion (V/Q) mismatch, intrapulmonary right‐to‐left blood shunting, or diffusion impairment, or a combination of these (Petersson 2014; Roussos 2003). Hypoventilation in the ICU is typically caused by an acute depression of the central nervous system, either through administration of sedative or analgesic agents, or due to critical illness with indirect (e.g. circulatory, hypoxic, or hypercapnic failure) or direct (e.g. traumatic brain injury, intracranial haemorrhage, or meningoencephalitis) cerebral affection. Hypoxaemia due to hypoventilation is always accompanied by hypercapnia since hypoventilation affects the alveolar clearance of carbon dioxide to a larger degree than the alveolar oxygenation, and hypoventilation does not affect the alveolar‐arterial gradient (Petersson 2014; Roussos 2003). V/Q mismatch with a low V/Q ratio evolves when ventilation in certain lung regions is disproportionally decreased as compared to perfusion. This is seen in various conditions (Petersson 2014), including pneumonia, ARDS, pulmonary oedema, and chronic obstructive pulmonary disease (COPD) (Kent 2011). The impact of a low V/Q ratio is partially compensated by physiological hypoxic pulmonary vasoconstriction in the affected segments of the lung (Rodríguez‐Roisin 2005). V/Q mismatch with a high V/Q ratio evolves when perfusion in certain lung regions is disproportionally decreased as compared to ventilation, as is classically seen in pulmonary embolism (Petersson 2014), but is also prevalent in COPD, Wagner 1977, and ARDS (Donahoe 2011). Intrapulmonary shunting is the consequence of complete V/Q mismatch with abolished ventilation which allows the passing of blood through sections of the pulmonary vascular bed without being oxygenated. This is seen in all types of pulmonary atelectasis (including absorption atelectasis) and is especially prevalent in ARDS and pneumonia (Petersson 2014). V/Q mismatch and intrapulmonary shunting are the most common causes of hypoxaemia in the ICU (Petersson 2014). Diffusion impairment occurs when the diffusion pathway for oxygen from the alveolar space to the pulmonary capillaries is pathologically increased, either acutely as seen in pneumonia, pulmonary oedema, or ARDS, or chronically as seen in the large group of interstitial lung diseases (Petersson 2014).
Description of the intervention
Administration of supplemental oxygen, defined as the fraction of inspired oxygen (FiO2) above 0.21, is a frequent intervention in adults admitted to the ICU. Oxygen is often administered during acute conditions in the pre‐hospital setting and during hospital admission. Adults admitted to the ICU often receive mechanical ventilation, and oxygen support to correct or prevent hypoxaemia. Treatment is usually a combination of ventilatory and non‐ventilatory strategies (Esan 2010; Raoof 2010), where the aim is to reduce morbidity and mortality associated with hypoxaemia by restoring arterial oxygenation to normal values. Due to the administration of oxygen, adults often achieve supranormal levels of PaO2 (de Graaff 2011; de Jonge 2008; Eastwood 2012; Itagaki 2015; Kraft 2018; Suzuki 2013; Zhang 2016).
Oxygen strategies used to treat hypoxaemia in adults admitted to the ICU are associated with harm in some studies, possibly because adults who receive oxygen in the ICU are the most ill, but it may also be that 'too much' oxygen is as harmful as 'too little' (Kallet 2013). The harms associated with lung injury caused by mechanical ventilation as well as by oxygen toxicity following high FiO2 may exceed the benefit of normalizing oxygenation (PaO2 and SaO2).
How the intervention might work
The purpose of oxygen therapy is to increase oxygen delivery to tissues. Tissue hypoxia can cause cell death, but the precise level at which this occurs has not been determined, and the level may differ between tissues, organs, and individuals (O'Driscoll 2017).
Supplemental oxygen therapy has several potential advantages including maintenance of delivery of oxygen to tissues and prevention of organ dysfunction followed by anoxic injury (Budinger 2013). Several additional beneficial effects of supplemental oxygen have been proposed and include: induction of antioxidant enzymes, anti‐inflammatory proteins, anti‐inflammatory cytokines and certain growth factors; reduced postoperative infections, neutrophil activation, and markers of cerebral tissue breakdown; anti‐apoptotic effects in brain and myocardium; normalization of cerebral extracellular homeostasis; and stabilization of the blood‐brain barrier (Tan 2014).
High inspiratory oxygen concentrations have been associated with adverse outcomes in emergency medical conditions in patients with exacerbation of COPD (Austin 2010); after resuscitation after cardiac arrest (Kilgannon 2010); in patients with myocardial infarction (Cabello 2016); and in patients with traumatic brain injury (Brenner 2012). Additionally, treating perioperative adults with high FiO2 may be associated with increased mortality without reducing surgical site infections in surgical adults (Wetterslev 2015). These adverse outcomes may be caused by postoperative pulmonary complications due to atelectasis formation, Benoit 2002; Rothen 1995a; Rothen 1995b, or pulmonary formation of reactive oxygen species (Chow 2003; Helmerhorst 2015; Kallet 2013). However, they may also be related to decreased local blood flow on normal and non‐diseased vasculature induced by hyperoxaemic vasoconstriction (Sjöberg 2013), which has been described in the vascular system, for example in the heart and brain (Kenmure 1971; Watson 2000).
Knowledge about cell biology also suggests that oxygen might have harmful effects. Prolonged exposure to hyperoxia causes lung injury, which is thought to be caused by the production and accumulation of reactive oxygen species that overwhelm natural antioxidant defences and destroy cellular structures (Kallet 2013). Exposure to hyperoxia is associated with a boost in the production of reactive oxygen species, which eventually may overwhelm the cell repair processes, thereby causing cell injury (Crapo 1986). It has been proposed that reactive oxygen species may trigger apoptosis within pulmonary cells leading to necrosis, thereby causing an inflammation which damages lung tissue further (Zaher 2007).
Mechanical ventilation may in itself also be associated with complications including increased risk of pneumonia, impaired cardiac performance, and neuromuscular problems relating to sedation and muscle relaxants (Whitehead 2002). Also, applying pressure to the lungs can cause damage, which is known as ventilator‐induced lung injury. Ventilator‐associated lung injury has been shown to be augmented by hyperoxia in animal studies (Bailey 2003; Helmerhorst 2017b; Sinclair 2004).
Why it is important to do this review
The mainstay treatment for hypoxaemia is supplemental oxygen therapy, which is given to the vast majority of adults admitted to the ICU. It is estimated that 2 to 3 million adults yearly require mechanical ventilation in the ICU in high‐income countries (Adhikari 2010), and is associated with morbidity, Kahn 2010, and mortality (Metnitz 2009; Wunsch 2010).
The current practice of oxygen administration has usually been more liberal and may result in hyperoxaemia or high partial tension of oxygen in the lungs (de Graaff 2011; de Jonge 2008; Itagaki 2015; Kraft 2018; Panwar 2013; Rachmale 2012; Suzuki 2013; Zhang 2016). Some studies have indicated an association between hyperoxaemia and mortality (Dahl 2015; Helmerhorst 2017a; Kilgannon 2010; Meyhoff 2012; Zhang 2016), whilst other studies have not (Bellomo 2011; Eastwood 2012; Kraft 2018; Raj 2013; Young 2012). Two meta‐analyses of observational data found an association between hyperoxaemia and mortality after cardiac arrest, stroke, and traumatic brain injury (Damiani 2014), and overall across critically ill adults (Helmerhorst 2015). Permissive hypoxaemia has been studied by Gilbert‐Kawai and colleagues (Gilbert‐Kawai 2014), who compared permissive hypoxaemia to normoxaemia in critically ill adults in a systematic review but found no relevant randomized controlled trials (RCTs).
Although the possible adverse effects of hyperoxaemia are known, prevention of hypoxia through hyperoxaemia seems to be prioritized (Pannu 2016). The ideal target oxygenation for adults admitted to the ICU is uncertain due to limited evidence from RCTs. Despite a lack of robust evidence of effectiveness, oxygen administration is widely recommended in international clinical practice guidelines (AARC 2002; ARC 2014; Dellinger 2013; O'Driscoll 2017). However, it appears that a change towards a more restrictive approach is under way (Chu 2018; Siemieniuk 2018). Panwar and colleagues, Panwar 2015, and Girardis and colleagues, Girardis 2016, published data on RCTs comparing higher with lower oxygenation targets in adults admitted to the ICU, and Asfar and colleagues, Asfar 2017, published data on an RCT comparing high FiO2 with lower oxygenation targets throughout the first 24 hours of ICU admission in adults with septic shock. Additional RCTs comparing high versus low targeted oxygen therapy in the critically ill are ongoing and may soon be published (NCT02321072; NCT03174002).
Oxygen is a common intervention in adults admitted to ICU and might have beneficial effects as well as harmful effects (Hafner 2015). The potential benefit of supplemental oxygen must be weighed against the potentially harmful effects of hyperoxaemia (Jakobsen 2013).
Objectives
To assess the benefits and harms of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation in adults in intensive care units.
Methods
Criteria for considering studies for this review
Types of studies
We included RCTs, irrespective of publication status, reported outcomes, publication date, and language.
We included unpublished trials only if methodological descriptions and trial data were provided by direct contact with trial authors or in written form.
We excluded randomized cross‐over trials and quasi‐randomized trials.
Types of participants
We included any adult aged 18 years or older admitted to the ICU. We only included participants if they were admitted to the ICU when randomization was allocated.
Types of interventions
We included trials having a clear differentiation of participants randomized to either a high‐target (liberal) or a low‐target (conservative) oxygenation strategy. Both mechanically ventilated and non‐mechanically ventilated adults were eligible for inclusion. In order to include all relevant trials, we did not use predefined arbitrary thresholds of oxygenation for the two groups.
Intervention group: adults receiving a high‐target (liberal) oxygenation strategy administered by any device, the aim of which was exposure to hyperoxia in the lungs, either by high FiO2 or high‐target PaO2 or SaO2/SpO2.
Control group: adults receiving a low‐target (conservative) oxygenation strategy administered by any device, the aim of which was to minimize exposure to hyperoxia in the lungs and reduce exposure to high FiO2 or high‐target PaO2 or SaO2/SpO2.
Eligible trials were required to have a difference between the intervention and control groups of minimum 1 kPa in PaO2, minimum 10% in FiO2, or minimum 2% in SaO2/SpO2, either as aimed or achieved saturation or target. We only required one of these separation criteria to be fulfilled (PaO2, SaO2 or FiO2), either aimed or achieved, for the trial to be eligible for inclusion.
We excluded trials/groups randomized to hypoxaemia (FiO2 below 0.21, SaO2/SpO2 below 80%, and PaO2 below 6 kPa). We furthermore excluded interventions with hyperbaric oxygen.
Types of outcome measures
Primary outcomes
All‐cause mortality at the time point closest to three months.
Proportion of participants with one or more serious adverse events, defined as a dichotomous outcome according to participants having at least one serious adverse event or none at time point closest to three months. We defined a serious adverse event as any untoward medical occurrence that: resulted in death; was life‐threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability; or jeopardized the participant (ICH‐GCP 1997). We performed two analyses on the proportion of participants with one or more serious adverse events according to the International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) (ICH‐GCP 1997). We considered all other adverse events as non‐serious.
Quality of life (any valid scale such as the 36‐item Short Form Health Survey (SF‐36)) at the time point closest to three months.
Secondary outcomes
Lung injury diagnosed after randomization (composite outcome) at the time point closest to three months. This composite outcome was defined as either: ARDS (defined by the onset of a known clinical insult within one week or acute worsening of respiratory symptoms; chest imaging; origin of oedema; and oxygenation may be mild, moderate, or severe (ARDS Definition Task Force 2012), or as defined by trialists); pulmonary fibrosis (defined as evolved from any cause or as defined by trialists); or pneumonia (defined as pneumonia occurring 48 hours or more after admission in non‐intubated participants or pneumonia arising more than 48 to 72 hours after endotracheal intubation (ATS 2005), or as defined by trialists). As a secondary analysis, we analysed each component of the composite outcome separately. We performed two analyses on the proportion of participants with one or more lung injury.
Acute myocardial infarction diagnosed after randomization at the time point closest to three months (defined as the demonstration of myocardial cell death due to significant and sustained ischaemia (Thygesen 2012), or as defined by trialists).
Stroke diagnosed after randomization at the time point closest to three months (defined as central nervous system infarction, ischaemic stroke, silent central nervous system infarction, intracerebral haemorrhage, stroke caused by intracerebral haemorrhage, silent cerebral haemorrhage, subarachnoid haemorrhage, stroke caused by subarachnoid haemorrhage, stroke caused by cerebral venous thrombosis, and stroke not otherwise specified (Sacco 2013), or as defined by trialists).
Severe sepsis diagnosed after randomization at the time point closest to three months (defined as sepsis plus sepsis‐induced organ dysfunction or tissue hypoperfusion (Dellinger 2013), or as defined by trialists).
Search methods for identification of studies
Electronic searches
We identified eligible RCTs through literature searching with systematic and sensitive search strategies specifically designed to identify relevant RCTs without restrictions to language, publication year, and journal.
We searched the following databases:
Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 12, 2018) (Appendix 1);
MEDLINE (Ovid, 1946 to 20 December 2018) (Appendix 2);
Embase (Ovid, 1974 to 20 December 2018) (Appendix 3);
Science Citation Index (Web of Science, 1900 to 20 December 2018) (Appendix 4);
BIOSIS Previews (Web of Science, 1969 to 20 December 2018) (Appendix 5);
Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCO, 1981 to 20 December 2018) (Appendix 6);
Latin American and Caribbean Health Science Information database (LILACS) (1982 to 20 December 2018) (Appendix 7).
Searching other resources
We manually screened the reference lists of included trial reports, reviews, relevant papers, randomized and non‐randomized trials, and editorials for potentially relevant trials.
Furthermore, we searched for ongoing and unpublished trials using the following trial registers:
US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov) (searched 21 December 2018);
World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/en/) (searched 21 December 2018);
EU Clinical Trials Register (www.clinicaltrialsregister.eu/) (searched 21 December 2018);
Australian New Zealand Clinical Trials Registry (ANZCTR) (www.anzctr.org.au/) (searched 21 December 2018).
Data collection and analysis
We used the following methods for data collection and data analyses.
Selection of studies
Three review authors (MB, OLS or SRK), independently and in pairs, screened each title and abstract of all reports identified by the searches. We obtained the full texts of those reports deemed potentially relevant and assessed these for inclusion in the review. Any disagreements were resolved by consensus or by consulting another review author (JW) when necessary.
Data extraction and management
Three review authors (MB, OLS or SRK), independently and in pairs, extracted predefined data of the included trials using a data collection form that was specifically designed and piloted by the review team (Appendix 8). We collected the following data:
trial: country, duration of the trial, date of publication, and type of trial;
participants: numbers randomized, numbers analysed, numbers lost to follow‐up or withdrawn, type of population, mean or median age, sex, inclusion criteria, and exclusion criteria;
interventions: intervention, comparator, and concomitant interventions;
outcomes: predefined primary and secondary outcomes.
Any disagreements concerning the extracted data were resolved by discussion or by consulting a third review author (JW) when necessary. Where required, we contacted corresponding authors to clarify issues relating to data reporting or if further study details were needed.
Assessment of risk of bias in included studies
At least two review authors (MB, OLS or SRK) independently assessed the methodological quality of each included trial, as defined by the design of the trial and reporting. Any disagreements were resolved by discussion. We assessed the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a), employing the criteria described in Appendix 9.
We assessed the following risk of bias domains for all included trials: random sequence generation, allocation sequence concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, other potential sources of bias, and overall risk of bias. In addition, we assessed the domains blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective outcome reporting for each outcome, which permitted an assessment of the risk of bias for each result. Based on this assessment, we defined the included trials and each outcome result as low risk of bias if all bias domains were judged as at low risk of bias.
We provided a summary assessment of the risk of bias across trials and for each important outcome (across domains) by preparing a 'Summary of findings' table, 'Risk of bias' graph, and a 'Risk of bias' summary figure (Higgins 2011a).
Measures of treatment effect
We calculated the risk ratio (RR) with 95% confidence interval (Cl) and Trial Sequential Analysis (TSA) CI, adjusted for multiple outcomes, sparse data, and repetitive testing for dichotomous outcomes. For continuous outcomes, we planned to include both end scores and change scores in the analyses; we would use end scores if both were reported. We planned to calculate the mean difference (MD) and standardized mean difference (SMD) with 95% CIs and TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing for continuous outcomes.
Unit of analysis issues
Had we found a multi‐arm trial that compared, for example, three different oxygenation targets, we would have combined the two experimental intervention groups of the study (if they each fulfilled the minimum difference compared with the control group of 1 kPa in PaO2, 10% in FiO2, and 2% in SaO2/SpO2) into a single group and compared these to the control group. If only one of the experimental groups fulfilled the minimum difference to the control, we would have compared this group to the control group.
For multi‐arm trials that compare, for example, three different oxygenation targets, where the control group is the middle group, and the minimum difference in oxygenation target was fulfilled, we planned to compare the higher oxygenation group to the control group, as the lower group would be excluded due to being randomized to an extreme permissive hypoxaemia.
For cluster‐randomized trials, we planned to define the ICU as the unit of allocation, and we would use the generic inverse‐variance method in Review Manager 5 to calculate effect estimates for these trials (Review Manager 2014).
Dealing with missing data
We contacted trial investigators of the original reports for important missing data.
We did not impute missing data for any outcomes in the primary analysis, and we did not use intention‐to‐treat data if the original report did not contain such data.
If trial reports did not report standard deviations (SD), we would calculate the SDs using data from the trial report if possible.
We used imputed data in the sensitivity analysis for dichotomous and continuous outcomes (see Sensitivity analysis).
Assessment of heterogeneity
We assessed signs of heterogeneity by visual inspection of the forest plots.
We assessed the presence of statistical heterogeneity using the Chi2 test with significance set at P < 0.10, and by measuring the quantities of heterogeneity using the I2 statistic (Higgins 2003). Overall, we considered an I2 statistic of 0% to 40% as not important, 30% to 60% as moderate, 50% to 90% as substantial, and 75% to 100% as considerable heterogeneity (Higgins 2011a). High statistical heterogeneity is generally more prevalent when meta‐analysing continuous outcomes (Alba 2016). Because we anticipated large clinical heterogeneity as well as statistical heterogeneity, we generally preferred to use a random‐effects model. However, if one or two trials dominate the acquired evidence (e.g. with more than 80% of the randomized participants) (Higgins 2002; MAGIC 2002; Woods 2002), the random‐effects model may grossly overestimate the intervention effect; in such a situation, we would primarily report the results from a fixed‐effect model. Hence, we primarily reported the result from the model with the most conservative point estimate of the two (Jakobsen 2014a), being the estimate closest to zero effect. If the two estimates were approximately equal, we used the estimate with the widest CI.
We explored potential clinical heterogeneity by conducting the prespecified subgroup analyses (see Subgroup analysis and investigation of heterogeneity).
Assessment of reporting biases
We planned to visually assess funnel plots for signs of asymmetry if an analysis included 10 or more trials (Higgins 2011a; Jakobsen 2014a).
We planned to test asymmetry within dichotomous outcomes using the Harbord test (Harbord 2006), and for continuous outcomes using the asymmetry test (Egger 1997). We would also use adjusted rank correlation (Begg 1994).
Data synthesis
Meta‐analysis
We undertook the systematic review according to the recommendations provided in the Cochrane Handbook for Systematic Reviews of Interventions and the eight‐step assessment suggested by Jakobsen and colleagues (Higgins 2011a; Jakobsen 2014a), including TSA and calculation of Bayes factors. We performed meta‐analysis of outcomes with comparable effect measures where more than one trial was included. If clinical and statistical heterogeneity were large or unexpected, we planned to reconsider performing meta‐analysis. We used the statistical software Review Manager 5 provided by Cochrane and the TSA software version 0.9 CTU to meta‐analyse data (Review Manager 2014; TSA 2011).
Assessment of significance
We assessed our intervention effects with both random‐effects model meta‐analyses, Deeks 2010; DerSimonian 1986; Mantel 1959, and fixed‐effect model meta‐analyses, DeMets 1987; Mantel 1959, and reported the most conservative estimate, being the point estimate closest to no effect or the estimate with the widest CI.
We used three co‐primary outcomes and therefore considered P ≤ 0.025 as statistically significant analysing the primary outcomes (Jakobsen 2014a; Jakobsen 2016). We used four co‐secondary outcomes and therefore considered P ≤ 0.02 as statistically significant analysing the secondary outcomes (Jakobsen 2014a). We used the eight‐step procedure to assess if the thresholds for significance were crossed (Jakobsen 2014a).
Trial Sequential Analysis (TSA)
The chance of type I error (a false‐positive finding) is increased when multiple testing is done (e.g. when analysing multiple primary and secondary outcomes or repeated testing of the data). In small studies, notably for binary outcomes, type I error is likely because the effect estimates tend to be more unstable (Mascha 2015). In meta‐analyses the chance of finding a type I error is increased when they are updated over time when new trials are added (Mascha 2015). Cochrane recommends updating systematic reviews when, for example, new trials are available that will or might change the findings or credibility of the review, making it highly important to adjust for the multiplicity issue.
Current practice often uses a 0.05 significance criterion each time meta‐analyses are updated, thus increasing the overall chance of a type I error (Mascha 2015). In addition, type II error (the probability of missing true findings) is a problem in many meta‐analyses due to sparse data. Statistically significant meta‐analyses with few participants have low reliability, and the interventional effect is often overrated (Turner 2013). In a random sample of 50 meta‐analyses of anaesthesiology interventions with dichotomous outcome variables, Imberger and colleagues found 88% of the meta‐analyses to be underpowered, meaning that although significant at P < 0.05, the meta‐analyses should have included more participants (Imberger 2015). Furthermore, only 32% of the meta‐analyses preserved the risk of type I error at 5% or less when powered for detecting a relative risk of 20% between groups (Imberger 2015).
Consequently, cumulative meta‐analyses are at risk of producing random errors due to sparse data and multiple testing of accumulating data (Brok 2008; Brok 2009; Higgins 2011b; Imberger 2015; Mascha 2015; Pogue 1997; Terkawi 2016; Thorlund 2009; Wetterslev 2008), and TSA, Imberger 2016; TSA 2011, can be applied to assess this risk (Gluud 2011). The required information size and the required number of trials (i.e. the number of participants and trials needed in a meta‐analysis to detect or reject an a priori prespecified realistic intervention effect) can be calculated to minimize random errors (Kulinskaya 2014; Wetterslev 2009). The required information size takes into account the event proportion in the control group, the assumption of a plausible relative risk reduction (RRR), and the heterogeneity variance of the meta‐analysis (Turner 2013; Wetterslev 2009). Trial Sequential Analysis enables testing for significance to be conducted each time a new trial is included in the meta‐analysis. On the basis of the required information size and the required number of trials, trial sequential monitoring boundaries can be constructed. This enables determination of the statistical inference concerning cumulative meta‐analysis that has not yet reached the required information size (Imberger 2015; Mascha 2015; Terkawi 2016; Wetterslev 2008).
Firm evidence for benefit or harms may be established if the trial sequential monitoring boundary is crossed before reaching the required information size, in which case further trials may turn out to be superfluous. In contrast, if the boundary is not surpassed, the determination can be made that it is necessary to continue with further trials before a certain intervention effect can be detected or rejected. TSA can also assess firm evidence for lack of the postulated intervention effect, which occurs when the cumulative Z‐score crosses the trial sequential monitoring boundaries for futility.
We used relatively conservative estimations of the anticipated intervention effect estimates in order to reduce the risk of random error (Jakobsen 2014a). Large anticipated intervention effects lead to small required information sizes, and the thresholds for significance will be less strict after the information size has been reached (Jakobsen 2014a).
We analysed all primary and secondary outcomes with TSA. We estimated the diversity (meta‐analytic heterogeneity‐adjustment factor) and calculated the required information size (Wetterslev 2009), based on the proportion of participants with an outcome in the control group. In addition, we used a family‐wise error rate (FWER) of 5% (Jakobsen 2014a), leading to a statistical significance level of 2.5% for each of the co‐primary outcomes, a beta of 10%, and a diversity (D2), Wetterslev 2009, suggested by the trials in the meta‐analysis (Jakobsen 2014a). We have presented TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing (Gluud 2011). As a sensitivity analysis, we used a diversity of 20% if the actual measured heterogeneity was zero because in this case heterogeneity will most likely increase when further trials are added until the required information size is reached. As anticipated intervention effects for the primary and secondary outcomes in the TSA, we used realistic a priori RRR of 20% or a 20% relative risk increase (RRI). Furthermore, we used an RRR or an RRI based on the confidence limit closest to null effect in the 95% Cl in the traditional meta‐analysis.
Bayes factor
A low P value indicates that an observed result is unlikely given the null hypothesis is true (Jakobsen 2014b). In meta‐analyses, a low P value can be misleading if there is also a low probability that data are compatible with an anticipated intervention effect (e.g. RRR or RRI of 20%). Bayes factor may be used to consider whether the probability that the actual measured difference in the effect of the compared interventions results from an a priori anticipated ‘true’ difference (Jakobsen 2014a). We calculated Bayes factors for the co‐primary outcomes, which is the ratio between the probability of the meta‐analysis result given the null hypothesis (H0) is true divided by the probability of the meta‐analysis result given the alternative hypothesis (HA) is true using a Bayes factor calculator (Bayes factor calculator 2014). A high Bayes factor indicates that the meta‐analysis result is produced by an intervention effect that is lower than the anticipated intervention effect, and thus the meta‐analysis result should be interpreted with caution. A low Bayes factor together with a low P value corresponds to a high probability of an intervention effect similar to or greater than the anticipated intervention effect used in the calculation of the required information size. A Bayes factor less than 0.1 (a tenfold higher likelihood of compatibility with the alternative hypothesis than with the null hypothesis) has been suggested as the threshold for significance (Jakobsen 2014b).
Subgroup analysis and investigation of heterogeneity
We meta‐analysed all included trials regardless of oxygenation strategy (PaO2, SaO2, SpO2, FiO2). We believed a meta‐analysis of the specified strategies was feasible, as the amount of oxygen absorbed overlaps to a great extent. Whether FiO2 is raised, or the aim is a higher target PaO2, the result is that more oxygen is delivered, and the PaO2 will be elevated in both strategies. However, we recognize that, especially in adults with ARDS, there are individuals where it would be extremely difficult to reach a predefined target of PaO2 by either strategy, but both strategies would certainly expose the lungs to high oxygen levels, whilst other individuals may subsequently develop different PaO2 levels with the two strategies.
We sought to determine if the efficacy and safety of the treatment options were influenced by types of ICU populations and type of oxygen administration.
We performed the following subgroup analyses.
-
According to different types of oxygen interventions:
oxygen level defined by FiO2 (as defined and set by trialists);
oxygenation target measured using PaO2 (as defined by trialists);
oxygenation target measured using SaO2 or SpO2 (as defined by trialists);
oxygenation target measured using either PaO2 or SaO2 or SpO2 (as defined by trialists).
-
According to FiO2 or oxygenation/target in the higher‐oxygen‐administration group:
low targets defined as FiO2 of 0.5 or lower or PaO2 of 10 kPa or lower or SaO2/SpO2 of 95% or lower;
high targets defined as FiO2 above 0.5 or PaO2 above 10 kPa or SaO2/SpO2 above 95%.
-
According to FiO2 or oxygenation/target in the lower‐oxygen‐administration group:
low targets defined as FiO2 between or at 0.21 to 0.30 or PaO2 between or at 6 kPa to 8 kPa or SaO2/SpO2 between or at 85% to 90%;
high targets defined as FiO2 above 0.30 to 0.40 or PaO2 above 8 kPa to 10 kPa or SaO2/SpO2 above 90%.
-
According to ICU population:
medical;
surgical;
mixed;
adults with any respiratory failure;
adults with any cerebral disease;
adults with any heart disease;
adults with any trauma;
adults with COPD.
-
According to oxygen delivery system:
invasive mechanical ventilation with endotracheal tube;
any non‐invasive oxygen administration.
Sensitivity analysis
To assess the potential impact of bias, we planned to conduct a sensitivity analysis for each outcome excluding trials with overall ’high risk of bias’.
To assess the potential impact of the missing data for dichotomous outcomes, we performed the two following analyses:
'best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group survived, had no serious adverse event, and had no morbidity; and all participants with missing outcomes in the control group did not survive, had a serious adverse event, and had morbidity;
'worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group did not survive, had a serious adverse event, and had morbidity; and all participants with missing outcomes in the control group did survive, had no serious adverse event, and had no morbidity.
Results from both scenarios are presented in the review.
To assess the potential impact of the missing data for continuous outcomes, we planned to perform the two following analyses:
'best‐worst‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had mean (from participants with follow‐up) + 2 × SD, and all participants with missing outcomes in the control group had mean (from participants with follow‐up) − 2 × SD;
'worst‐best‐case' scenario: we assumed that all participants lost to follow‐up in the experimental group had mean (from participants with follow‐up) − 2 × SD, and all participants with missing outcomes in the control group had mean (from participants with follow‐up) + 2 × SD (Jakobsen 2014a).
To assess the potential impact of missing SDs for continuous outcomes, we planned to perform the following sensitivity analyses: where SDs were missing and it was not possible to calculate them, we planned to impute SDs from trials with similar populations and low risk of bias. If there were no such trials, we would impute SDs from trials with a similar population. As the final option, we planned to impute SDs from all trials.
To assess the potential impact of meta‐analysing trials comparing two low targets (FiO2 below 0.5 or PaO2 below 10 kPa or SaO2/SpO2 below 95%) or two high targets (FiO2 above 0.5 or PaO2 above 10 kPa or SaO2/SpO2 above 95%), we performed sensitivity analysis excluding trials comparing two low targets or two high targets.
To assess the impact of longer follow‐up, we performed analyses at maximum follow‐up.
'Summary of findings' tables and GRADE
We used the GRADE system to assess the certainty of the body of evidence associated with each of the primary outcomes (all‐cause mortality, proportion of participants with one or more serious adverse events, quality of life) and secondary outcomes (lung injury, acute myocardial infarction, stroke, sepsis) by constructing Table 1 (Guyatt 2008), employing GRADEpro GDT software (GRADEpro GDT). For each primary and secondary outcome, we planned first to present summaries of findings in RCTs with an overall low risk of bias, and second results in all trials.
The GRADE approach appraises the certainty of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The measure of a body of evidence considers within‐study risk of bias, directness of the evidence, heterogeneity of the data, precision of effect estimates (Jakobsen 2014a), and risk of publication bias. We did not expect to identify any trials using adequate blinding of participants and personnel due to the practice of administration of oxygen. Hence, we planned to base our primary conclusions on the results of the analyses of the primary outcomes with low risk of bias in all 'Risk of bias' domains except 'blinding of participants and personnel'.
Results
Description of studies
Results of the search
We screened 32,813 titles and abstracts, which included forward and backward citation searches, clinical trials registers, and grey literature. We obtained 303 full‐text reports to assess eligibility (Figure 1) and excluded 293 references (98 wrong population, 54 wrong intervention, 34 wrong study design, 24 wrong type of publication, 77 duplicate full text, 5 ongoing studies, and 1 study awaiting classification) from the meta‐analyses.
Ten RCTs including a total of 1458 participants fulfilled our inclusion criteria. We approached all 10 corresponding authors to request missing or unclear information and received a reply from six. Detailed descriptions are shown in the Characteristics of included studies table.
See Figure 1.
Included studies
We included 10 RCTs involving a total of 1458 participants randomly assigned to a higher versus lower fraction of inspired oxygen or targets of arterial oxygenation. Seven trials reported on outcomes for this review (Characteristics of included studies).
Trial characteristics
Seven trials reported on mortality (1285 participants) (Asfar 2017; Girardis 2016; Gomersall 2002; Jakkula 2018; Lång 2018; Mazdeh 2015; Panwar 2016).
The same seven trials reported on the proportion of participants with one or more serious adverse events or any serious adverse event (1285 participants).
Five trials reported on lung injury (1167 participants) (Asfar 2017; Girardis 2016; Jakkula 2018; Lång 2018; Panwar 2016), and one trial reported on sepsis (445 participants) (Girardis 2016). Three trials did not report on any of our outcomes (Ishii 2018; Taher 2016; Young 2017). Eight trials used a two‐arm, parallel‐group design, and two trials used a two‐factorial design. The trials were published from 2002 to 2018. Five trials were conducted in Europe; two in Iran; one in New Zealand; one in Australia, New Zealand, and France; and one in Japan.
Participants
The number of participants in the trials ranged from 36 to 480. The approximate weighted mean age of participants was 61 years, and the approximate mean proportion of men was 64%.
All trials included adults admitted to the ICU. Five trials included adults admitted to a multidisciplinary ICU (Asfar 2017; Girardis 2016; Gomersall 2002; Panwar 2016; Young 2017), and one to a surgical ICU (Ishii 2018). Two trials included adults with traumatic brain injury (Lång 2018; Taher 2016); one trial adults after cardiac arrest and resuscitation (Jakkula 2018); and one trial adults with stroke (Mazdeh 2015). Six trials included adults receiving invasive mechanical ventilation; three trials adults receiving any non‐invasive oxygen administration; and one trial both adults on invasive mechanical ventilation and adults receiving non‐invasive oxygen administration.
Funding
Seven trials were funded by public grants (Asfar 2017; Girardis 2016; Gomersall 2002; Lång 2018; Mazdeh 2015; Panwar 2016; Taher 2016; Young 2017); one trial did not report how it was funded (Ishii 2018); and one trial was funded by public and private funds and specified that funding bodies had no input regarding the design, management, or reporting of the trial (Jakkula 2018).
Experimental intervention
Of the 10 included trials, four trials randomized participants to higher versus lower oxygen using FiO2 (Ishii 2018; Lång 2018; Mazdeh 2015; Taher 2016); five trials randomized participants to an oxygenation target (Girardis 2016; Gomersall 2002; Jakkula 2018; Panwar 2016; Young 2017); and one trial randomized participants to a specific FiO2 in the experimental group and to target an oxygen saturation in the control group (Table 7) (Asfar 2017).
1. Interventions used in the higher and lower group.
Higher group | Lower group | |||||
FiO2 | PaO2 | SaO2/SpO2 | FiO2 | PaO2 | SaO2/SpO2 | |
Asfar 2017 | 1.00 | ‐ | ‐ | ‐ | ‐ | 88% to 95% |
Girardis 2016 | ≥ 0.40 | ≤ 20 kPa (150 mmHg) | 97% to 100% | ‐ | 9.3 to 13.3 kPa (70 to 100 mmHg) | 94% to 98% |
Gomersall 2002 | ‐ | > 9.0 kPa (67.5 mmHg) | ‐ | ‐ | > 6.6 kPa (50 mmHg) | ‐ |
Ishii 2018 | 1.00 | ‐ | ‐ | ‐ | 100 mmHg (13.3 kPa) | ‐ |
Jakkula 2018 | ‐ | 20 to 25 kPa (150 to 187.5 mmHg) | ‐ | ‐ | 10 to 15 kPa (75 to 112.5 mmHg) | 95% to 98% |
Lång 2018 | 0.70 | ‐ | ‐ | 0.40 | ‐ | ‐ |
Mazdeh 2015 | 0.50 | ‐ | ‐ | Supplemental oxygen not used | ||
Panwar 2016 | ‐ | ‐ | ≥ 96% | ‐ | ‐ | 88% to 92% |
Taher 2016 | 0.80 | ‐ | ‐ | 0.50 | ‐ | ‐ |
Young 2017 | No specific measures taken to avoid high FiO2 or SpO2, FiO2 < 0.30 discouraged. | ‐ | ‐ | 91% to 96% |
FiO2: fraction of inspired oxygen; PaO2: partial pressure of arterial oxygen; SaO2: arterial oxygen saturation of haemoglobin; SpO2: peripheral oxygen saturation
Of the five trials using FiO2 in the experimental group, two trials used a FiO2 of 1.0 (Asfar 2017; Ishii 2018); one used FiO2 of 0.80 (Taher 2016); one used FiO2 of 0.70 (Lång 2018); and one trial used FiO2 of 0.50 (Mazdeh 2015). Of the five trials aiming to reach a target in the experimental group, one trial targeted an SpO2 of 97% to 100% (Girardis 2016); one trial targeted an SpO2 of ≥ 96% (Panwar 2016); one trial targeted a PaO2 above 9.0 kPa (67.5 mmHg) (Gomersall 2002); one trial targeted 20 to 25 kPa (150 to 187.5 mmHg) (Jakkula 2018); and one trial randomized participants to standard care (no specific measures taken to avoid high FiO2 or SpO2; however, FiO2< 0.30 was discouraged) (Young 2017).
Two trials were categorized as using a low target in the experimental (higher) group (Gomersall 2002; Mazdeh 2015), and seven trials were categorized as using a high target in the experimental group (Asfar 2017; Girardis 2016; Ishii 2018; Jakkula 2018; Lång 2018; Panwar 2016; Taher 2016). One trial could not be categorized according to our definitions, as no specific target was used (Young 2017).
Comparator intervention
Three trials used FiO2 in the control group; one trial used expected FiO2 to achieve a PaO2 of 100 mmHg (13.3 kPa) (Ishii 2018); one trial used FiO2 of 0.40 (Lång 2018); and one trial used FiO2 of 0.50 (Table 7) (Taher 2016). Six trials used a target in the control group: one trial used SpO2 88% to 92% (Panwar 2016); one trial used SaO2 between 88% and 95% (Asfar 2017); one trial used SpO2 between 94% and 98% (Girardis 2016); one trial used PaO2 of > 6.6 kPa (50 mmHg) (Gomersall 2002); one trial used SpO2 between 95% and 98% (Jakkula 2018); and one trial used SaO2/SpO2 between 91% to 96% (Young 2017). One trial used no supplemental oxygen (Mazdeh 2015).
Six trials were categorized as using a low target in the control group (Asfar 2017; Gomersall 2002; Mazdeh 2015; Panwar 2016; Taher 2016; Young 2017), and four trials were categorized as using a high target in the control group (Girardis 2016; Ishii 2018; Jakkula 2018; Lång 2018).
Excluded studies
We excluded RCTs of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation that were conducted in populations not being admitted to an ICU. We listed the reasons for exclusion of 26 key excluded studies, which included RCTs of higher versus lower oxygen tensions for participants who were critically ill but not admitted to the ICU, as detailed in the Characteristics of excluded studies table.
Awaiting classification
One trial is awaiting classification (ICU‐ROX 2019). This study was ongoing at the time of the search and will be included in future updates of this review. See Characteristics of studies awaiting classification.
Ongoing studies
We identified five ongoing trials (NCT02321072; NCT02713451; NCT03141099; NCT03174002; NCT03287466), which we will include in future updates of this review. See Characteristics of ongoing studies.
Risk of bias in included studies
Two trials had low risk of bias in all domains, except for blinding of participants and personnel. The remaining eight trials had high or unclear risk of bias in one or more bias domains other than blinding of participants and personnel. See the 'Risk of bias' graph (Figure 2) and 'Risk of bias' summary (Figure 3).
Allocation
Generation of the allocation sequence
Six trials described generation of the allocation sequence adequately, using computer‐generated random numbers. Four trials did not describe the method of sequence generation and were considered to have an unclear risk of bias.
Allocation concealment
Seven trials described adequate allocation concealment, whilst three trials did not describe whether allocation concealment was adequate and were thus judged as having an unclear risk of bias.
Blinding
Blinding of participants and personnel
We judged no trials as having a low risk of bias for blinding of participants and personnel. Three trials blinded participants; five trials did not blind participants and personnel to the interventions; and two trials did not describe whether participants and personnel were blinded to the intervention and were thus judged as having an unclear risk of bias.
Blinding of outcome assessors
Four trials described adequate blinding of outcome assessors; three trials did not describe blinding of outcome assessors and were thus judged as at unclear risk of bias; and three trials used non‐blinded outcome assessors.
Incomplete outcome data
Five trials provided numbers and reasons for dropouts and withdrawals or reported no dropouts or withdrawals, whilst five trials were judged as at high risk of bias due either to a high number of dropouts or lost to follow‐up, dropouts and participants lost to follow‐up not specified by allocation group, or participants being excluded due to mortality or lost to follow‐up.
Selective reporting
Five trials were registered before randomization and reported on predefined outcomes; three trials provided insufficient information to determine if they had registered their trial or published a protocol before randomization; and two trials were judged as at high risk of bias due to being registered retrospectively.
Seven trials reported on all‐cause mortality; one trial reported on proportion of participants with one or more serious adverse events, and seven trials reported on individual serious adverse events; no trials reported on quality of life; no trials reported on proportion of participants with lung injury, but five trials reported on either ARDS or pneumonia; no trials reported on acute myocardial infarction or stroke; and one trial reported on sepsis.
Other potential sources of bias
We assessed three trials as at high risk of bias due to early stopping: one trial was stopped after a pre‐planned interim analysis for a reason that was not prespecified; one trial was stopped after an interim analysis that was not pre‐planned; and one trial was stopped early due to lack of funding and slow recruitment.
We judged one trial as at high risk of bias due to a difference in co‐interventions between groups, in which the participants in the low‐oxygen tension group also received doxapram if they developed an acidosis with pH < 7.2, whereas those in the high‐oxygen tension group received doxapram if they developed symptomatic acidosis.
We assessed two trials as at unclear risk of bias for this domain: one trial did not describe funding sources, and one trial was very poorly reported.
Overall risk of bias
We judged all included trials as at overall high risk of bias. Our assessment of risk of bias of the published trial reports is shown in Figure 2 and Figure 3 (Characteristics of included studies).
Effects of interventions
See: Table 1
See Table 1
Primary outcomes
All‐cause mortality
Time point closest to three months
Four of 10 trials with a total of 1135 participants and a mean follow‐up of 2 months (range 1 to 3 months) reported on all‐cause mortality (Asfar 2017; Girardis 2016; Jakkula 2018; Panwar 2016).
A total of 39.1% in the higher group versus 33.1% in the lower group died. Meta‐analysis showed evidence of a harmful effect of higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing mortality (random‐effects model risk ratio (RR) 1.18, 95% confidence interval (CI) 1.01 to 1.37; I2 = 0%; 1135 participants; 4 trials; Analysis 1.1; very low‐certainty evidence).
Heterogeneity
Neither visual inspection of the forest plot nor inconsistency factor (I2 = 0%; 95% CI 0.00 to 0.59; P = 0.63) indicated statistical heterogeneity.
Trial Sequential Analysis
Trial Sequential Analysis showed that with an anticipated RRI of 20%, mortality in the control group of 33%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 0%, the required information size was 2623 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRI of higher versus lower oxygen (Figure 4). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.88 to 1.57.
Bayes factor
Bayes factors are presented in Table 8.
2. Calculated Bayes factors for the primary outcomes.
Outcome | Intervention effect hypothesised | Intervention effect shown by the meta‐analysis | Bayes factor (BF) | Interpretation |
Mortality Time point closest to 3 months |
RR 0.80 | RR 1.18 | 18078 | * |
Mortality Time point closest to 3 months |
RR 1.20 | RR 1.18 | 0.12 (BF‐1 = 8.3) | ** |
Mortality Maximum follow‐up |
RR 0.80 | RR 1.16 | 12867 | * |
Mortality Maximum follow‐up |
RR 1.20 | RR 1.16 | 0.18 (BF‐1 = 5.6) | ** |
Estimated highest reported proportion of serious adverse events Time point closest to 3 months |
RR 0.80 | RR 1.13 | 2114269 | * |
Estimated highest reported proportion of serious adverse events Time point closest to 3 months |
RR 1.20 | RR 1.13 | 0.21 (BF‐1 = 4.8) | ** |
Estimated cumulated number of serious adverse events Time point closest to 3 months |
RR 0.80 | RR 1.08 | 6.2*1020 | * |
Estimated cumulated number of serious adverse events Time point closest to 3 months |
RR 1.20 | RR 1.08 | 19 (BF‐1 = 0.05) | ** |
Estimated highest reported proportion of serious adverse events Maximum follow‐up |
RR 0.80 | RR 1.13 | 1624463 | * |
Estimated highest reported proportion of serious adverse events Maximum follow‐up |
RR 1.20 | RR 1.13 | 0.21 (BF‐1 = 4.8) | ** |
Estimated cumulated number of serious adverse events Maximum follow‐up |
RR 0.80 | RR 1.07 | 1.96*1019 | * |
Estimated cumulated number of serious adverse events Maximum follow‐up |
RR 1.20 | RR 1.07 | 117 (BF‐1 = 0.01) | ** |
Abbreviations: RR: risk ratio
*The result is likely BF times more compatible with the null‐hypothesis of a relative risk reduction of 0% than the alternative hypothesis of a relative risk reduction of 20% for an effect of higher versus lower supplemental oxygen on all‐cause mortality. **The result is likely BF‐1 times more compatible with the alternative hypothesis of a relative risk increase of 20% than the null‐hypothesis of a relative risk increase of 0% for an effect of higher versus lower supplemental oxygen on all‐cause mortality.
Sensitivity analyses
We were unable to perform the sensitivity analysis excluding trials at overall high risk of bias (except for blinding of participants and personnel) as only one trial reporting on mortality was at overall low risk of bias (except for blinding of participants and personnel) (Jakkula 2018).
The sensitivity analysis excluding trials comparing two low targets or two high targets indicated no evidence of a difference in the effect of higher versus lower oxygen on all‐cause mortality (RR 1.11, 95% CI 0.92 to 1.35; I2 = 0%; 537 participants; 2 trials; Analysis 1.2).
The sensitivity analysis based on missing data indicated that incomplete outcome data alone had the potential to influence the results:
best‐worst‐case scenario random‐effects meta‐analysis: RR 1.13, 95% CI 0.97 to 1.31; 1149 participants; 4 trials; Analysis 1.3;
worst‐best‐case scenario random‐effects meta‐analysis: RR 1.21, 95% CI 1.04 to 1.41; 1149 participants; 4 trials; Analysis 1.4).
However, both sensitivity analyses indicated harm of higher versus lower oxygen supplementation. Data were imputed for four trials (Asfar 2017; Girardis 2016; Jakkula 2018; Panwar 2016).
Subgroup analyses
We found no evidence of a difference in subgroup analyses according to different types of oxygen interventions (Analysis 1.5); FiO2 or oxygenation target in the higher oxygen‐administration group (analysis not applicable; Analysis 1.6); FiO2 or oxygenation target in the lower oxygen‐administration group (Analysis 1.7); ICU population (Analysis 1.8); and oxygen delivery system (Analysis 1.9).
Maximum follow‐up
Seven of 10 trials with a total of 1285 participants and a mean follow‐up of 3.33 months (range 1 month to 6 months) reported all‐cause mortality. A total of 36.41% in the higher group versus 31.39% in the lower group died. Meta‐analysis showed evidence of a harmful effect of higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing mortality (random‐effects model RR 1.16, 95% CI 1.00 to 1.35; I2 = 0%; 1285 participants; 7 trials; Analysis 2.1; very low‐certainty evidence).
Heterogeneity
Neither visual inspection of the forest plot nor inconsistency factor (I2 = 0%; 95% CI 0.00 to 0.46; P = 0.76) indicated any heterogeneity.
Trial Sequential Analysis
Trial Sequential Analysis showed that with an anticipated RRI of 20%, mortality in the control group of 31%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 0%, the required information size was 2903 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRI of higher versus lower oxygen (Figure 5). The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.88 to 1.53.
Bayes factor
Bayes factors are presented in Table 8.
Sensitivity analyses
We were unable to perform the sensitivity analysis excluding trials at overall high risk of bias (except for blinding of participants and personnel) as only one trial reporting on mortality was at overall low risk of bias (except for blinding of participants and personnel) (Jakkula 2018).
The sensitivity analysis excluding trials comparing two low targets or two high targets indicated a harmful effect of higher versus lower oxygen on all‐cause mortality (RR 1.11, 95% CI 0.92 to 1.35; I2 = 0%; 537 participants; 2 trials; Analysis 2.2).
The sensitivity analysis on missing data indicated that incomplete outcome data alone had the potential to influence the results:
best‐worst‐case scenario random‐effects meta‐analysis: RR 1.11, 95% CI 0.96 to 1.28; 1306 participants; 7 trials; Analysis 2.3;
worst‐best‐case scenario random‐effects meta‐analysis: RR 1.21, 95% CI 1.05 to 1.41; 1306 participants, 7 trials; Analysis 2.4.
However, both analyses indicated harm of higher versus lower oxygen supplementation. Data were imputed for six trials (Asfar 2017; Girardis 2016; Gomersall 2002; Jakkula 2018; Lång 2018; Panwar 2016).
Subgroup analyses
We found no evidence of a difference in subgroup analyses according to different types of oxygen interventions (Analysis 2.5); FiO2 or oxygenation/target in the higher oxygen‐administration group (Analysis 2.6); FiO2 or oxygenation/target in the lower oxygen‐administration group (Analysis 2.7); ICU population (Analysis 2.8); and oxygen delivery system (Analysis 2.9).
Proportion of participants with one or more serious adverse events
One of 10 trials reported on the proportion of participants with one or more serious adverse events as a composite outcome, according to our primary analysis on the proportion of participants with one or more serious adverse events (Asfar 2017). A total of 85% in the higher group versus 76% in the lower group had at least one serious adverse event. Another six trials, Girardis 2016; Gomersall 2002; Jakkula 2018; Lång 2018; Mazdeh 2015; Panwar 2016, reported on outcomes categorized by us as serious adverse events according to the ICH‐GCP definition (ICH‐GCP 1997).
As the reporting of serious adverse events as a combined outcome was not carried out according to the ICH‐GCP recommendation, we estimated the reported proportion of participants with one or more serious adverse events in two ways:
by choosing the one specific serious adverse event with the highest proportion reported in each trial that addresses the lowest possible proportion of participants with one or more serious adverse events (somehow a best‐case scenario);
by cumulating all reported serious adverse events, assuming that participants only experience one serious adverse event (the number of participants in each group will constitute a maximum), address the highest possible reported proportion of participants with one or more serious adverse events (somehow a worst‐case scenario).
Time point closest to three months (follow‐up range 3 days to 90 days)
Meta‐analysis showed evidence of a harmful effect of higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated highest reported proportion of specific serious adverse events in each trial (random‐effects model RR 1.13, 95% CI 1.04 to 1.23; I2 = 0%; 1234 participants; 6 trials; Analysis 3.1; very low‐certainty evidence). Individual types of serious adverse events included mortality (Girardis 2016; Jakkula 2018; Panwar 2016); proportion of participants with one or more serious adverse events (Asfar 2017); mechanical ventilation (reported as a poor outcome) (Gomersall 2002); and pneumonia (Lång 2018).
Meta‐analysis showed no evidence of a difference of higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated cumulated number of serious adverse events (random‐effects model RR 1.08, 95% CI 0.99 to 1.18; I2 = 49%; 1234 participants; 6 trials; Analysis 3.2; very low‐certainty evidence). Individual types of serious adverse events included mortality; ARDS; pneumonia; sepsis; respiratory failure; cardiovascular failure; liver failure; renal failure; bloodstream infection; respiratory infection; surgical site infection; peripheral arterial thrombosis, pneumothorax; ventricular arrhythmias; new infections (composite outcome: when events were reported individually, they were not included in the analysis); haemodynamic instability; mechanical ventilation; severe hypercapnia and respiratory acidosis (PaCO2 > 10 kPa and pH < 7.15); and unexplained brain oedema on computed tomography (CT) scan.
Trial Sequential Analysis
Trial Sequential Analysis of the estimated highest reported proportion of serious adverse events showed that with an anticipated RRI of 20%, serious adverse events in the control group of 44.33%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 0%, the required information size was 1577 participants (Figure 6). The cumulative Z‐curve crossed the trial sequential monitoring boundary for harm, indicating there is evidence that higher versus lower oxygen may increase the relative risk of participants with one or more serious adverse events at three months follow‐up. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 1.00 to 1.27.
Trial Sequential Analysis of the estimated cumulated number of serious adverse events showed that with an anticipated RRR of 20%, serious adverse events in the control group of 76.03%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 78.95%, the required information size was 2204 (Figure 7). The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility (although reaching futility boundary). This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR of higher versus lower oxygen. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.94 to 1.25.
Bayes factor
Bayes factors are presented in Table 8.
Maximum follow‐up (follow‐up range 6 days to 6 months)
Meta‐analysis showed evidence of a harmful effect of higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated highest reported proportion of serious adverse events (random‐effects model RR 1.13, 95% CI 1.04 to 1.23; I2 = 0%; 1285 participants; 7 trials; Analysis 4.1). Individual types of serious adverse events included mortality (Girardis 2016; Jakkula 2018; Lång 2018; Mazdeh 2015; Panwar 2016); proportion of participants with one or more serious adverse events (Asfar 2017); and mechanical ventilation (Gomersall 2002).
Meta‐analysis showed no evidence of a difference between higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated cumulated number of serious adverse events (random‐effects model RR 1.07, 95% CI 0.97 to 1.18; I2 = 49%; 1285 participants; 7 trials; Analysis 4.2). Individual types of serious adverse events included mortality; ARDS; pneumonia; sepsis; respiratory failure; cardiovascular failure; liver failure; renal failure; bloodstream infection; respiratory infection; surgical site infection; peripheral arterial thrombosis, pneumothorax; ventricular arrhythmias; new infections (composite outcome: when events were reported individually, they were not included in the analysis); cardiac arrhythmia; coma; haemodynamic instability; mechanical ventilation; severe hypercapnia and respiratory acidosis (PaCO2 > 10 kPa and pH < 7.15); and unexplained brain oedema on CT scan.
Trial Sequential Analysis
Trial Sequential Analysis of the estimated highest reported proportion of serious adverse events showed that with an anticipated RRI of 20%, serious adverse events in the control group of 43.38%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 0%, the required information size was 1644 participants. The cumulative Z‐curve crossed the trial sequential monitoring boundary for harm. This indicated that there was firm evidence that higher versus lower oxygen increases serious adverse events at maximum follow‐up. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 1.01 to 1.27.
Trial Sequential Analysis of the estimated cumulated number of serious adverse events showed that with an anticipated RRR of 20%, serious adverse events in the control group of 74.92%, a type 1 error of 2.5%, a type 2 error of 10%, and a diversity of 82.80%, the required information size was 2826 participants. The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility (although reaching futility boundary). This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRI of higher versus lower oxygen. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.92 to 3.01.
Bayes factor
Bayes factors are presented in Table 8.
Quality of life (any valid scale such as the 36‐item Short Form Health Survey (SF‐36))
None of the included trials reported any data on quality of life at any time point.
Secondary outcomes
Lung injury
None of the 10 included trials reported any data on lung injury (as a composite outcome defined as either ARDS, pulmonary fibrosis, or pneumonia) at any time point. Five of the 10 trials reported on specific lung outcomes: ARDS (Jakkula 2018; Lång 2018; Panwar 2016); pulmonary fibrosis not reported; pneumonia (Asfar 2017; Girardis 2016; Lång 2018), during index admission.
We estimated the reported proportion of participants with one or more lung injury in two ways:
by choosing the one specific lung injury event with the highest proportion reported in each trial that addresses the lowest possible proportion of participants with one or more lung injuries (somehow a best‐case scenario);
by cumulating all reported lung injury events, assuming that participants only experience one lung injury event (the number of participants in each group will constitute a maximum), address the highest possible reported proportion of participants with one or more lung injuries (somehow a worst‐case scenario).
Time point closest to three months (follow‐up range median 4 days to median 23 days)
Meta‐analysis showed no evidence of a difference between higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated highest reported proportion of lung injury (fixed‐effect model RR 1.03, 95% CI 0.78 to 1.36; I2 = 0%; 1167 participants; 5 trials; Analysis 5.1; very low‐certainty evidence).
Meta‐analysis showed no evidence of a difference between higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing the estimated cumulated number of lung injury events (fixed‐effect model RR 0.99, 95% CI 0.75 to 1.30; I2 = 0%; 1167 participants; 5 trials; Analysis 5.2; very low‐certainty evidence).
Three of 10 trials with a total of 288 participants reported ARDS. A total of 10.7% in the lower group versus 8.1% in the higher group had ARDS. Meta‐analysis showed no evidence of a difference between higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing ARDS (random‐effects model RR 0.79, 95% CI 0.28 to 2.20; I2 = 16%; 288 participants; 3 trials; Analysis 5.3; very low‐certainty evidence).
Three of 10 trials with a total of 944 participants reported pneumonia. A total of 14.7% in the lower group versus 15.2% in the higher group had pneumonia. Meta‐analysis showed no evidence of a difference between higher fraction of inspired oxygen or targets compared with lower fraction or targets of arterial oxygenation when assessing pneumonia (fixed‐effect model RR 1.03, 95% CI 0.76 to 1.40; I2 = 0%; 944 participants; 3 trials; Analysis 5.4; very low‐certainty evidence).
Trial Sequential Analysis
Trial Sequential Analysis of the estimated highest reported proportion of lung injuries showed that with an anticipated RRI of 20%, lung injury in the control group of 14%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 8653 participants (Figure 8). The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or 20% RRI for benefit or harm of higher versus lower oxygen. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.33 to 3.23.
Trial Sequential Analysis of the estimated cumulated number of lung injuries showed that with an anticipated RRI of 20%, lung injury in the control group of 14%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 8653 participants (Figure 9). The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or 20% RRI for benefit or harm of higher versus lower oxygen. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.32 to 3.05.
We were unable to conduct Trial Sequential Analysis of ARDS due to insufficient information (1.34%). The required information size was 21,533 participants.
Trial Sequential Analysis of pneumonia showed that with an anticipated RRI of 20%, pneumonia in the control group of 14%, a type 1 error of 2%, a type 2 error of 10%, and a diversity of 0%, the required information size was 10,200 participants (Figure 10). The cumulative Z‐curve did not cross any boundaries for benefit and harm, nor trial sequential monitoring boundaries for futility. This indicated that considering sparse data and repetitive testing, evidence was insufficient to confirm or refute a 20% RRR or 20% RRI for benefit or harm of higher versus lower oxygen. The TSA CI, adjusted for multiple outcomes, sparse data, and repetitive testing, for the intervention effect was 0.30 to 3.57.
Maximum follow‐up
None of the 10 trials reported any data on lung injury (as a composite outcome defined as either ARDS, pulmonary fibrosis, or pneumonia), including specific lung outcomes (ARDS, pulmonary fibrosis, or pneumonia), with longer follow‐up than during index admission.
Acute myocardial infarction
None of the included trials reported any data on acute myocardial infarction at any time point.
Stroke
None of the included trials reported any data on stroke at any time point.
Sepsis
One trial reported on sepsis during ICU stay (median 6 days; interquartile range 1 to 11) (Girardis 2016). A total of 9.78% in the higher group versus 5.00% in the lower group had sepsis (RR 1.87, 95% CI 0.93 to 3.87; 1 study; 445 participants; very low‐certainty evidence).
Discussion
Summary of main results
We included 10 trials that randomized a total of 1458 participants in this systematic review. Seven trials with a total of 1285 participants contributed data to the analyses. We found no evidence for a beneficial effect of higher versus lower supplemental oxygen for adults admitted to the ICU.
Mortality seems to have been increased with higher supplemental oxygen at the time point closest to three months follow‐up (RR 1.18, 95% CI 1.01 to 1.37; 4 studies; 1135 participants; I2 = 0%; Analysis 1.1; very low‐certainty of evidence) (Table 1). Trial Sequential Analysis, considering multiple outcomes, sparse data, and repetitive testing, revealed that the information size required to detect or reject an RRI of 20% was not achieved (Figure 11). When mortality was analysed at maximum follow‐up, the traditional meta‐analysis indicated increased mortality with higher supplemental oxygen (Analysis 2.1), but TSA highlighted that the required information size to detect or reject a 20% RRI in mortality was not achieved (Figure 11).
The estimated highest reported proportion of serious adverse events at the time point closest to three months follow‐up was significantly increased with higher supplemental oxygen (RR 1.13, 95% CI 1.04 to 1.23; 6 studies; 1234 participants; I2 = 0%; Analysis 3.1; very low‐certainty evidence). However, the estimated cumulated number of serious adverse events at the time point closest to three months follow‐up did not show evidence of a difference (RR 1.08, 95% CI 0.99 to 1.18; 6 studies; 1234 participants; I2 = 49%; Analysis 3.2; very low‐certainty evidence). Trial Sequential Analysis showed that the monitoring boundary for harm for a 20% RRI was crossed when serious adverse events were analysed as the estimated highest proportion (Figure 6). However, when analysed as the estimated cumulated number of serious adverse events, the TSA revealed that the information size required to detect or reject an RRI of 20% was not achieved (Figure 7).
When serious adverse events were analysed at maximum follow‐up, the traditional meta‐analysis again showed that serious adverse events were increased with higher supplemental oxygen when analysed as the highest proportion (Analysis 4.1), but were not significantly increased when analysed as cumulated events (Analysis 4.2). Trial Sequential Analysis again showed that the monitoring boundary for harm for a 20% RRI was crossed when serious adverse events were analysed as estimated highest proportion, and when analysed as estimated cumulated number of serious adverse events, the TSA again revealed that the information size required to detect or reject an RRI of 20% was not achieved.
There was no evidence of a difference in lung injury with higher supplemental oxygen when analysed as a composite outcome nor as individual components of the composite outcome, but the evidence is very uncertain (Analysis 5.1; Analysis 5.2). However, TSA, considering multiple outcomes, sparse data, and repetitive testing, revealed that only 13% of the required information size was reached to detect or reject a 20% RRI, and that neither conventional nor trial sequential monitoring boundaries for benefit, harm, and futility had been crossed (Figure 8; Figure 9).
Only one trial reported on sepsis. Based on this one trial, we found that sepsis was not affected by higher supplemental oxygen (RR 1.87, 95% CI 0.93 to 3.87; 1 study; 445 participants; very low‐certainty evidence).
No trials reported on quality of life, acute myocardial infarction, or stroke.
Overall completeness and applicability of evidence
We included all RCTs up to December 2018 comparing higher to lower oxygen fractions or targets of oxygenation in adults admitted to the ICU.
We found that clinical heterogeneity, especially relating to the intervention, but also to the population and setting, was present. Six trials were conducted in Europe, Australia, and New Zealand (Asfar 2017; Girardis 2016; Jakkula 2018; Lång 2018; Panwar 2016; Young 2017), two in Iran (Mazdeh 2015; Taher 2016), one in Hong Kong (Gomersall 2002), and one in Japan (Ishii 2018). The trials were conducted from 1994, Gomersall 2002, to 2018, Ishii 2018; Young 2017. Mean age spanned from 44 years, Lång 2018, to 68 years, Gomersall 2002, and the percentage of males versus females spanned from 49%, Jakkula 2018, to 84%, Lång 2018. All participants were admitted to the ICU; however, some trials included participants admitted to the ICU regardless of condition, whilst others included specific populations: five trials included adults from multidisciplinary ICUs (Asfar 2017; Girardis 2016; Gomersall 2002Panwar 2016; Young 2017); two included adults with traumatic brain injury (Lång 2018; Taher 2016); one included adults admitted to a surgical ICU (Ishii 2018); one included adults with acute stroke (Mazdeh 2015); and one included adults resuscitated during out‐of‐hospital cardiac arrest (Jakkula 2018). In addition, disease severity differed, for example median Acute Physiology, Age, Chronic Health Evaluation II (APACHE II) of 22, Lång 2018, and median APACHE II of 28, Jakkula 2018. Furthermore, the interventions varied to a great extent. The duration of the intervention ranged from one hour, in Ishii 2018, to the entire duration of ICU admission, in Girardis 2016. The intervention targets compared also differed, and only three trials assessed targets categorized by us as higher versus lower oxygen fractions or targets of oxygenation (Asfar 2017; Panwar 2016; Taher 2016).
In general, statistical heterogeneity was low or moderate and was not explained by our subgroup analyses. Our sensitivity analysis on missing data (best‐worst‐case scenario and worst‐best‐case scenario) revealed that incomplete outcome data alone had the potential to influence the results on mortality; however, both analyses indicated harm with higher versus lower oxygen supplementation.
Only two trials had low risk of bias in all domains except for blinding of participants and personnel (Jakkula 2018; Young 2017). Only one of these trials contributed data to the meta‐analyses (Jakkula 2018). The meta‐analyses on mortality and lung injuries did not reach the required information size to detect or reject a 20% RRR or RRI. Trial Sequential Analysis on serious adverse events revealed that the trial sequential monitoring boundary for harm was crossed in one analysis (Figure 6), but not in the other (Figure 7).
Seven trials contributed data to the analyses on mortality and serious adverse events, and five trials contributed data to the analyses on lung injuries. No trials reported on quality of life, acute myocardial infarction, and stroke, and only one trial reported on sepsis.
Quality of the evidence
We used GRADE to assess the certainty of the evidence for the results on all‐cause mortality, serious adverse events, quality of life, lung injury, acute myocardial infarction, stroke, and sepsis at the time point closest to three months (Table 1).
The GRADE assessment showed that the certainty of evidence was very low for mortality due to serious risk of bias, indirectness, and imprecision.
The certainty of the evidence was very low for the estimated highest reported proportion of serious adverse events due to serious risk of bias, indirectness, and imprecision. Trial Sequential Analysis showed that the trial sequential monitoring boundary for harm was crossed; hence, even with strict control of random errors, disregarding risk of bias, there is evidence that higher versus lower oxygen tensions increases the risk of serious adverse events by at least 20%.
The certainty of the evidence was very low for lung injury due to serious risk of bias, indirectness, and imprecision.
The certainty of the evidence was very low for sepsis due to serious risk of bias, inconsistency, and imprecision.
The certainty of the evidence for quality of life, acute myocardial infarction, and stroke was not estimable due to lack of data.
Potential biases in the review process
Strengths
We included trials regardless of publication type, publication status, language, and choice of outcomes. In all cases we contacted relevant trial authors if additional information was needed.
We used predefined, up‐to‐date systematic review methodology, and the methodology was not changed during the review process. We used GRADE to assess the certainty of the evidence and TSA as a sensitivity analysis with adjusted thresholds for significance to strictly control the risk of random errors; we thoroughly assessed the risk of bias of each trial to evaluate the risk of systematic errors (bias); and we used an eight‐step procedure to assess if the thresholds for statistical and clinical significance were crossed (Jakobsen 2014a). This adds further robustness to our results and conclusions. We also tested the robustness of our results with sensitivity analyses.
We conducted two post hoc analyses that estimated the effects of higher versus lower oxygen supplementation on risk of having one or more serious adverse events and lung injury.
Limitations
We identified a high risk of clinical heterogeneity, especially within the interventions. The most obvious limitation was that trials did not use the same definition of lower targets and higher targets. Some trials used a fixed FiO2, whilst others used a target interval, and the achieved oxygen saturation may end up being high even though participants were allocated to the lower group. Furthermore, the targets used in some trials were not adequately different to be categorized as trials comparing real high to real low targets. That being said, statistical heterogeneity seemed to be low.
Our 'Risk of bias' assessment showed that none of the included trials had an overall low risk of bias and none were fully blinded, which was not unexpected due to the complexity and difficulties of blinding interventions of oxygen supplementation for participants and personnel. Nevertheless, only data from one trial used blinded outcome assessors, which may still be used when blinding of participants and personnel is not feasible (Pocock 2015). Inadequate blinding is therefore a limitation in the included trials, as it is associated with exaggeration of beneficial intervention effects and underestimation of harmful effects (Hrobjartsson 2014; Savovic 2018). We thus could not rule out a biased effect estimate of the included trials. As a result, we downgraded the certainty of the evidence for all trials one level for risk of bias.
Only one trial reported serious adverse events as a composite outcome of participants with one or more serious adverse events. To estimate the effect on serious adverse events reported in the included trials, we conducted two analyses to estimate the effect on the proportion of participants having one or more serious adverse events, which may be expected to lie between these two extremes. None of the trials reported on lung injuries as a composite outcome, and thus the same method was applied. Each component was analysed separately for the lung injury outcome, but this was not done for serious adverse events. Each component of composite outcomes may not have similar degrees of severity, and therefore could bias the results of the outcome (Garattini 2016). If, for example, more severe serious adverse events occur in one intervention group, and other less severe serious adverse events occur in the other intervention group, then there is a risk of overlooking actual severity differences between the compared groups when analysing the composite outcome.
Furthermore, the analyses estimating the highest proportion of serious adverse events/lung injuries imply that participants included in the highest proportion also include participants having other serious adverse events. For example, if mortality is the highest proportion, then it is implied that all the participants that did not die did not experience another serious adverse event; this analysis thus underestimates the proportion of participants with one or more serious adverse events, as participants not included in the highest proportion would be expected to experience other serious adverse events not included in the highest proportion. In addition, the analyses estimating the cumulated proportion of serious adverse events/lung injuries imply that all participants who experience a serious adverse event had only this specific serious adverse event, which overestimates the proportion of participants with one or more serious adverse events, since a minimum of one participant would be expected to have more than one serious adverse event.
Only seven relatively small trials contributed data to the meta‐analyses. An insufficient number of trials precluded an assessment of publication bias. Although we did not observe statistically significant heterogeneity in our subgroup analyses, they were naturally relatively small, thus we cannot exclude the possibility of subgroup differences.
Agreements and disagreements with other studies or reviews
Systematic reviews of observational data have found an association between hyperoxaemia and mortality in critically ill adults (Damiani 2014; Helmerhorst 2015), which has launched the initiation of several RCTs. Some meta‐analyses of RCTs have been published in recent years (Cabello 2016; Chu 2018; Sepehrvand 2018; You 2018).
Critical illness of adults in the reviews is often defined differently or represented as subgroups. We included trials assessing adults admitted to and randomized in the ICU, whereas other reviews also included other settings, such as trauma, surgery, or pre‐hospital initiated oxygen supplementation. Previous meta‐analyses consistently report that too much supplemental oxygen may be/is harmful or not beneficial. However, it appears that none of these meta‐analyses included proper bias risk assessment in their conclusions/recommendations. Limitations due to clinical heterogeneity are to a greater or lesser extent highlighted in the reviews, but these also seem not to be reflected in the conclusions. We performed TSA in order to control the risk of random errors in a cumulative meta‐analysis and to prevent premature statements regarding the superiority of higher versus lower oxygen supplementation, which was also used by Chu and colleagues but without adjusting for multiple outcomes and using a possible inadequate power of 80% (Chu 2018).
Despite methodological discrepancies between our review and other meta‐analyses and reviews, we agree with recently published reviews reporting a possible association between high oxygenation targets and mortality. However, we did not find the available evidence to be of high certainty (Chu 2018). Furthermore, we did not find that the current evidence necessitates a clinical practice guideline recommending a specific target of FiO2, SpO2, and PaO2, particularly due to the very high heterogeneity in the types of interventions in the trials included in this review. (Rasmussen 2018; Siemieniuk 2018).
Authors' conclusions
Implications for practice.
We are very uncertain about the effects of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit on all‐cause mortality, serious adverse events, lung injuries, and sepsis at the time point closest to three months due to very low‐certainty evidence. Our results suggest that oxygen supplementation with higher versus lower fractions or oxygenation targets may increase mortality. None of the included trials reported the proportion of participants with one or more serious adverse events according to the International Conference on Harmonisation Good Clinical Practice (ICH‐GCP) criteria; however, we found an increase in the number of serious adverse events reported by the trials with higher fractions of inspired oxygen or oxygenation targets using strict control of the risk of random errors. The effects of the interventions on quality of life, acute myocardial infarction, and stroke were inconclusive due to lack of data.
Implications for research.
Randomized controlled trials assessing the benefits and harms of higher versus lower oxygen supplementation are needed. Such trials should be conducted with the lowest possible risk of bias, low risk of other design errors, and low risk of random errors. Future trials should focus their assessments on multidisciplinary intensive care units and critically ill adults in general and not only subgroups of this population group (Barbateskovic 2018). Oxygen supplementation is standard care, and the assessed intervention and duration should therefore reflect clinically relevant and accepted supplemental oxygen targets (Schjørring 2018). Furthermore, trials should aim to differentiate the intervention groups so that trials are in fact comparing higher versus lower oxygenation targets, and if possible by stratifying according to presence or absence of hypoxaemia at baseline. Patient‐centred clinical outcomes should also be reported.
What's new
Date | Event | Description |
---|---|---|
27 November 2019 | Amended | The ICU‐ROX trial (ICU‐ROX 2019) was added as a reference awaiting classification. ICU‐ROX was published after our literature search was run and thus was not included in this review. The ICU‐ROX trial will be included in a review update. |
History
Protocol first published: Issue 4, 2017 Review first published: Issue 11, 2019
Date | Event | Description |
---|---|---|
27 November 2019 | Amended | Author affiliations updated |
8 January 2019 | Amended | Editorial team changed to Cochrane Emergency and Critical Care |
20 September 2017 | Amended | We have cited the systematic review Permissive hypoxaemia versus normoxaemia for mechanically ventilated critically ill patients (Gilbert‐Kawai 2014). |
Acknowledgements
We would like to thank Arash Afshari (Content Editor), Nathan Pace (Statistical Editor), Daniel Martin and Rakshit Panwar (Peer Reviewers), Janet Wale (Consumer Referee), Janne Vendt (Information Specialist), Jane Cracknell and Teo Quay (Managing Editors), and Harald Herkner (Co‐ordinating Editor) for their help and editorial advice during the preparation of this systematic review.
Appendices
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Hyperoxia] explode all trees #2 MeSH descriptor: [Anoxia] explode all trees #3 MeSH descriptor: [Oxygen Inhalation Therapy] explode all trees #4 MeSH descriptor: [Oxygen] explode all trees #5 (inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or level* or tension* or supply* or supplement* or supplie* or therap* or administr* or dosag* or dose* or dosing*) near/3 (oxygen):ti,ab,kw #6 (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or arterial oxygen or high oxygen or oxygenat* or blood gas or oxygen saturation or pao2 or sao2 or spo2 or fio2):ti,ab,kw #7 (#1 or #2 or #3 or #4 or #5 or #6) #8 MeSH descriptor: [Critical Illness] explode all trees #9 MeSH descriptor: [Critical Care] explode all trees #10 MeSH descriptor: [Intensive Care Units] explode all trees #11 MeSH descriptor: [Emergency Medicine] explode all trees #12 MeSH descriptor: [Emergency Service, Hospital] explode all trees #13 (emergency department* or ED or emergency room* or ER or high dependency unit* or HDU or prehospital* or critically ill or acutely ill or intensive care or critical care or ICU* or coronary care unit or neurological intermediate care unit):ti,ab,kw #14 MeSH descriptor: [Heart Arrest] explode all trees #15 MeSH descriptor: [Myocardial Ischemia] explode all trees #16 (cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome):ti,ab,kw #17 MeSH descriptor: [Shock] explode all trees #18 (shock):ti,ab,kw #19 MeSH descriptor: [Meningitis] explode all trees #20 (meningitis):ti,ab,kw #21 MeSH descriptor: [Pneumonia] explode all trees #22 (pneumonia):ti,ab,kw #23 MeSH descriptor: [Pulmonary Disease, Chronic Obstructive] explode all trees #24 (COPD or chronic obstructive pulmonary disease):ti,ab,kw #25 MeSH descriptor: [Acute Lung Injury] explode all trees #26 (acute lung injury):ti,ab,kw #27 MeSH descriptor: [Respiratory Distress Syndrome, Adult] explode all trees #28 (adult respiratory distress syndrome or ARDS):ti,ab,kw #29 MeSH descriptor: [Pulmonary Embolism] explode all trees #30 (pulmonary embolism or pulmonary infarct*):ti,ab,kw #31 MeSH descriptor: [Multiple Trauma] explode all trees #32 (severe trauma or multiple trauma):ti,ab,kw #33 MeSH descriptor: [Craniocerebral Trauma] explode all trees #34 (traumatic brain injury or TBI or head trauma or craniocerebral trauma):ti,ab,kw #35 MeSH descriptor: [Stroke] explode all trees #36 (stroke):ti,ab,kw #37 MeSH descriptor: [Sepsis] explode all trees #38 MeSH descriptor: [Shock, Septic] explode all trees #39 (sepsis or septic shock):ti,ab,kw #40 MeSH descriptor: [Intracranial Hemorrhages] explode all trees #41 intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding:ti,ab,kw #42 MeSH descriptor: [Poisoning] explode all trees #43 (severe poisoning):ti,ab,kw #44 MeSH descriptor: [Diabetic Ketoacidosis] explode all trees #45 (diabetic ketoacidosis):ti,ab,kw #46 MeSH descriptor: [Liver Failure, Acute] explode all trees #47 (acute hepatic failure or fulminating hepatic failure):ti,ab,kw #48 MeSH descriptor: [Acute Kidney Injury] explode all trees #49 (acute kidney failure or acute renal injuries):ti,ab,kw #50 MeSH descriptor: [Intestinal Perforation] explode all trees #51 MeSH descriptor: [Appendicitis] explode all #52 (intestinal perforation or appendicitis):ti,ab,kw #53 (acute or emergency) near/2 (surgery or operat* or resection):ti,ab,kw #54 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53) #55 (#7 and #54)
Appendix 2. MEDLINE (OvidSP) search strategy
1. exp Hyperoxia/ 2. exp Anoxia/ 3. exp Oxygen Inhalation Therapy/ 4. exp Oxygen/ 5. ((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or level* or tension* or supply* or supplement* or supplie* or therap* or administr* or dosag* or dose* or dosing*) adj3 oxygen).tw. 6. (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or arterial oxygen or high oxygen or oxygenat* or blood gas or oxygen saturation or pao2 or sao2 or spo2 or fio2).tw. 7. (1 or 2 or 3 or 4 or 5 or 6) 8. exp Critical Illness/ 9. exp Critical Care/ 10. exp Intensive Care Units/ 11. exp Emergency Medicine/ 12. exp Emergency Service, Hospital/ 13. (emergency department* or ED or emergency room* or ER or high dependency unit* or HDU or prehospital* or critically ill or acutely ill or intensive care or critical care or ICU* or coronary care unit or neurological intermediate care unit).tw. 14. exp Heart Arrest/ 15. exp Myocardial Ischemia/ 16. (cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome).tw. 17. exp Shock/ 18. shock.tw. 19. exp Meningitis/ 20. meningitis.tw. 21. exp Pneumonia/ 22. pneumonia.tw. 23. exp Pulmonary Disease, Chronic Obstructive/ 24. (COPD or chronic obstructive pulmonary disease).tw. 25. exp Acute Lung Injury/ 26. acute lung injury.tw. 27. exp Respiratory Distress Syndrome, Adult/ 28. (adult respiratory distress syndrome or ARDS).tw. 29. exp Pulmonary Embolism/ 30. (pulmonary embolism or pulmonary infarct*).tw. 31. exp Multiple Trauma/ 32. (severe trauma or multiple trauma).tw. 33. exp Craniocerebral Trauma/ 34. (traumatic brain injury or TBI or head trauma or craniocerebral trauma).tw. 35. exp Stroke/ 36. stroke.tw. 37. exp Sepsis/ 38. exp Shock, Septic/ 39. (sepsis or septic shock).tw. 40. exp Intracranial Hemorrhages/ 41. (intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding).tw. 42. exp Poisoning/ 43. severe poisoning.tw. 44. exp Diabetic Ketoacidosis/ 45. diabetic ketoacidosis.tw. 46. exp Liver Failure, Acute/ 47. (acute hepatic failure or fulminating hepatic failure).tw. 48. exp Acute Kidney Injury/ 49. (acute kidney failure or acute renal injuries).tw. 50. exp Intestinal Perforation/ 51. exp Appendicitis/ 52. (intestinal perforation or appendicitis).tw. 53. ((acute or emergency) adj2 (surgery or operat* or resection)).tw. 54. (8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53) 55. (7 and 54) 56. randomized controlled trial.pt. 57. controlled clinical trial.pt. 58. randomized.ab. 59. placebo.ab. 60. clinical trial.sh. 61. randomly.ab. 62. trial.ti. 63. (56 or 57 or 58 or 59 or 60 or 61 or 62) 64. exp animals/not humans.sh. 65. (63 not 64) 66. (55 and 65)
Appendix 3. Embase (OvidSP) search strategy
1. *hyperoxia/ 2. *hypoxia/ 3. *oxygen therapy/ 4. *oxygen/ 5. *arterial oxygen saturation/ 6. *oxygen blood level/ 7. *arterial oxygen tension/ 8. *blood oxygen tension/ 9. ((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or level* or tension* or supply* or supplement* or supplie* or therap* or administr* or dosag* or dose* or dosing*) adj3 oxygen).tw. 10. (hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or arterial oxygen or high oxygen or oxygenat* or blood gas or oxygen saturation or pao2 or sao2 or spo2 or fio2).tw. 11. (1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10) 12. *critical illness/ 13. *intensive care/ 14. *intensive care unit/ 15. *emergency medicine/ 16. *emergency health service/ 17. *coronary care unit/ 18. (emergency department* or ED or emergency room* or ER or high dependency unit* or HDU or prehospital* or critically ill or acutely ill or intensive care or critical care or ICU* or coronary care unit or neurological intermediate care unit).tw. 19. *heart arrest/ 20. *acute heart infarction/ 21. (cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome).tw. 22. *shock/ 23. shock.tw. 24. *meningitis/ 25. meningitis.tw. 26. *pneumonia/ 27. pneumonia.tw. 28. *chronic obstructive lung disease/ 29. (COPD or chronic obstructive pulmonary disease).tw. 30. *acute lung injury/ 31. acute lung injury.tw. 32. *adult respiratory distress syndrome/ 33. (adult respiratory distress syndrome or ARDS).tw. 34. *lung embolism/ 35. (pulmonary embolism or pulmonary infarct*).tw. 36. *multiple trauma/ 37. (severe trauma or multiple trauma).tw. 38. *head injury/ 39. *brain injury/ 40. (traumatic brain injury or TBI or head trauma or craniocerebral trauma).tw. 41. *cerebrovascular accident/ 42. *stroke unit/ 43. stroke.tw. 44. *sepsis/ 45. *septic shock/ 46. (sepsis or septic shock).tw. 47. *brain hemorrhage/ 48. (intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding).tw. 49. *intoxication/ 50. severe poisoning.tw. 51. *diabetic ketoacidosis/ 52. diabetic ketoacidosis.tw. 53. *acute liver failure/ 54. (acute hepatic failure or fulminating hepatic failure).tw. 55. *acute kidney failure/ 56. (acute kidney failure or acute renal injuries).tw. 57. *intestine perforation/ 58. *appendicitis/ 59. (intestinal perforation or appendicitis).tw. 60. ((acute or emergency) adj2 (surgery or operat* or resection)).tw. 61. (12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60) 62. (11 and 61) 63. CROSSOVER PROCEDURE.sh. 64. DOUBLE‐BLIND PROCEDURE.sh. 65. SINGLE‐BLIND PROCEDURE.sh. 66. (crossover* or cross over*).ti,ab. 67. placebo*.ti,ab. 68. (doubl* adj blind*).ti,ab. 69. allocat*.ti,ab. 70. trial.ti. 71. RANDOMIZED CONTROLLED TRIAL.sh. 72. random*.ti,ab. 73. (63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72) 74. (exp animal/ or exp invertebrate/ or animal.hw. or nonhuman/) not (exp human/ or human cell/ or (human or humans or man or men or wom?n).ti.) 75. (73 not 74) 76. (62 and 75)
Appendix 4. Science Citation Index ‐ Expanded search strategy
#27 (#26 AND #25) #26 TOPIC: (((random* OR control* OR RCT OR placebo OR group* OR trial*))) #25 (#24 AND #3) #24 (#23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4) #23 TITLE: (((acute or emergency) and (surgery or operat* or resection))) #22 TOPIC: ((intestinal perforation or appendicitis)) #21 TOPIC: ((acute kidney failure or acute renal injuries)) #20 TOPIC: ((acute hepatic failure or fulminating hepatic failure)) #19 TOPIC: ((diabetic ketoacidosis)) #18 TOPIC: ((severe poisoning)) #17 TOPIC: ((intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding)) #16 TOPIC: ((sepsis or septic shock)) #15 TOPIC: (stroke) #14 TOPIC: ((traumatic brain injury or TBI or head trauma or craniocerebral trauma)) #13 TOPIC: ((severe trauma or multiple trauma)) #12 TOPIC: ((pulmonary embolism or pulmonary infarct*)) #11 TOPIC: ((adult respiratory distress syndrome or ARDS)) #10 TOPIC: (acute lung injury) #9 TOPIC: ((COPD or chronic obstructive pulmonary disease)) #8 TOPIC: (pneumonia) #7 TOPIC: (meningitis) #6 TOPIC: (shock) #5 TOPIC: ((cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome)) #4 TOPIC: ((emergency department* or ED or emergency room* or ER or high dependency unit* or HDU or prehospital* or critically ill or acutely ill or intensive care or critical care or ICU* or coronary care unit or neurological intermediate care unit)) #3 (#2 OR #1) #2 TITLE: (((hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or arterial oxygen or high oxygen or oxygenat* or blood gas or oxygen saturation or pao2 or sao2 or spo2 or fio2))) #1 TITLE: ((((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or level* or tension* or supply* or supplement* or supplie* or therap* or administr* or dosag* or dose* or dosing*) and oxygen)))
Appendix 5. BIOSIS Previews search strategy
#27 (#26 AND #25) #26 TOPIC: ((random* OR control* OR RCT OR placebo OR group* OR trial*)) #25 (#24 AND #3) #24 (#23 OR #22 OR #21 OR #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6 OR #5 OR #4) #23 TITLE: ((((acute or emergency) and (surgery or operat* or resection)))) #22 TOPIC: (((intestinal perforation or appendicitis))) #21 TOPIC: (((acute kidney failure or acute renal injuries))) #20 TOPIC: (((acute hepatic failure or fulminating hepatic failure))) #19 TOPIC: (((diabetic ketoacidosis))) #18 TOPIC: (((severe poisoning))) #17 TOPIC: (((intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding))) #16 TOPIC: (((sepsis or septic shock))) #15 TOPIC: ((stroke)) #14 TOPIC: (((traumatic brain injury or TBI or head trauma or craniocerebral trauma))) #13 TOPIC: (((severe trauma or multiple trauma))) #12 TOPIC: (((pulmonary embolism or pulmonary infarct*))) #11 TOPIC: (((adult respiratory distress syndrome or ARDS))) #10 TOPIC: ((acute lung injury)) #9 TOPIC: (((COPD or chronic obstructive pulmonary disease))) #8 TOPIC: ((pneumonia)) #7 TOPIC: ((meningitis)) #6 TOPIC: ((shock)) #5 TOPIC: (((cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome))) #4 TOPIC: (((emergency department* or ED or emergency room* or ER or high dependency unit* or HDU or prehospital* or critically ill or acutely ill or intensive care or critical care or ICU* or coronary care unit or neurological intermediate care unit))) #3 (#2 OR #1) #2 TITLE: (((hyperoxia or hyperoxemia or hyperoxaemia or hypoxia or hypoxemia or hypoxaemia or anoxia or anoxemia or anoxaemia or arterial oxygen or high oxygen or oxygenat* or blood gas or oxygen saturation or pao2 or sao2 or spo2 or fio2))) #1 TITLE: (((inspir* or inhal* or fraction* or concentrat* or arterial* or saturation or level* or tension* or supply* or supplement* or supplie* or therap* or administr* or dosag* or dose* or dosing*) and oxygen))
Appendix 6. CINAHL search strategy
S66 (S53 AND S65) S65 (S54 or S55 or S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64) S64 TX allocat* random* S63 (MH "Quantitative Studies") S62 (MH "Placebos") S61 TX placebo* S60 TX random* allocat* S59 (MH "Random Assignment") S58 TX randomi* control* trial* S57 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) S56 TX clinic* n1 trial* S55 PT Clinical trial S54 (MH "Clinical Trials+") S53 (S7 AND S52) S52 (S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51) S51 AB ( (acute or emergency) ) AND AB ( (surgery or operat* or resection) ) S50 AB (intestinal perforation or appendicitis) S49 MW Appendicitis S48 MW Intestinal Perforation S47 AB (acute kidney failure or acute renal injuries) S46 MW acute kidney failure S45 AB (acute hepatic failure or fulminating hepatic failure) S44 MW Liver Failure, Acute S43 AB diabetic ketoacidosis S42 MW Diabetic Ketoacidosis S41 AB severe poisoning S40 MW Poisoning S39 AB (intracranial hemorrhage or subarachnoid hemorrhage or cerebral hemorrhage or intracranial bleeding or life‐threatening bleeding) S38 MW Intracranial Hemorrhage S37 AB (sepsis or septic shock) S36 MW Shock, Septic S35 MW Sepsis S34 AB stroke S33 MW Stroke S32 AB (traumatic brain injury or TBI or head trauma or craniocerebral trauma) S31 AB (severe trauma or multiple trauma) S30 MW Multiple Trauma S29 AB (pulmonary embolism or pulmonary infarct*) S28 MW Pulmonary Embolism S27 AB (adult respiratory distress syndrome or ARDS) S26 MW Respiratory Distress Syndrome S25 AB acute lung injury S24 MW Acute Lung Injury S23 MW (COPD or chronic obstructive pulmonary disease) S22 MW Pulmonary Disease, Chronic Obstructive S21 AB pneumonia S20 MW Pneumonia S19 AB meningitis S18 MW Meningitis S17 AB shock S16 MW Shock S15 AB (cardiac arrest or cardiac failure or CPR or heart arrest or heart failure or myocardial infarct* or myocardial ischemia or acute coronary syndrome) S14 MW Myocardial Ischemia S13 MW heart arrest S12 AB (emergency department*) or (ED) or (emergency room*) or (ER) or (high dependency unit*) or (HDU) or (prehospital*) or (critically ill) or (acutely ill) or (intensive care) or (critical care) or (ICU*) or (coronary care unit) or (neurological intermediate care unit) S11 MW emergency medicine S10 MW intensive care units S9 MW critical care S8 MW critical illness S7 (S1 OR S2 OR S3 OR S4 OR S5 OR S6) S6 AB (hyperoxia) or (hyperoxemia) or (hyperoxaemia) or (hypoxia) or (hypoxemia) or (hypoxaemia) or (anoxia) or (anoxemia) or (anoxaemia) or (arterial oxygen) or (high oxygen) or (oxygenat*) or (blood gas) or (oxygen saturation) or (pao2) or (sao2) or (spo2) or (fio2) S5 AB ( ((inspir*) or (inhal*) or (fraction*) or (concentrat*) or (arterial*) or (saturation) or (level*) or (tension*) or (supply*) or (supplement*) or (supplie*) or (therap*) or (administr*) or (dosag*) or (dose*) or (dosing*)) ) AND AB (oxygen) S4 MW oxygen S3 MW oxygen therapy S2 MW anoxia S1 MW hyperoxia
Appendix 7. LILACS search strategy
(tw:((hyperoxia OR hyperoxemia OR hyperoxaemia OR hypoxia OR hypoxemia OR hypoxaemia OR anoxia OR anoxemia OR anoxaemia OR oxygenation OR oxygen OR pao2 OR sao2 OR spo2 OR fio2))) AND (tw:((acute surgery OR acute operation OR acute resection OR emergency surgery OR emergency operation OR emergency resection) OR (intestinal perforation OR appendicitis) OR (acute kidney failure OR acute renal injuries) OR (acute hepatic failure OR fulminating hepatic failure) OR (diabetic ketoacidosis) OR (severe poisoning) OR (intracranial hemorrhage OR subarachnoid hemorrhage OR cerebral hemorrhage OR intracranial bleeding OR life‐threatening bleeding) OR (sepsis OR septic shock) OR (stroke) OR (traumatic brain injury OR tbi OR head trauma OR craniocerebral trauma) OR (severe trauma OR multiple trauma) OR (pulmonary embolism OR pulmonary infarction) OR (adult respiratory distress syndrome OR ards) OR (acute lung injury) OR (copd OR chronic obstructive pulmonary disease) OR (pneumonia) OR (meningitis) OR (shock) OR (cardiac arrest OR cardiac failure OR cpr OR heart arrest OR heart failure OR myocardial infarction OR myocardial ischemia OR acute coronary syndrome) OR (emergency department OR ed OR emergency room OR er OR high dependency unit OR hdu OR prehospital OR critically ill OR acutely ill OR intensive care OR critical care OR icu OR coronary care unit OR neurological intermediate care unit) )) AND (tw:((randomized OR randomised OR random OR randomly OR controlled OR rct OR placebo OR group OR trial))) AND (instance:"regional") AND ( db:("LILACS"))
Appendix 8. Data collection form
TRIAL IDENTIFICATION | ||
Author and year | ||
Publication type | Lead trial: |
Secondary publ.: Name of primary publication of the same trial |
STUDY ELIGIBILITY | |||||||||||
RCT | Relevant participants | Relevant intervention | Relevant outcomes | ||||||||
Yes | No | Unclear | Yes | No | Unclear | Yes | No | Unclear | Yes | No* | Unclear |
*Issue relates to selective reporting when study authors may have taken measurements for particular outcomes but did not report these within the paper(s). Review authors should contact trialists for information on possible non‐reported outcomes and reasons for exclusion from publication. Study should be listed in 'Studies awaiting assessment' until clarified. If no clarification is received after three attempts, study should be excluded.
DO NOT PROCEED IF ANY OF THE ABOVE ANSWERS IS 'NO'
Include |
Exclude Record reason for exclusion, which is to be inserted into the 'Table of excluded studies' |
PARTICIPANTS | |
Eligibility | How was participant eligibility defined? |
Age (mean, median, range, etc.) | |
Sex of participants (numbers/%, etc.) | |
Disease status/type, etc. (if applicable) | |
Notes |
INTERVENTIONS | |
Experimental intervention | Describe experimental intervention (incl. oxygenation target, oxygen administration system, duration) |
Control intervention | Describe control intervention (incl. oxygenation target, oxygen administration system, duration) |
Co‐interventions (any intervention given equally in both interventions) |
Specify any other co‐interventions |
OTHER TRIAL INFORMATION | |
Aim of trial | |
Country/Countries | |
Trial design (parallel/cross‐over) |
|
Trial duration (intervention and follow‐up) |
Weeks, months, years, not stated |
The trial included only participants admitted to ICU? | |
Which targets did the participants actually achieve? | |
Withdrawals | Were these described? |
Study funding source (Incl. role of funders) |
|
Possible conflicts of interest (for study authors) |
|
Other | |
Notes |
RISK OF BIAS ASSESSMENT
L: low risk of bias, U: unclear risk of bias, H: high risk of bias
Random sequence generation | |
Low risk: if sequence generation is achieved using computer, random number generator or a random numbers table. Drawing lots, tossing a coin, shuffling cards and throwing dice are also adequate if performed by an independent adjudicator. Unclear risk: if the method of randomization is not specified. High risk: if the allocation sequence is not random. |
Grade L / U / H |
Support for judgement |
Allocation sequence concealment* | |
Low risk: if the allocation of participants is performed by a central independent unit, on‐site locked computer, identically looking numbered sealed opaque envelopes, drug bottles or containers prepared by an independent investigator. There must be no risk of the investigator knowing the sequence. Unclear risk: if the trial is classified as randomized but the allocation concealment process is not described. High risk: if the allocation sequence is known to the investigators who assigned participants. |
Grade L / U / H |
Support for judgement |
*Process used to prevent foreknowledge of group assignment in a RCT, which should be seen as distinct from blinding
Blinding of participants and personnel | |
Person responsible for participant care | Yes / No |
Participant | Yes / No |
Outcome assessor | Yes / No |
Other (please specify) | Yes / No |
Low risk: if the participants and the personnel are blinded to treatment allocation and this is described. Unclear risk: if the procedure of blinding is insufficiently described or not described at all. High risk: if blinding of participants and personnel is not performed. |
Grade L / U / H |
Support for judgement |
Blinding of outcome assessment | |
Low risk: if the trial investigators performing the outcome assessments, analyses and calculations are blinded to the intervention. Unclear risk: if the procedure of blinding is insufficiently described or not described at all. High risk: if blinding of outcome assessment is not performed. |
Grade L / U / H |
Support for judgement |
Incomplete outcome data | |
Low risk: there are no dropouts or withdrawals for all outcomes, or the numbers and reasons for the withdrawals and dropouts for all outcomes are clearly stated and can be described as being similar in both groups. As a general rule the trial is judged as at a low risk of bias due to incomplete outcome data if the number of dropouts is less than 5%. However, the 5% cut‐off is not definitive. Unclear risk: the numbers and reasons for withdrawals and dropouts are not clearly stated. High risk: the pattern of dropouts can be described as being different in the two intervention groups or the trial uses improper methodology in dealing with the missing data, e.g. last observation carried forward. |
Grade L / U / H |
Support for judgement |
Selective outcome reporting | |
Low risk: a protocol is published before or at the time the trial is begun and the outcome called for in the protocol is reported on. Unclear risk: if there is no protocol and the outcome is not reported on. High risk: if the outcomes which are called on in a protocol are not reported on. |
Grade L / U / H |
Support for judgement |
Baseline imbalance | |
Low risk: no baseline imbalance in important characteristics was noted. Unclear risk: baseline characteristics were not reported. High risk: baseline imbalance was due to chance or was due to imbalanced exclusion after randomization. |
Grade L / U / H |
Support for judgement |
Early stopping | |
Low risk: sample size calculation was reported and the trial was not stopped, or if the trial was stopped early by formal stopping rules at a point at which the likelihood of observing an extreme intervention effect due to chance was low. Unclear risk: sample size calculation was not reported, and if it is not clear whether or not the trial was stopped early. High risk: the trial was stopped early because of informal stopping rules, or if the trial was stopped early by a formal stopping rule at a point at which the likelihood of observing an extreme intervention effect due to chance was high. |
Grade L / U / H |
Support for judgement |
Other bias risk | |
Low risk: the trial appears to be free of other components (e.g. academic bias or for‐profit bias) that could put it at risk of bias. Unclear risk: the trial may or may not be free of other components that could put it at risk of bias. High risk: there are other factors in the trial that could put it at risk of bias (e.g. authors have conducted trials on the same topic, for‐profit bias, etc.) |
Grade L / U / H |
Support for judgement |
Overall risk of bias | |
Low risk: each outcome result will be classified as overall 'low risk of bias' only if all of the bias domains described in the above paragraphs are classified as low risk of bias. High risk: the outcome result will be classified 'high risk of bias' if any of the bias risk domains described in the above are classified as 'unclear' or 'high risk of bias'. In addition, if one or more of the bias domains described in the above paragraphs are classified as 'unclear' or at 'high risk of bias'. |
Grade L / H |
Support for judgement |
OUTCOMES
PRIMARY OUTCOMES | Available for the trial |
All‐cause mortality | Yes / No |
Number of participants with one or more serious adverse events (dichotomous outcome) | Yes / No |
Quality of life | Yes / No |
*We used the International Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice's definition of a serious adverse event (ICH‐GCP 1997), that is, any untoward medical occurrence that results in death, is life‐threatening, requires hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability or incapacity. We will consider all other adverse events as non‐serious.
SECONDARY OUTCOMES | Available for the trial |
Lung injury* | Yes / No |
Acute myocardial infarction** | Yes / No |
Stroke** | Yes / No |
Severe sepsis** | Yes / No |
* Diagnosed after randomization (composite outcome) defined as either ARDS, lung fibrosis, or pulmonary embolism. ** Diagnosed after randomization.
OTHER OUTCOMES OF THE TRIAL | |
Additional outcomes | List additional reported outcomes |
SUBGROUPS | |
Overall risk of bias | High risk of bias Low or uncertain risk of bias |
According to ICU population | Medical Surgical |
According to different definitions of oxygen target | Oxygen level measured using FiO2 Oxygen level measured using PaO2 Oxygen level measured using SaO2 or SpO2 Oxygen level measured using PaO2 or SaO2 or SpO2 |
According to oxygen delivery system | Invasive mechanical ventilation with endotracheal tube Any non‐invasive oxygen administration |
OUTCOMES | |||||||
Follow‐up periods | List all follow‐up periods given in report | ||||||
Total no. of randomized participants | Participants in experimental group | Participants in control group | |||||
Primary outcomes | |||||||
(dichotomous 'end point' outcome) | Participants analysed | Number of events in the groups: E = experimental C = control |
Bias of the outcome | ||||
All‐cause mortality | Maximum follow‐up | E (n) | E (n) | L / U / H | |||
C (n) | C (n) | ||||||
End of trial intervention period | E (n) | E (n) | L / U / H | ||||
C (n) | C (n) | ||||||
Serious adverse events: Nb. Number of counts. If SAE is reported, list them individually |
Maximum follow‐up | E (n) | E (n) | L / U / H | |||
C (n) | C (n) | ||||||
End of trial intervention period | E (n) | E (n) | L / U / H | ||||
C (n) | C (n) | ||||||
(continuous outcome) | Participants analysed | Mean (endpoint or change) |
SD | Bias of the outcome | |||
Quality of life: Type of QoL scale: |
Maximum follow‐up | E (n) | E | E | L / U / H | ||
C (n) | C | C | L / U / H | ||||
End of trial intervention period | E (n) | E | E | L / U / H | |||
C (n) | C | C | L / U / H |
Secondary outcomes | ||||
(dichotomous outcome) | Participants analysed | Number of events in the groups: E = experimental C = control |
Bias of the outcome | |
Lung injury | Maximum follow‐up | E (n) | E (n) | L / U / H |
C (n) | C (n) | |||
End of trial intervention period | E (n) | E (n) | L / U / H | |
C (n) | C (n) | |||
Acute myocardial infarction | Maximum follow‐up | E (n) | E (n) | L / U / H |
C (n) | C (n) | |||
End of trial intervention period | E (n) | E (n) | L / U / H | |
C (n) | C (n) | |||
Stroke | Maximum follow‐up | E (n) | E (n) | L / U / H |
C (n) | C (n) | |||
End of trial intervention period | E (n) | E (n) | L / U / H | |
C (n) | C (n) | |||
Severe sepsis | Maximum follow‐up | E (n) | E (n) | L / U / H |
C (n) | C (n) | |||
End of trial intervention period | E (n) | E (n) | L / U / H | |
C (n) | C (n) |
OTHER INFORMATION
Key conclusion of study authors as stated in paper |
Information relevant to the results |
Indicate if any data were obtained from the primary author; if results were estimated from graphs, etc. or were calculated by you using a formula (should be stated and the formula given). In general, if results not reported in paper(s) are not obtained, this should be made clear here to be cited in the review. |
Appendix 9. Criteria for 'Risk of bias' evaluation
Random sequence generation
Low risk: if sequence generation is achieved using computer, random number generator, or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are also adequate if performed by an independent adjudicator.
Unclear risk: if the method of randomization is not specified.
High risk: if the allocation sequence is not random.
Allocation sequence concealment
Low risk: if the allocation of participants is performed by a central, independent unit; on‐site locked computer; identically appearing, numbered, sealed, opaque envelopes; or drug bottles or containers prepared by an independent investigator. There must be no risk of the investigator knowing the sequence.
Unclear risk: if the trial is classified as randomized but the allocation concealment process is not described.
High risk: if the allocation sequence is known to the investigators who assigned participants.
Blinding of participants and personnel
Low risk: if the participants and personnel are blinded to treatment allocation and this is described.
Unclear risk: if the description of the blinding procedure is insufficient or absent.
High risk: if blinding of participants and personnel is not performed.
Blinding of outcome assessment
Low risk: if the trial investigators performing the outcome assessments, analyses, and calculations are blinded to the intervention.
Unclear risk: if the description of the blinding procedure is insufficient or absent.
High risk: if blinding of outcome assessment is not performed.
Incomplete outcome data
Low risk: there are no dropouts or withdrawals for all outcomes, or the numbers and reasons for withdrawals and dropouts for all outcomes are clearly stated and are described as being similar in both groups. As a general rule, a judgement of low risk of bias is made if the number of dropouts is less than 5%; however, the 5% cut‐off is not definitive.
Unclear risk: the numbers and reasons for withdrawals and dropouts are not clearly stated.
High risk: the pattern of dropouts is described as being different in the two intervention groups, or the trial uses improper methodology in dealing with the missing data, e.g. last observation carried forward.
Selective outcome reporting
Low risk: a protocol is published before or at the time the trial is begun, and the outcome called for in the protocol is reported on.
Unclear risk: if there is no protocol and the outcome is not reported on.
High risk: if the outcomes called for in the protocol are not reported on.
Other bias
Low risk: the trial appears to be free of other issues (e.g. academic bias or for‐profit bias) that could put it at risk of bias.
Unclear risk: the trial may or may not be free of other components that could put it at risk of bias.
High risk: there are other factors in the trial that could put it at risk of bias (e.g. authors have conducted trials on the same topic, for‐profit bias, etc.).
Overall risk of bias
Low risk: the trial will be classified as overall 'low risk of bias' only if all of the 'Risk of bias' domains described above are classified as low risk of bias.
High risk: the trial will be classified as overall 'high risk of bias' if any of the 'Risk of bias' domains described above are classified as 'unclear' or 'high risk of bias'.
Data and analyses
Comparison 1. All‐cause mortality ‐ at time point closest to 3 months follow‐up.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 All‐cause mortality ‐ at time point closest to 3 months | 4 | 1135 | Risk Ratio (M‐H, Random, 95% CI) | 1.18 [1.01, 1.37] |
2 Sensitivity analysis: all‐cause mortality ‐ at time point closest to 3 months ‐ high vs high and low vs low targets excluded | 2 | 537 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.92, 1.35] |
3 Sensitivity analysis: all‐cause mortality ‐ at time point closest to 3 months ‐ best‐worst‐case scenario | 4 | 1149 | Risk Ratio (M‐H, Random, 95% CI) | 1.13 [0.97, 1.31] |
3.1 All‐cause mortality | 4 | 1149 | Risk Ratio (M‐H, Random, 95% CI) | 1.13 [0.97, 1.31] |
4 Sensitivity analysis: all‐cause mortality ‐ at time point closest to 3 months ‐ worst‐best‐case scenario | 4 | 1149 | Risk Ratio (M‐H, Random, 95% CI) | 1.21 [1.04, 1.41] |
4.1 All‐cause mortality | 4 | 1149 | Risk Ratio (M‐H, Random, 95% CI) | 1.21 [1.04, 1.41] |
5 All‐cause mortality ‐ at time point closest to 3 months ‐ types of oxygen interventions | 4 | 1135 | Risk Ratio (M‐H, Random, 95% CI) | 1.18 [1.01, 1.37] |
5.1 PaO2 (SaO2 or SpO2) | 3 | 701 | Risk Ratio (M‐H, Random, 95% CI) | 1.20 [0.96, 1.50] |
5.2 Difference between groups | 1 | 434 | Risk Ratio (M‐H, Random, 95% CI) | 1.16 [0.94, 1.43] |
6 All‐cause mortality ‐ at time point closest to 3 months ‐ level of FiO2/target in higher group | 4 | 1135 | Risk Ratio (M‐H, Random, 95% CI) | 1.18 [1.01, 1.37] |
6.1 Higher | 4 | 1135 | Risk Ratio (M‐H, Random, 95% CI) | 1.18 [1.01, 1.37] |
7 All‐cause mortality ‐ at time point closest to 3 months ‐ level of FiO2/target in lower group | 4 | 1135 | Risk Ratio (M‐H, Random, 95% CI) | 1.18 [1.01, 1.37] |
7.1 Lower | 2 | 537 | Risk Ratio (M‐H, Random, 95% CI) | 1.12 [0.92, 1.35] |
7.2 Higher | 2 | 598 | Risk Ratio (M‐H, Random, 95% CI) | 1.29 [1.00, 1.66] |
8 All‐cause mortality ‐ at time point closest to 3 months ‐ ICU population | 4 | 1135 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.19 [1.02, 1.38] |
8.1 Mixed ICU | 3 | 1015 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.19 [1.01, 1.40] |
8.2 Any cerebral disease | 1 | 120 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.15 [0.68, 1.95] |
9 Mortality ‐ at time point closest to 3 months ‐ oxygen delivery system | 4 | 1135 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.19 [1.02, 1.38] |
9.1 Invasive mechanical ventilation | 3 | 657 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.12 [0.93, 1.34] |
9.2 Mixed | 1 | 478 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.33 [1.00, 1.78] |
Comparison 2. Sensitivity analysis: all‐cause mortality ‐ at maximum follow‐up.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 All‐cause mortality ‐ at maximum follow‐up | 7 | 1285 | Risk Ratio (M‐H, Random, 95% CI) | 1.16 [1.00, 1.35] |
1.1 All‐cause mortality | 7 | 1285 | Risk Ratio (M‐H, Random, 95% CI) | 1.16 [1.00, 1.35] |
2 Sensitivity analysis: all‐cause mortality ‐ at maximum follow‐up ‐ high vs high and low vs low excluded | 2 | 537 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.92, 1.35] |
3 Sensitivity analysis: all‐cause mortality ‐ at maximum follow‐up ‐ best‐worst‐case scenario | 7 | 1306 | Risk Ratio (M‐H, Random, 95% CI) | 1.11 [0.96, 1.28] |
3.1 All‐cause mortality | 7 | 1306 | Risk Ratio (M‐H, Random, 95% CI) | 1.11 [0.96, 1.28] |
4 Sensitivity analysis: all‐cause mortality ‐ at maximum follow‐up ‐ worst‐best‐case scenario | 7 | 1306 | Risk Ratio (M‐H, Random, 95% CI) | 1.21 [1.05, 1.41] |
4.1 All‐cause mortality | 7 | 1306 | Risk Ratio (M‐H, Random, 95% CI) | 1.21 [1.05, 1.41] |
5 All‐cause mortality ‐ at maximum follow‐up ‐ types of oxygen interventions | 7 | 1285 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.17 [1.00, 1.36] |
5.1 PaO2 (SaO2 or SpO2) | 4 | 735 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.20 [0.96, 1.50] |
5.2 FiO2 | 2 | 116 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.00 [0.50, 1.98] |
5.3 Difference between groups | 1 | 434 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.16 [0.94, 1.43] |
6 All‐cause mortality ‐ at maximum follow‐up ‐ level of FiO2/target in higher group | 7 | 1285 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.17 [1.00, 1.36] |
6.1 Lower | 2 | 85 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.37, 3.81] |
6.2 Higher | 5 | 1200 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.17 [1.00, 1.36] |
7 All‐cause mortality ‐ at maximum follow‐up ‐ level of FiO2/target in lower group | 7 | 1285 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.17 [1.00, 1.36] |
7.1 Lower | 4 | 622 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.11 [0.92, 1.35] |
7.2 Higher | 3 | 663 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.24 [0.97, 1.57] |
8 All‐cause mortality ‐ at maximum follow‐up ‐ ICU population | 7 | 1350 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.15 [0.99, 1.33] |
8.1 Mixed ICU | 3 | 1015 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.19 [1.01, 1.40] |
8.2 Medical ICU | 1 | 34 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.33 [0.01, 7.65] |
8.3 Any trauma | 1 | 65 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.80 [0.35, 1.81] |
8.4 Any cerebral disease | 3 | 236 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.09 [0.71, 1.65] |
9 Mortality ‐ at maximum follow‐up ‐ oxygen delivery system | 7 | 1285 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.17 [1.00, 1.36] |
9.1 Invasive mechanical ventilation | 4 | 722 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.10 [0.92, 1.31] |
9.2 Any non‐invasive oxygen administration | 2 | 85 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.18 [0.37, 3.81] |
9.3 Mixed | 1 | 478 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.33 [1.00, 1.78] |
Comparison 3. Serious adverse events ‐ at time point closest to 3 months.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Serious adverse events ‐ at time point closest to three months ‐ highest proportion | 6 | 1234 | Risk Ratio (M‐H, Random, 95% CI) | 1.13 [1.04, 1.23] |
2 Serious adverse events ‐ at time point closest to three months ‐ cumulated | 6 | 1234 | Risk Ratio (M‐H, Random, 95% CI) | 1.08 [0.99, 1.18] |
Comparison 4. Sensitivity analysis: serious adverse events ‐ at maximum follow‐up.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Serious adverse events ‐ at maximum follow‐up ‐ highest proportion | 7 | 1285 | Risk Ratio (M‐H, Random, 95% CI) | 1.13 [1.04, 1.23] |
2 Serious adverse events ‐ at maximum follow‐up ‐ cumulated | 7 | 1285 | Risk Ratio (M‐H, Random, 95% CI) | 1.07 [0.97, 1.18] |
Comparison 5. Lung injury ‐ at time point closest to 3 months.
Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
---|---|---|---|---|
1 Lung injury ‐ at time point closest to three months ‐ highest proportion | 5 | 1167 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.78, 1.36] |
2 Lung injury ‐ at time point closest to three months ‐ cumulated | 5 | 1167 | Risk Ratio (M‐H, Fixed, 95% CI) | 0.99 [0.75, 1.30] |
3 Lung injury ‐ at time point closest to three months ‐ ARDS | 3 | 288 | Risk Ratio (M‐H, Random, 95% CI) | 0.79 [0.28, 2.20] |
4 Lung injury ‐ at time point closest to three months ‐ pneumonia | 3 | 944 | Risk Ratio (M‐H, Fixed, 95% CI) | 1.03 [0.76, 1.40] |
Characteristics of studies
Characteristics of included studies [ordered by study ID]
Asfar 2017.
Methods | RCT 2‐by‐2 factorial trial randomizing to 4 groups. 2 groups were included in our analysis. |
|
Participants |
Sample size: 442 randomized (219 experimental, 223 control) Sex (male): experimental 63%, control 65% Age (mean): experimental 67.8, control 66.3 Country: France Setting: multidisciplinary ICU Disease severity score: SAPS III median 71 Inclusion criteria
Septic shock was defined by the presence of 2 or more diagnostic criteria of systemic inflammatory response syndrome, proven or suspected infection, and sudden dysfunction of at least 1 organ. Exclusion criteria
|
|
Interventions |
Experimental: hyperoxia group (mechanical ventilation with FiO2 of 1.0 for 24 hours after inclusion; thereafter FiO2 as in the normoxia group). Categorized by us as using a high target in the experimental group. Control: target SaO2 of 88% to 95% using mechanical ventilation Co‐intervention: not specified Duration: 24 hours |
|
Outcomes |
Primary outcome
Secondary outcomes
Outcomes not prespecified
|
|
Notes | Email sent to Dr Asfar 5 December 2018 and reply was received. The trial was funded by public grants (the French ministry of health). |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Computer‐generated randomization list stratified by site and presence or absence of ARDS using permuted blocks of random sizes (nQuery Advisor 6.0) |
Allocation concealment (selection bias) | Low risk | The pharmacists assigned a random number to each therapeutic package. The attribution of a given therapeutic package to a participant in accordance to the randomization list was done with a web‐based secured randomization system (Clinsight software). |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Unblinded |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Unblinded |
Incomplete outcome data (attrition bias) All outcomes | Low risk | 2.7% in the experimental group and 0.9% in the control were excluded from analysis. |
Selective reporting (reporting bias) | Low risk | The trial was registered prior to randomisation (NCT01722422), and all prespecified outcomes were reported on. |
Other bias | High risk | Early stopping bias: the trial was stopped after a pre‐planned interim analysis, criteria for stopping not specified |
Girardis 2016.
Methods | RCT | |
Participants |
Sample size: 480 (experimental 244, control 236) Sex (male %): experimental 57%, control 56% Age (median): experimental 65, control 63 Country: Italy Setting: multidisciplinary ICU Disease severity score: SAPS II score median 38 Inclusion criteria
Exclusion criteria
|
|
Interventions |
Experimental: oxygen therapy was administered according to standard ICU practice; FiO2 of at least 0.4, allowing PaO2 values up to 150 mmHg and an SpO2 between 97% and 100%. If the SpO2 decreased below 95% to 97%, the FiO2 was increased to reach the target value of SpO2. Participants received FiO2 of 1.0 during intubation, airway suction, or hospital transfer. Categorized by us as using a high target in the experimental group. Control: oxygen therapy was administered at the lowest possible FiO2 to maintain the PaO2 between 70 and 100 mmHg or SpO2 values between 94% and 98%. FiO2 was gradually reduced or oxygen supplementation discontinued whenever the PaO2 or SpO2 exceeded 100 mmHg or 98%. Supplemental oxygen was administered only if SpO2 decreased below 94%. Categorized by us as using a high target in the control group. Co‐intervention: not specified Duration: until ICU discharge |
|
Outcomes |
Secondary outcomes not prespecified
|
|
Notes | Email sent 6 December 2018 to Dr Girardis and reply was received. The trial was funded by public grants. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Computer‐generated random numbers |
Allocation concealment (selection bias) | Low risk | The randomization sequence was concealed from the researchers by use of sequentially numbered, closed, opaque envelopes that were opened after patient study inclusion. |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Open‐label |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Not described; however, blinding of outcome assessment was clarified by email |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Results from intention‐to‐treat analyses are provided in the supplementary. 2 participants withdrew consent, randomization groups for these 2 participants were not reported, thus they could not be included in the sensitivity analysis on losses to follow‐up. Outcome respiratory failure: 18 in experimental and 15 in control group were lost to follow‐up |
Selective reporting (reporting bias) | High risk | The trial was registered retrospectively (NCT01319643) |
Other bias | High risk | Early stopping bias: the trial was stopped after an interim analysis that was not pre‐planned |
Gomersall 2002.
Methods | RCT | |
Participants |
Sample size: 36 (experimental 19, control 17) Sex (male %): experimental 82%, control 76% Age (mean): experimental 68, control 69 Country: Hong Kong Setting: multidisciplinary ICU Disease severity score: not reported Inclusion criteria
Exclusion criteria
|
|
Interventions | Oxygen therapy was provided via a Venturi‐type mask and adjusted according to the results of arterial blood samples with the aim of reaching the desired target oxygen tension within 1 hour of trial entry. Experimental: target PaO2 above 9.0 kPa (70 mmHg) (categorized by us as using a low target in the experimental group) Control: target PaO2 of > 6.6 kPa (50 mmHg) (categorized by us as using a low target in the control group) Co‐intervention: participants in the low‐oxygen tension group also received doxapram if they developed an acidosis with pH < 7.2, whereas those in the high‐oxygen tension group received doxapram if they developed symptomatic acidosis. Bronchodilator, steroid, and antibiotic therapy was standardized. Duration: treatment protocols, including oxygen therapy, were continued after discharge from the ICU until oxygen therapy was no longer considered necessary |
|
Outcomes |
|
|
Notes | Email sent to Dr Gomersall 6 December 2018 but no reply was received. The trial was funded by public grants. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Computer‐generated numbers |
Allocation concealment (selection bias) | Low risk | Unmarked, sealed envelopes |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Only participants were blinded. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | High risk | 2/19 (11%) of participants in the experimental group were excluded from analysis due to protocol violation. |
Selective reporting (reporting bias) | Unclear risk | No protocol could be found. |
Other bias | High risk | Doxapram co‐intervention differed between groups. |
Ishii 2018.
Methods | RCT | |
Participants |
Sample size: 44 (experimental 21, control 23) Sex: not specified Age: not specified Country: Japen Setting: surgical ICU Disease severity score: not reported Inclusion criteria: mechanically ventilated patients admitted to surgical ICU for more than 12 hours Exclusion criteria: not specified |
|
Interventions |
Experimental: FiO2 of 1.0 using high‐flow nasal cannula. Categorized by us as using a high target in the experimental group Control: expected FiO2 to achieve a PaO2 of 100 mmHg (13.3 kPa) using high‐flow nasal cannula The interventions are 'non‐invasive', as they are initiated after extubation (of the mechanical ventilated), whereas after oxygen they are administered via high‐flow nasal cannula. Categorized by us as using a low target in the control group Co‐intervention: not specified Duration: 1 hour |
|
Outcomes |
|
|
Notes | Email sent 6 December 2018 to Dr Ishii but no reply was received. It was unclear how the trial was funded. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | It was stated that the trial was randomized, but method of sequence generation not described. |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | The trial was described as double‐blinded, but it was unclear who was blinded and how blinding was maintained. |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Radiologist was blinded. |
Incomplete outcome data (attrition bias) All outcomes | High risk | 14% were lost to follow‐up; randomization groups were not reported. |
Selective reporting (reporting bias) | Unclear risk | No protocol could be found. |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
Jakkula 2018.
Methods | RCT with a 2‐by‐3 factorial design. We only extracted data from the normoxia and moderate‐hyperoxia groups. | |
Participants |
Sample size: 123 (experimental 60, control 63) Sex (male %): experimental 48%, control 50% Age: experimental 60, control 59 Country: Finland Setting: adults admitted to the ICU after OHCA Disease severity score: APACHE II score median 28 Inclusion criteria
Exclusion criteria
|
|
Interventions |
Experimental: target PaO2of 20 to 25 kPa (150 to 187.5 mmHg). Categorized by us as using a high target in the experimental group Control: target PaO2 of 10 to 15 kPa (75 to 112.5 mmHg) or target SpO2 of 95% to 98%. Categorized by us as using a high target in the control group Co‐intervention: all adults received TTM at 33 °C or 36 °C and were sedated according to the treating clinicians’ instructions. All adults received standard care, monitoring and assessments based on the protocol of the ICU, including direct blood pressure monitoring via an arterial catheter. Duration: 36 hours |
|
Outcomes |
Primary outcome
Secondary outcomes
Feasibility outcomes
|
|
Notes | Email sent 6 December 2018 to Dr Jakkula but no reply was received. The trial was funded by public and private funds. The funding bodies had no input regarding the design, management, or reporting of the trial. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Computer‐generated random numbers |
Allocation concealment (selection bias) | Low risk | Web‐based system |
Blinding of participants and personnel (performance bias) All outcomes | High risk | The treating personnel were not blinded to treatment targets. |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | The neurophysiologist analysing the EEG results and the neurologist evaluating the neurologic recovery of the participants were blinded to the study group allocations. |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Less than 5% were lost to follow‐up. |
Selective reporting (reporting bias) | Low risk | The trial was registered prior to randomization (NCT02698917). |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
Lång 2018.
Methods | RCT | |
Participants |
Sample size: 65 (experimental 38, control 27) Sex (male): experimental 82%, control 85% Age: experimental 45, control 43 Country: Finland Setting: mechanically ventilated adults with traumatic brain disease admitted to the ICU Disease severity score: APACHE II score median 22 Inclusion criteria
Exclusion criteria
|
|
Interventions |
Experimental: FiO2 of 0.70. Categorized by us as using a high target in the experimental group Control: FiO2 of 0.40. Categorized by us as using a low target in the control group Co‐intervention: not specified Duration: maximum 14 days |
|
Outcomes |
|
|
Notes | Email sent 6 December 2018 to Dr Lång and a reply was received. It was unclear how the trial was funded. According to protocol, the trial was supported by Kuopio University Hospital. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Stated that the trial was randomized, but the method of sequence generation was not described |
Allocation concealment (selection bias) | Low risk | Sealed, opaque envelopes |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Open‐label |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Only the neurologist assessing the neurological outcomes was blinded. |
Incomplete outcome data (attrition bias) All outcomes | High risk | 8% were lost to follow‐up, and allocation groups were not specified in the publication. The number of participants lost to follow‐up in each group was clarified by email. |
Selective reporting (reporting bias) | Low risk | The trial was registered prior to randomization (NCT01201291), however quality of life is not reported; however trial authors are planning to publish these results. |
Other bias | High risk | Unplanned trial stop |
Mazdeh 2015.
Methods | RCT | |
Participants |
Sample size: 51 (experimental 26, control 25) Sex (male %): experimental 54%, control 56% Age: not specified Country: Iran Setting: adults with stroke initially referred to the Department of Neurology, but admitted to the ICU Disease severity score: not reported Inclusion criteria
Quote: "Participants were selected from adults referred to the Department of Neurology of Farshchian Hospital, an affiliated hospital of Hamadan University of Medical Sciences. The participants were admitted to the ICU and monitored by nurses." Due to participants being transferred from the Department of Neurology to the ICU to be monitored, we do not regard these adults as typical adults admitted to the ICU. Exclusion criteria
|
|
Interventions |
Experimental: FiO2 of 0.5 ‐ oxygen therapy with Venturi mask (categorized by us as using a low target in the experimental group) Control: no supplemental oxygen was administered (categorized by us as using a low target in the control group) Co‐intervention: routine medication (as stated in protocol) Duration: oxygen administration was given in the first 12 hours of admission |
|
Outcomes |
|
|
Notes | Email sent 6 December 2018 to Dr Seifirad, who forwarded the email on to Dr Mazdeh, however no reply was received. The trial was funded by a public hospital (Vice Chancellor of Research and Technology, Hamadan Medical University). Overall poor reporting quality. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Stated that the trial was randomized, but the method of sequence generation was not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Unblinded |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | High risk | 1 out of 52 (2%) randomized participants was lost to follow‐up, and this was not described in the manuscript. It is not stated to which group this person was allocated. Participants in the control group for whom oxygen therapy was inevitable were excluded. |
Selective reporting (reporting bias) | High risk | We judged the trial to be registered retrospectively (IRCT201212199647N2). It was registered 3 November 2013 and submitted to journal 30 December 2013. |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
Panwar 2016.
Methods | RCT | |
Participants |
Sample size: 104 (experimental 51, control 53 (1 lost to follow‐up)) Sex (male %): experimental 65%, control 62% Age: experimental 62, control 62 Country: Australia, New Zealand, and France Setting: mechanically ventilated adults admitted to a multidisciplinary ICU Disease severity score: APACHE III score median 80 (control) and 70 (experimental) Inclusion criteria
The reason for the inclusion criterion of receiving invasive MV for < 24 hours was to ensure that participants who would be assigned to the conservative oxygen group were not exposed to standard liberal oxygen therapy for prolonged periods prior to randomization. Exclusion criteria
The exclusion criterion "lacked equipoise‟ included those clinical situations where the most appropriate approach (conservative versus liberal) to oxygen therapy is well established. For example, in hypercapnic patients with chronic respiratory failure or exacerbation of COPD, there is level I evidence supporting a conservative approach to oxygen therapy (1), and in patients with carbon monoxide poisoning or necrotizing fasciitis a liberal approach is preferred. However, amongst patients who had COPD listed as 1 of the prior comorbid conditions, the treating clinicians could permit enrolment of those adults who were admitted for reasons unrelated to COPD. |
|
Interventions |
Experimental: SpO2 target ≥ 96%. Categorized by us as using a high target in the experimental group Control: target SpO2 of 88% to 92%. When FiO2 requirement was < 0.50, an SpO2 of 90% to 92% was recommended, and when FiO2 requirement was ≥ 0.50, an SpO2 of 88% to 90% was recommended. Categorized by us as using a low target in the control group Co‐intervention: participating sites were requested to adhere to best practice guidelines in relation to other potentially confounding co‐interventions such as adjustment of tidal volume, PEEP, fluid management, blood transfusion, muscle relaxation, sedation interruption, ventilator weaning, nutrition, use of steroids, early mobilization, and physiotherapy. Duration: entire duration of mechanical ventilation |
|
Outcomes |
Primary outcomes
Secondary outcomes
|
|
Notes | Email sent to Dr Panwar 5 December 2018. Reminder sent 10 December 2018; reply was received. The trial was supported by public grants. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Computer‐generated randomization list |
Allocation concealment (selection bias) | Low risk | Opaque, sealed envelopes |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Participants were unaware of their assigned group, but blinding of treating clinicians was not considered feasible. |
Blinding of outcome assessment (detection bias) All outcomes | High risk | Not described; however, Dr Panwar clarified in an email that outcome assessment was not blinded |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Only 1 (1/104) participant was lost to follow‐up. |
Selective reporting (reporting bias) | Low risk | A study protocol was registered prior to randomization (ACTRN12613000505707), and all outcomes were reported on. |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
Taher 2016.
Methods | RCT | |
Participants |
Sample size: 68 (experimental 34, control 34) Sex (male %): experimental 74%, control 68% Age: experimental 40, control 46 Country: Iran Setting: adults with traumatic brain injury initially referred to the emergency department, but who were admitted to the ICU Disease severity score: GCS score mean 7.4 Inclusion criteria
Exclusion criteria
Participants in the control group for whom oxygen therapy was inevitable were also excluded from this study. |
|
Interventions |
Experimental: FiO2 of 80% oxygen by mechanical ventilator in the first 6 hours after the traumatic accident. Categorized by us as using a high target in the experimental group Control: FiO2 of 0.5 using mechanical ventilator in the first 6 hours after the traumatic accident. Categorized by us as using a low target in the control group Co‐intervention: not specified Duration: 6 hours |
|
Outcomes |
|
|
Notes | No relevant outcomes reported. Participants who died were excluded (from analyses). Email sent 6 December 2018 to Dr Pilehvari but no reply was received. The trial was funded by public funds. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Stated that the trial was randomized, but sequence generation was not described |
Allocation concealment (selection bias) | Unclear risk | Not described |
Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | The trial was described as double‐blind; however, it was unclear who was blinded and how blinding was maintained. |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Not described |
Incomplete outcome data (attrition bias) All outcomes | High risk | Participants who died or were lost to follow‐up were excluded. |
Selective reporting (reporting bias) | Unclear risk | No protocol could be found. |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
Young 2017.
Methods | RCT | |
Participants |
Sample size: 100 (experimental 51, control 49 (48 analysed)) Sex (male %): experimental 67%, control 65% Age: experimental 60, control 61 Country: New Zealand Setting: mechanically ventilated adults admitted to a multidisciplinary ICU Disease severity score: APACHE II score median 22.1 Inclusion criteria
Exclusion criteria
|
|
Interventions |
Experimental: no specific measures taken to avoid high FiO2 or SpO2, FiO2< 0.30 discouraged (thus we could not categorize the experimental group as using either a low or high target). Participants assigned to the ‘higher group’ received ‘standard care’ both whilst ventilated and after extubation with no specific measures taken to avoid high FiO2 or high SpO2. The use of upper alarm limits for SpO2 in the higher group was prohibited, as upper alarm limits for SpO2 were not used as part of standard care. The lower limit alarm for SpO2 was set at 90% (or lower if clinically appropriate). If the PaO2 or SaO2 was lower than the acceptable limit, inspired oxygen might be increased if clinically appropriate, irrespective of the SpO2 reading. The use of an FiO2 of less than 0.3 whilst ventilated was discouraged. Control: target SaO2/SpO2 91% to 96%. When a participant was allocated to conservative oxygen therapy, the inspired oxygen concentration was decreased to room air as rapidly as possible provided that the SpO2 measured by peripheral pulse oximetry was greater than the acceptable lower limit. SpO2 levels of greater than 96% were strictly avoided, and an upper SpO2 alarm limit of 97% applied whenever supplemental oxygen was administered in the ICU to minimize the risk of hyperoxaemia. After extubation, in the conservative oxygen group, the upper monitored alarm limit of acceptable SpO2 of 97% was applied whenever supplemental oxygen was being administered. In the event that the SpO2 exceeded the acceptable upper limit, downward titration of supplemental oxygen was undertaken as a high priority and supplemental oxygen was discontinued as soon possible. The lower limit alarm for SpO2 was set at 90% (or lower if clinically appropriate). If the PaO2 or SaO2 was lower than the acceptable limit, inspired oxygen might be increased if clinically appropriate, irrespective of the SpO2 reading. Categorized by us as using a low target in the control group Co‐intervention: there were no restrictions on concomitant treatments provided to participants. If an increase in FiO2 for procedures performed in the ICU included (but were not limited to) bronchoscopy, suctioning, tracheostomy, or preparation for extubation, this was permitted in both groups. Duration: until death or discharge from the ICU, or day 28 postrandomization |
|
Outcomes | *Outcomes that will be reported in the final trial report:
|
|
Notes | *The trial report included data from a pilot phase of the ICU‐ROX trial. It included the first 100 patients of an overall sample of 1000, which was to examine the feasibility. Only feasibility outcomes were reported, and outcomes prespecified in protocol will be reported in final trial report including 1000 participants, thus no relevant outcomes were reported. Email sent 6 December 2018 to Dr Young and reply was received. The trial was supported by public funds. |
|
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Low risk | Encrypted web‐based system |
Allocation concealment (selection bias) | Low risk | Central randomization |
Blinding of participants and personnel (performance bias) All outcomes | High risk | Not blinded |
Blinding of outcome assessment (detection bias) All outcomes | Low risk | Not described; however, blinding of outcome assessment was clarified by email |
Incomplete outcome data (attrition bias) All outcomes | Low risk | Less than 5% were lost to follow‐up. |
Selective reporting (reporting bias) | Low risk | The trial was registered prior to randomization (ACTRN12615000957594). Only feasibility outcomes were reported, and outcomes prespecified in the protocol will be reported in the final trial report including 1000 participants. However, mortality is reported in total (30.3%), but is not specified according to treatment group. |
Other bias | Low risk | The trial appeared to be free of other issues that could put it at risk of bias. |
APACHE II: Acute Physiology, Age, Chronic Health Evaluation II; ARDS: acute respiratory distress syndrome; AUC: area under the curve; C5: cervical spine vertebral level 5; COPD: chronic obstructive pulmonary disease; CPC: cerebral performance category; CPR: cardiopulmonary resuscitation; EEG: electroencephalogram; FiO2: fraction of inspired oxygen; GCS: Glasgow Coma Scale; H2O: dihydrogen monoxide (water); ICU: intensive care unit; MAP: mean arterial pressure; mRS: modified ranking scale; MV: mechanical ventilation; NIRS: cerebral near‐infrared spectroscopy; NIHSS: National Institutes of Health Stroke Scale; NSE: neuron‐specific enolase; OHCA: out‐of‐hospital cardiac arrest; PaCO2: partial pressure of arterial carbon dioxide; PaO2: partial pressure of arterial oxygen; PEEP: positive end‐expiratory pressure; PaO2/FiO2 ratio: ratio of arterial oxygen partial pressure to fractional inspired oxygen; RCT: randomized controlled trial; ROSC: return of spontaneous circulation; SaO2: arterial oxygen saturation of haemoglobin; SAPS: simplified acute physiology score; SOFA: sequential organ failure assessment; SpO2: peripheral oxygen saturation; TBI: traumatic brain injury; TnT: cardiac troponin; TTM: targeted temperature management; VF: ventricular fibrillation; VT: ventricular tachycardia
Characteristics of excluded studies [ordered by study ID]
Study | Reason for exclusion |
---|---|
Ali 2013 | Wrong population |
Amar 1994 | Wrong population |
Austin 2010 | Wrong population |
Bickel 2011 | Wrong population |
Bray 2018 | Wrong population |
Hofmann 2017 | Wrong population |
Huynh Ky 2017 | Wrong population |
Khoshnood 2018 | Wrong population |
Khosnood 2017 | Wrong population |
Kuisma 2006 | Wrong population |
Meyhoff 2009 | Wrong population |
Padma 2010 | Wrong population |
Perrin 2011 | Wrong population |
Ranchord 2012 | Wrong population |
Rawles 1976 | Wrong population |
Rodrigo 2003 | Wrong population |
Roffe 2010 | Wrong population |
Roffe 2017 | Wrong population |
Sills 2003 | Wrong population |
Singhal 2005 | Wrong population |
Singhal 2013 | Wrong population |
Stub 2014 | Wrong population |
Ukholkina 2005 | Wrong population |
Wu 2014 | Wrong population |
Young 2014 | Wrong population |
Zughaft 2013 | Wrong population |
Characteristics of studies awaiting assessment [ordered by study ID]
ICU‐ROX 2019.
Methods | RCT |
Participants |
Sample size: 1000 (experimental 501, control 499) Country: New Zealand Setting: mechanically ventilated adults admitted to a multidisciplinary ICU |
Interventions |
Experimental: no specific measures taken to avoid high FiO2 or SpO2, FiO2<0.30 discouraged (thus, we could not categorize the experimental group as either using a low or a high target). Patients assigned to the ‘higher group’ received ‘standard care’ both while ventilated and after extubation with no specific measures taken to avoid high FiO2 or high SpO2. The use of upper alarm limits for SpO2 in the ‘higher group’ was prohibited as upper alarm limits for SpO2 were not used as part of standard care. The lower limit alarm for SpO2 was set at 90% (or lower if clinically appropriate). If the PaO2 or the SaO2 were lower than the acceptable limit, inspired oxygen might be increased if clinically appropriate, irrespective of the SpO2 reading. The use of an FiO2 of less than 0.3 whilst ventilated was discouraged. Control: target SaO2/SpO2 91% to 96%. When a participant was allocated to conservative oxygen therapy, the inspired oxygen concentration was decreased to room air as rapidly as possible provided that the SpO2 measured by peripheral pulse oximetry was greater than the acceptable lower limit. SpO2 levels of greater than 96% were strictly avoided and an upper SpO2 alarm limit of 97% applied whenever supplemental oxygen was administered in the ICU to minimise the risk of hyperoxaemia. After extubation, in the conservative oxygen group, the upper monitored alarm limit of acceptable SpO2 of 97% was applied whenever supplemental oxygen was being administered. In the event that the SpO2 exceeded the acceptable upper limit, downward titration of supplemental oxygen was undertaken as a high priority and supplemental oxygen was discontinued as soon possible. The lower limit alarm for SpO2 was set at 90% (or lower if clinically appropriate). If the PaO2 or the SaO2 were lower than the acceptable limit, inspired oxygen might be increased if clinically appropriate, irrespective of the SpO2 reading. Categorized by us as using a low target in the control group. Duration: until death or discharge from the ICU, or day 28 post randomization |
Outcomes |
Primary outcome:
Secondary outcomes:
Functional outcome assessed by the extended Glasgow outcome scale (in patients with acute brain pathologi) |
Notes | The ICU‐ROX trial was published post our literature search and thus was not included in this review. The ICU‐ROX trial will be included in a review update. |
Characteristics of ongoing studies [ordered by study ID]
NCT02321072.
Trial name or title | The effects of hyperoxia on organ dysfunction and outcome in critically ill patients with SIRS (O2‐ICU) |
Methods | RCT |
Participants | Patients admitted to the ICU with ≥ 2 positive SIRS criteria and an expected ICU stay of more than 48 hours |
Interventions |
Active comparator: high‐normal PaO2 In participants requiring respiratory monitoring, supplemental oxygen is titrated to achieve a PaO2 of 120 mmHg (16 kPa), range 105 to 135 mmHg (14 to 18 kPa). Active comparator: low‐normal PaO2 In participants requiring respiratory monitoring, supplemental oxygen is titrated to achieve a target PaO2 of 75 mmHg (10 kPa), range 60 to 90 mmHg (8 to 18 kPa). |
Outcomes |
Primary outcome
Secondary outcomes:
|
Starting date | February 2015 |
Contact information | Dr HJS de Grooth |
Notes |
NCT02713451.
Trial name or title | Liberal oxygenation versus conservative oxygenation in ARDS (LOCO2) |
Methods | RCT |
Participants | Patients with ARDS |
Interventions |
Active comparator: liberal oxygenation (LO) group A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 90 to 105 mmHg, which will be checked on ABG. Between these measurements, SpO2 will be kept at ≥ 96%. Alarms will be set at 95% for SpO2. Experimental: conservative oxygenation (CO) group A modulation of inspired fraction of oxygen will be performed with an objective of PaO2 between 55 to 70 mmHg, which will be checked on ABG. Between these measurements, SpO2 will be kept between 88% and 92%. Alarms will be set between 87% and 93% for SpO2. |
Outcomes |
Primary outcome
Secondary outcomes
|
Starting date | June 2016 |
Contact information | Loïc Barrot |
Notes |
NCT03141099.
Trial name or title | Blood pressure and oxygenation targets in post‐resuscitation care (BOX) |
Methods | RCT |
Participants | Comatose OHCA patients |
Interventions |
Active comparator: low normal MAP and low normal PaO2 MAP 63 mmHg and PaO2 9 to 10 kPa during targeted temperature management (36 hours) after OHCA Active comparator: high normal MAP and low normal PaO2 MAP 77 mmHg and PaO2 9 to 10 kPa during targeted temperature management (36 hours) after OHCA Active comparator: low normal MAP and high normal PaO2 MAP 63 mmHg and PaO2 13 to 14 kPa during targeted temperature management (36 hours) after OHCA Active comparator: high normal MAP and high normal PaO2 MAP 77 mmHg and PaO2 13 to 14 kPa during targeted temperature management (36 hours) after OHCA |
Outcomes |
Primary outcome
Secondary outcomes
Other outcome measures
|
Starting date | March 2017 |
Contact information | Dr Jesper Kjaergaard |
Notes |
NCT03174002.
Trial name or title | Handling oxygenation targets in adults with acute hypoxaemic respiratory failure in the intensive care unit (HOT‐ICU) |
Methods | RCT |
Participants | ICU patients |
Interventions |
Experimental: low oxygenation target Partial pressure of oxygen in arterial blood (PaO2) 8 kPa (60 mmHg) Active comparator: high oxygenation target Partial pressure of oxygen in arterial blood (PaO2) 12 kPa (90 mmHg) |
Outcomes |
Primary outcome
Secondary outcomes
|
Starting date | June 2017 |
Contact information | Dr Bodil Steen Rasmussen |
Notes |
NCT03287466.
Trial name or title | A randomised controlled trial of targeted oxygen therapy in mechanically ventilated critically ill patients (TOXYC) |
Methods | RCT |
Participants | Mechanically ventilated adults |
Interventions |
Experimental: SpO2 88% to 92% The intervention is TO2T to achieve an arterial haemoglobin oxygen saturation (SpO2) of 88% to 92%. Active comparator: SpO2 96% or above The control group will also receive TO2T, but to achieve an SpO2 of 96% or above (standard care). |
Outcomes |
Primary outcome measures
Secondary outcomes
|
Starting date | January 2018 |
Contact information | Dr Jack D Grierson |
Notes |
ABG: arterial blood gases; APACHE: Acute Physiology, Age, Chronic Health Evaluation; ARDS: acute respiratory distress syndrome; CO: conservative oxygenation; CPC: cerebral performance category; eGFR: estimated glomerular filtration rate; EQ‐5D‐5L: an instrument for measuring quality of life; FiO2: fraction of inspired oxygen; ICU: intensive care unit; LVEF: left ventricular ejection fraction; LO: liberal oxygenation; MAP: mean arterial pressure; MOCA: Montreal Cognitive Assessment; NT‐pro‐BNP: cardiac biomarker; OHCA: out‐of‐hospital cardiac arrest; PaO2: partial pressure of arterial oxygen; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; RCT: randomized controlled trial; SaO2: arterial oxygen saturation of haemoglobin; SIRS: systemic inflammatory response syndrome; SOFA: sequential organ failure assessment; SpO2: peripheral oxygen saturation; TO2T: targeted oxygen therapy
Differences between protocol and review
We changed the title from 'Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients' to 'Higher versus lower fraction of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit'.
We used a power of 90%, not 80% as reported in the protocol (Barbateskovic 2017), as a meta‐analysis should use higher (or same) power as its included trials in order to communicate the best available evidence.
We changed the wording in the Types of interventions section from "the aim of which was exposure to hyperoxaemia" to "the aim of which was exposure to hyperoxia in the lungs".
We added the subgroup 'mixed ICU' to the subgroup analysis (including five trials) of ICU setting, as only one trial included adults admitted to a medical ICU and none to a surgical ICU.
In our protocol we stated that we would search the Allied and Complementary Medicine Database (AMED) for eligible trials. We had no access to AMED, and so this search was not conducted.
We stated in the 'Types of outcome measures' section of the protocol that we would estimate all continuous and dichotomous outcomes at two time points: the time point closest to three months, which was our assessment time point of primary interest; and at maximum follow‐up, as reported by trialists. We realized that this information was confusing. We intended for the assessments at maximum follow‐up to be considered as a sensitivity analyses, thus we have specified this in the Sensitivity analysis section.
We have now precisely defined the analyses estimating the effect of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation on the proportion of participants with one or more serious adverse events. As the reporting of serious adverse events as a combined outcome was not carried out strictly according to the ICH‐GCP recommendation, we estimated the proportion of participants with one or more serious adverse events in a primary analysis: highest proportion of specific serious adverse event reported in each trial. We estimated the effect of higher versus lower inspired fraction or target of oxygen in a sensitivity analysis: the proportion estimated as cumulated number of serious adverse events reported in each trial divided by the number of participants in each intervention group.
We have now precisely defined the analyses estimating the effect of higher versus lower fraction of inspired oxygen or targets of arterial oxygenation on the proportion of participants with lung injuries. No trial reported on lung injury as a composite outcome, however some trials reported on ARDS and pneumonia. We estimated the proportion of participants with one or more lung injuries in a primary analysis: highest proportion of specific lung injuries reported in each trial. We estimated the effect of higher versus lower inspired fraction or target of oxygen in a sensitivity analysis: the proportion estimated as cumulated number of lung injuries reported in each trial divided by the number of participants in each intervention group.
We changed the wording of the second co‐primary outcome (proportion of participants with one or more serious adverse events), without changing the content and implication of the definition.
We added a paragraph on Bayes factors in the Methods section. In our protocol, we did not explicitly state that we would present Bayes factors, however we did state that the review would be conducted following the recommendations by Jakobsen and colleagues (Jakobsen 2014a), which include an eight‐step assessment involving Bayes factors. In addition, we specified in the Methods section that TSA and calculation of Bayes factors are included in the eight‐step assessment.
Contributions of authors
Marija Barbateskovic (MB), Olav L Schjørring (OLS), Sara Russo Krauss, (SRK), Janus C Jakobsen (JJ), Christian S Meyhoff (CM), Rikke M Dahl (RD), Bodil S Rasmussen (BR), Anders Perner (AP), Jørn Wetterslev (JW).
Writing first draft protocol and co‐ordinating the protocol: MB
Performing search strategies, searches, and analyses: MB
Literature screening and data extraction: MB, OLS, SRK
Writing first draft review: MB
Writing the review: MB, OLS, SRK, JJ, CM, RD, BR, AP, JW
Person responsible for reading and checking the review before submission: MB
Sources of support
Internal sources
No sources of support supplied
External sources
-
Innovation Fund Denmark, Denmark.
Marija Barbateskovic and Olav L Schjørring are supported by grants from Innovation Fund Denmark, which is a public fund.
Declarations of interest
Marija Barbateskovic: Innovation Fund Denmark provided a grant to Center for Research in Intensive Care (CRIC), which made it possible for Copenhagen Trial Unit as a partner of CRIC to write the review during Marija Barbateskovic’s PhD study.
Olav L Schjørring: Oliver's PhD study is funded through a grant from the Innovation Fund Denmark. Furthermore, he is the co‐ordinating investigator of the Handling Oxygenation Targets in the Intensive Care Unit (HOT‐ICU) trial, a randomized clinical trial comparing a higher versus lower oxygenation target in adult patients with hypoxaemic respiratory failure acutely admitted to the intensive care unit.
Sara Russo Krauss: None known.
Janus C Jakobsen: None known.
Christian S Meyhoff: Dr Meyhoff is the chief investigator for the VitamIn and oXygen Interventions and Cardiovascular Events (VIXIE) trial (a randomized controlled trial comparing perioperative oxygen fractions); site investigator in the HOT‐ICU trial (a randomized controlled trial investigating oxygenation targets in the intensive care unit); co‐author of several Cochrane Reviews about oxygen therapy; and was the primary investigator of the PROXI trial (a randomized controlled trial comparing perioperative oxygen fractions).
Rikke M Dahl: None known.
Bodil S Rasmussen: Bodil is the sponsor and primary investigator of a randomized clinical trial comparing a higher versus lower oxygenation target in adult patients with hypoxaemic respiratory failure acutely admitted to the intensive care unit (the Handling Oxygenation Targets in the Intensive Care Unit (HOT‐ICU) trial (NCT03174002)).
Anders Perner: Anders's institution receives money for research from Ferring Pharmaceuticals and the Novo Nordisk Foundation
Jørn Wetterslev: Jørn is a member of the task force on Trial Sequential Analysis (TSA) at the Copenhagen Trial Unit, developing and programming TSA (see www.ctu.dk/tsa). I am a supervisor for PhD student Marija Barbateskovic, and the work concerning this review was paid for in part by a grant from Innovation Fund Denmark.
Edited (no change to conclusions)
References
References to studies included in this review
Asfar 2017 {published data only}
- Asfar P, Schortgen F, Boisramé‐Helms J, Charpentier J, Guérot E, Megarbane B, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two‐by‐two factorial, multicentre, randomised, clinical trial. Lancet. Respiratory Medicine 2017;5(3):180‐90. [PUBMED: 28219612] [DOI] [PubMed] [Google Scholar]
Girardis 2016 {published data only}
- Girardis M, Busani S, Damiani E, Donati A, Rinaldi L, Marudi A, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the oxygen‐ICU randomized clinical trial. JAMA 2016;316(15):1583‐9. [PUBMED: 27706466] [DOI] [PubMed] [Google Scholar]
Gomersall 2002 {published data only}
- Gomersall CD, Joynt GM, Freebairn RC, Lai CK, Oh TE. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Critical Care Medicine 2002;30(1):113‐6. [PUBMED: 11905405] [DOI] [PubMed] [Google Scholar]
Ishii 2018 {published data only}
- Ishii K, Morimatsu H, Hyodo T, Ono K, Hidaka H, Koyama Y, et al. Relationship between inspired oxygen concentration and atelectasis formation after extubation. Critical Care Medicine 2018;46(1 Suppl 1):533. [DOI: 10.1097/01.ccm.0000529104.66235.9e] [DOI] [Google Scholar]
Jakkula 2018 {published data only}
- Jakkula P, Reinikainen M, Hästbacka J, Loisa P, Tiainen M, Pettilä V, et al. Targeting two different levels of both arterial carbon dioxide and arterial oxygen after cardiac arrest and resuscitation: a randomised pilot trial. Intensive Care Medicine 2018;44(12):2112‐21. [PUBMED: 30430209] [DOI] [PMC free article] [PubMed] [Google Scholar]
Lång 2018 {published data only}
- Lång M, Skrifvars MB, Siironen J, Tanskanen P, Ala‐Peijari M, Koivisto T, et al. A pilot study of hyperoxemia on neurological injury, inflammation and oxidative stress. Acta Anaesthesiologica Scandinavica 2018;62(6):801‐10. [PUBMED: 29464691] [DOI] [PubMed] [Google Scholar]
Mazdeh 2015 {published data only}
- Mazdeh M, Taher A, Torabian S, Seifirad S. Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. Acta Medica Iranica 2015;53(11):676‐80. [PUBMED: 26786987] [PubMed] [Google Scholar]
Panwar 2016 {published data only}
- Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients. A pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2016;193(1):43‐51. [PUBMED: 26334785] [DOI] [PubMed] [Google Scholar]
Taher 2016 {published data only}
- Taher A, Pilehvari Z, Poorolajal J, Aghajanloo M. Effects of normobaric hyperoxia in traumatic brain injury: a randomized controlled clinical trial. Trauma Monthly 2016;21(1):e26772. [PUBMED: 27218057] [DOI] [PMC free article] [PubMed] [Google Scholar]
Young 2017 {published data only}
- Young PJ, Mackle DM, Bailey MJ, Beasley RW, Bennett VL, Deane AM, et al. Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU‐ROX): results of the pilot phase. Critical Care and Resuscitation 2017;19(4):344‐54. [PUBMED: 29202261] [PubMed] [Google Scholar]
References to studies excluded from this review
Ali 2013 {published data only}
- Ali K, Warusevitane A, Lally F, Sim J, Sills S, Pountain S, et al. The stroke oxygen pilot study: a randomized controlled trial of the effects of routine oxygen supplementation early after acute stroke ‐ effect on key outcomes at six months. PLOS ONE 2013;8(6):e59274. [PUBMED: 23755093] [DOI] [PMC free article] [PubMed] [Google Scholar]
Amar 1994 {published data only}
- Amar D, Greenberg MA, Menegus MA, Breitbart S. Should all patients undergoing cardiac catheterization or percutaneous transluminal coronary angioplasty receive oxygen?. Chest 1994;105(3):727‐32. [PUBMED: 8131533] [DOI] [PubMed] [Google Scholar]
Austin 2010 {published data only}
- Austin MA, Wills KE, Blizzard L, Walters EH, Wood‐Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010;341:c5462. [PUBMED: 20959284] [DOI] [PMC free article] [PubMed] [Google Scholar]
Bickel 2011 {published data only}
- Bickel A, Gurevits M, Vamos R, Ivry S, Eitan A. Perioperative hyperoxygenation and wound site infection following surgery for acute appendicitis: a randomized, prospective, controlled trial. Archives of Surgery 2011;146(4):464‐70. [PUBMED: 21502457] [DOI] [PubMed] [Google Scholar]
Bray 2018 {published data only}
- Bray JE, Hein C, Smith K, Stephenson M, Grantham H, Finn J. Oxygen titration after resuscitation from out‐of‐hospital cardiac arrest: a multi‐centre, randomised controlled pilot study (the EXACT pilot trial). Resuscitation 2018;128:211‐5. [PUBMED: 29684433] [DOI] [PubMed] [Google Scholar]
Hofmann 2017 {published data only}
- Hofmann R, James SK, Jernberg T, Lindahl B, Erlinge D, Witt N, et al. Oxygen therapy in suspected acute myocardial infarction. New England Journal of Medicine 2017;377(13):1240‐9. [PUBMED: 28844200] [DOI] [PubMed] [Google Scholar]
Huynh Ky 2017 {published data only}
- Huynh Ky M, Bouchard PA, Morin J, L'Her E, Sarrazin JF, Lellouche F. Closed‐loop adjustment of oxygen flowrate with FreeO2 in patients with acute coronary syndrome: comparison of automated titration with FreeO2 (set at two SpO2 target) and of manual titration. A randomized controlled study. Annals of Intensive Care 2017;7(Suppl 1):O59. [Google Scholar]
Khoshnood 2018 {published data only}
- Khoshnood A, Carlsson M, Akbarzadeh M, Bhiladvala P, Roijer A, Nordlund D, et al. Effect of oxygen therapy on myocardial salvage in ST elevation myocardial infarction: the randomized SOCCER trial. European Journal of Emergency Medicine 2018;25(2):78‐84. [PUBMED: 27893526] [DOI] [PubMed] [Google Scholar]
Khosnood 2017 {published data only}
- Khoshnood A, Akbarzadeh M, Roijer A, Meurling C, Carlsson M, Bhiladvala P, et al. Effects of oxygen therapy on wall‐motion score index in patients with ST elevation myocardial infarction ‐ the randomized SOCCER trial. Echocardiography 2017;34(8):1130‐7. [PUBMED: 28664557] [DOI] [PubMed] [Google Scholar]
Kuisma 2006 {published data only}
- Kuisma M, Boyd J, Voipio V, Alaspää A, Roine RO, Rosenberg P. Comparison of 30 and the 100% inspired oxygen concentrations during early post‐resuscitation period: a randomised controlled pilot study. Resuscitation 2006;69(2):199‐206. [PUBMED: 16500018] [DOI] [PubMed] [Google Scholar]
Meyhoff 2009 {published data only}
- Meyhoff CS, Wetterslev J, Jorgensen LN, Henneberg SW, Høgdall C, Lundvall L, et al. Effect of high perioperative oxygen fraction on surgical site infection and pulmonary complications after abdominal surgery: the PROXI randomized clinical trial. JAMA 2009;302(14):1543‐50. [PUBMED: 19826023] [DOI] [PubMed] [Google Scholar]
Padma 2010 {published data only}
- Padma MV, Bhasin A, Bhatia R, Garg A, Singh MB, Tripathi M, et al. Normobaric oxygen therapy in acute ischemic stroke: a pilot study in Indian patients. Annals of Indian Academy of Neurology 2010;13(4):284‐8. [PUBMED: 21264137] [DOI] [PMC free article] [PubMed] [Google Scholar]
Perrin 2011 {published data only}
- Perrin K, Wijesinghe M, Healy B, Wadsworth K, Bowditch R, Bibby S, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax 2011;66(11):937‐41. [PUBMED: 21597111] [DOI] [PubMed] [Google Scholar]
Ranchord 2012 {published data only}
- Ranchord AM, Argyle R, Beynon R, Perrin K, Sharma V, Weatherall M, et al. High‐concentration versus titrated oxygen therapy in ST elevation myocardial infarction: a pilot randomized controlled trial. American Heart Journal 2012;163(2):168‐75. [PUBMED: 22305833] [DOI] [PubMed] [Google Scholar]
Rawles 1976 {published data only}
- Rawles JM, Kenmure AC. Controlled trial of oxygen in uncomplicated myocardial infarction. BMJ 1976;1(6018):1121‐3. [PUBMED: 773507] [DOI] [PMC free article] [PubMed] [Google Scholar]
Rodrigo 2003 {published data only}
- Rodrigo GJ, Rodriquez Verde M, Peregalli V, Rodrigo C. Effects of short‐term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest 2003;124(4):1312‐7. [PUBMED: 14555560] [DOI] [PubMed] [Google Scholar]
Roffe 2010 {published data only}
- Roffe C, Sills S, Pountain SJ, Allen M. A randomized controlled trial of the effect of fixed‐dose routine nocturnal oxygen supplementation on oxygen saturation in patients with acute stroke. Journal of Stroke and Cerebrovascular Diseases 2010;19(1):29‐35. [PUBMED: 20123224] [DOI] [PubMed] [Google Scholar]
Roffe 2017 {published data only}
- Roffe C, Nevatte T, Sim J, Bishop J, Ives N, Ferdinand P, et al. Effect of routine low‐dose oxygen supplementation on death and disability in adults with acute stroke: the stroke oxygen study randomized clinical trial. JAMA 2017;318(12):1125‐35. [PUBMED: 28973619] [DOI] [PMC free article] [PubMed] [Google Scholar]
Sills 2003 {published data only}
- Sills S, Halim M, Roffe C. A pilot study of routine nocturnal oxygen supplementation in patients with acute stroke. Age and Ageing 2003;32(Suppl 2):ii41. [Google Scholar]
Singhal 2005 {published data only}
- Singhal AB, Benner T, Roccatagliata L, Koroshetz WJ, Schaefer PW, Lo EH, et al. A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 2005;36(4):797‐802. [PUBMED: 15761201] [DOI] [PubMed] [Google Scholar]
Singhal 2013 {published data only}
- Singhal A. A phase IIb clinical trial of normobaric oxygen therapy (NBO) in acute ischemic stroke (AIS). Neurology 2013;80(Suppl 7):S02.001. [Google Scholar]
Stub 2014 {published data only}
- Stub D, Smith K, Bernard S, Nehme Z, Stephenson M, Bray JE, et al. Air versus oxygen in S‐segment‐elevation myocardial infarction. Circulation 2015;131(24):2143‐50. [PUBMED: 26002889] [DOI] [PubMed] [Google Scholar]
Ukholkina 2005 {published data only}
- Ukholkina GB, Kostianov IIu, Kuchkina NV, Grendo EP, Gofman IaB. Effect of oxygenotherapy used in combination with reperfusion in patients with acute myocardial infarction. Kardiologiia 2005;45(5):59. [PUBMED: 16007057] [PubMed] [Google Scholar]
Wu 2014 {published data only}
- Wu J, Nevatte T, Roffe C. The stroke oxygen supplementation (S02S) study: comparison of postal and telephone responses of 12 months questionnaire follow up. International Journal of Stroke 2014;9(Suppl 4):37. [Google Scholar]
Young 2014 {published data only}
- Young P, Bailey M, Bellomo R, Bernard S, Dicker B, Freebairn R, et al. HyperOxic Therapy OR NormOxic Therapy after out‐of‐hospital cardiac arrest (HOT OR NOT): a randomised controlled feasibility trial. Resuscitation 2014;85(12):1686‐91. [PUBMED: 25261605] [DOI] [PubMed] [Google Scholar]
Zughaft 2013 {published data only}
- Zughaft D, Bhiladvala P, Dijkman A, Harnek J, Madsen Hardig B, Bjork J. The analgesic effect of oxygen during percutaneous coronary intervention (the OXYPAIN Trial). Acute Cardiac Care 2013;15(3):63‐8. [PUBMED: 23957447] [DOI] [PubMed] [Google Scholar]
References to studies awaiting assessment
ICU‐ROX 2019 {published data only}
- ICU‐ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Mackle D, Bellomo R, Bailey M, Beasley R, Deane A, Eastwood G, Finfer S, Freebairn R, King V, Linke N, Litton E, McArthur C, McGuinness S, Panwar R, Young P. Conservative Oxygen Therapy during Mechanical Ventilation in the ICU. New England Journal of Medicine 2019:[Epub ahead of print]. [PUBMED: 31613432]31613432 [Google Scholar]
References to ongoing studies
NCT02321072 {published data only}
- NCT02321072. Optimal oxygenation in the intensive care unit (O2‐ICU). clinicaltrials.gov/ct2/show/NCT02321072 (first received 9 December 2014).
NCT02713451 {published data only}
- NCT02713451. Liberal oxygenation versus conservative oxygenation in ARDS (LOCO2). clinicaltrials.gov/ct2/show/NCT02713451 (first received 18 March 2016).
NCT03141099 {published data only}
- NCT03141099. Blood pressure and OXygenation targets after OHCA (BOX). clinicaltrials.gov/ct2/show/NCT03141099 (first received 4 May 2017).
NCT03174002 {published data only}
- NCT03174002. Handling oxygenation targets in the intensive care unit (HOT‐ICU). clinicaltrials.gov/ct2/show/NCT03174002 (first received 2 June 2017).
NCT03287466 {published data only}
- Targeted OXYgen therapy in critical illness (TOXYC). clinicaltrials.gov/ct2/show/NCT03287466 (first received 19 September 2017).
Additional references
AARC 2002
- Kallstrom TJ, American Association for Respiratory Care. AARC clinical practice guideline. Oxygen therapy for adults in the acute care facility ‐ 2002 revision & update. Respiratory Care 2002;47(6):717‐20. [PUBMED: 12078655] [PubMed] [Google Scholar]
ACTRN12613000505707
- ACTRN12613000505707. Feasibility and safety of conservative versus liberal oxygen targets in the mechanically ventilated patients. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364185 (first received 5 May 2013).
ACTRN12615000957594
- ACTRN12615000957594. A multicentre, randomised, single‐blinded clinical trial comparing the effect of conservative oxygen therapy with standard care on ventilator‐free days in mechanically ventilated adults in the intensive care unit.. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369229&isReview=true (first received 1 September 2015).
Adhikari 2010
- Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet 2010;376(9749):1339‐46. [PUBMED: 20934212] [DOI] [PMC free article] [PubMed] [Google Scholar]
Alba 2016
- Alba AC, Alexander PE, Chang J, MacIsaac J, DeFry S, Guyatt GH. High statistical heterogeneity is more frequent in meta‐analysis of continuous than binary outcomes. Journal of Clinical Epidemiology 2016;70:129‐35. [PUBMED: 26386323] [DOI] [PubMed] [Google Scholar]
ARC 2014
- Australian Resuscitation Council. Guideline 11.6.1. Targeted oxygen therapy in adult advanced life support, 2014. resus.org.au/download/section_11/anzcor‐guideline‐11‐6‐1‐targeted‐oxygen‐therapy‐jan16.pdf (accessed 17 December 2015).
ARDS Definition Task Force 2012
- ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526‐33. [PUBMED: 22797452] [DOI] [PubMed] [Google Scholar]
ARDS Network 2000
- Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. New England Journal of Medicine 2000;342(18):1301‐8. [PUBMED: 10793162] [DOI] [PubMed] [Google Scholar]
ATS 2005
- American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital‐acquired, ventilator‐associated, and healthcare‐associated pneumonia. American Journal of Respiratory and Critical Care Medicine 2005;171(4):388‐416. [PUBMED: 15699079] [DOI] [PubMed] [Google Scholar]
Bailey 2003
- Bailey TC, Martin EL, Zhao L, Veldhuizen RA. High oxygen concentrations predispose mouse lungs to the deleterious effects of high stretch ventilation. Journal of Applied Physiology 2003;94(3):975‐82. [PUBMED: 12571129] [DOI] [PubMed] [Google Scholar]
Barbateskovic 2018
- Barbateskovic M, Schjørring OL, Jakobsen JC, Meyhoff CS, Rasmussen BS, Perner A, et al. Oxygen supplementation for critically ill patients ‐ a protocol for a systematic review. Acta Anaesthesiologica Scandinavica 2018;62(7):1020‐30. [PUBMED: 29708586] [DOI] [PubMed] [Google Scholar]
Bayes factor calculator 2014
- Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Bayes factor calculator. www.ctu.dk/tools‐and‐links/bayes‐factor‐calculation.aspx (accessed 13 August 2019).
Begg 1994
- Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088‐101. [PUBMED: 7786990] [PubMed] [Google Scholar]
Bellomo 2011
- Bellomo R, Bailey M, Eastwood GM, Nichol A, Pilcher D, Hart GK. Arterial hyperoxia and in‐hospital mortality after resuscitation from cardiac arrest. Critical Care 2011;15(2):R90. [PUBMED: 21385416] [DOI] [PMC free article] [PubMed] [Google Scholar]
Benoit 2002
- Benoît Z, Wicky S, Fischer JF, Frascarolo P, Chapuis C, Spahn DR, et al. The effect of increased FIO(2) before tracheal extubation on postoperative atelectasis. Anesthesia and Analgesia 2002;95(6):1777‐81. [PUBMED: 12456458] [DOI] [PubMed] [Google Scholar]
Brenner 2012
- Brenner M, Stein D, Hu P, Kufera J, Wooford M, Scalea T. Association between early hyperoxia and worse outcomes after traumatic brain injury. Archives of Surgery 2012;147(11):1042‐6. [PUBMED: 22801994] [DOI] [PubMed] [Google Scholar]
Brok 2008
- Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta‐analyses. Journal of Clinical Epidemiology 2008;61(8):763‐9. [PUBMED: 18411040] [DOI] [PubMed] [Google Scholar]
Brok 2009
- Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38(1):287‐98. [PUBMED: 18824466] [DOI] [PubMed] [Google Scholar]
Brower 2004
- Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M, et al. Higher versus lower positive end‐expiratory pressures in patients with the acute respiratory distress syndrome. New England Journal of Medicine 2004;351(4):327‐36. [PUBMED: 15269312] [DOI] [PubMed] [Google Scholar]
Budinger 2013
- Budinger GR, Mutlu GM. Balancing the risks and benefit of oxygen therapy in critically ill adults. Chest 2013;143(4):1151‐62. [PUBMED: 23546490] [DOI] [PMC free article] [PubMed] [Google Scholar]
Cabello 2016
- Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database of Systematic Reviews 2016, Issue 12. [DOI: 10.1002/14651858.CD007160.pub4] [DOI] [PMC free article] [PubMed] [Google Scholar]
Chow 2003
- Chow CW, Herrera Abreu MT, Suzuki T, Downey GP. Oxidative stress and acute lung injury. American Journal of Respiratory Cell and Molecular Biology 2003;29(4):427‐31. [PUBMED: 14500253] [DOI] [PubMed] [Google Scholar]
Chu 2018
- Chu DK, Kim LH, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta‐analysis. Lancet 2018;391(10131):1693‐705. [PUBMED: 29726345] [DOI] [PubMed] [Google Scholar]
Crapo 1986
- Crapo JD. Morphologic changes in pulmonary oxygen toxicity. Annual Review of Physiology 1986;48:721‐31. [PUBMED: 3518622] [DOI] [PubMed] [Google Scholar]
Crapo 1999
- Crapo RO, Jensen RL, Hegewald M, Tashkin DP. Arterial blood gas reference values for sea level and an altitude of 1,400 meters. American Journal of Respiratory and Critical Care Medicine 1999;160:1525‐31. [PUBMED: 10556115] [DOI] [PubMed] [Google Scholar]
Dahl 2015
- Dahl RM, Grønlykke L, Haase N, Holst LB, Perner A, Wetterslev J, et al. Variability in targeted arterial oxygenation levels in patients with severe sepsis or septic shock. Acta Anaesthesiologica Scandinavia 2015;59(7):859‐69. [PUBMED: 25914095] [DOI] [PubMed] [Google Scholar]
Damiani 2014
- Damiani E, Adrario E, Girardis M, Romano R, Pelaia P, Singer M, et al. Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta‐analysis. Critical Care 2014;18(6):711. [PUBMED: 25532567] [DOI] [PMC free article] [PubMed] [Google Scholar]
de Graaff 2011
- Graaff AE, Dongelmans DA, Binnekade JM, Jonge E. Clinicians' response to hyperoxia in ventilated patients in a Dutch ICU depends on the level of FiO2. Intensive Care Medicine 2011;37(1):46‐51. [PUBMED: 20878146] [DOI] [PMC free article] [PubMed] [Google Scholar]
de Jonge 2008
- Jonge E, Peelen L, Keijzers PJ, Joore H, Lange D, Voort PH, et al. Association between administered oxygen, arterial partial oxygen pressure and mortality in mechanically ventilated intensive care unit patients. Critical Care 2008;12(6):R156. [PUBMED: 19077208] [DOI] [PMC free article] [PubMed] [Google Scholar]
Deeks 2010
- Deeks JJ, Higgins JPT. Statistical algorithms in Review Manager 5. https://training.cochrane.org/handbook/statistical‐methods‐revman5 2010:1‐11.
Dellinger 2013
- Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical Care Medicine 2013;41(2):580‐637. [PUBMED: 23353941] [DOI] [PubMed] [Google Scholar]
DeMets 1987
- DeMets DL. Methods for combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341‐50. [PUBMED: 3616287] [DOI] [PubMed] [Google Scholar]
DerSimonian 1986
- DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. [PUBMED: 3802833] [DOI] [PubMed] [Google Scholar]
Donahoe 2011
- Donahoe M. Acute respiratory distress syndrome: a clinical review. Pulmonary Circulation 2011;1(2):192‐211. [PUBMED: 22034606] [DOI] [PMC free article] [PubMed] [Google Scholar]
Eastwood 2012
- Eastwood G, Bellomo R, Bailey M, Taori G, Pilcher D, Young P, et al. Arterial oxygen tension and mortality in mechanically ventilated patients. Intensive Care Medicine 2012;38(1):91‐8. [PUBMED: 22127482] [DOI] [PubMed] [Google Scholar]
Egger 1997
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. [PUBMED: 9310563] [DOI] [PMC free article] [PubMed] [Google Scholar]
Esan 2010
- Esan A, Hess DR, Raoof S, George L, Sessler CN. Severe hypoxemic respiratory failure: part 1 ‐ ventilatory strategies. Chest 2010;137(5):1203‐16. [PUBMED: 20442122] [DOI] [PubMed] [Google Scholar]
Garattini 2016
- Garattini S, Jakobsen JC, Wetterslev J, Bertelé V, Banzi R, Rath A, et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine 2016;32:13‐21. [PUBMED: 27160381] [DOI] [PubMed] [Google Scholar]
Gilbert‐Kawai 2014
- Gilbert‐Kawai ET, Mitchell K, Martin D, Carlisle J, Grocott MPW. Permissive hypoxaemia versus normoxaemia for mechanically ventilated critically ill patients. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD009931.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Gluud 2011
- Gluud C, Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G. User manual for Trial Sequential Analysis (TSA). www.ctu.dk/tsa/files/tsa_manual.pdf (accessed February 2016).
GRADEpro GDT [Computer program]
- McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 25 March 2019. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Guyatt 2008
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924‐6. [PUBMED: 18436948] [DOI] [PMC free article] [PubMed] [Google Scholar]
Hafner 2015
- Hafner S, Beloncle F, Koch A, Radermacher P, Asfar P. Hyperoxia in intensive care, emergency, and peri‐operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update. Annals of Intensive Care 2015;5(1):42. [PUBMED: 26585328] [DOI] [PMC free article] [PubMed] [Google Scholar]
Harbord 2006
- Harbord RM, Egger M, Sterne JA. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443‐57. [PUBMED: 16345038] [DOI] [PubMed] [Google Scholar]
Helmerhorst 2015
- Helmerhorst HJ, Roos‐Blom MJ, Westerloo DJ, Jonge E. Association between arterial hyperoxia and outcome in subsets of critical illness: a systematic review, meta‐analysis, and meta‐regression of cohort studies. Critical Care Medicine 2015;43(7):1508‐19. [PUBMED: 25855899] [DOI] [PubMed] [Google Scholar]
Helmerhorst 2017a
- Helmerhorst HJ, Arts DL, Schultz MJ, Voort PH, Abu‐Hanna A, Jonge E, et al. Metrics of arterial hyperoxia and associated outcomes in critical care. Critical Care Medicine 2017;45(2):187‐95. [PUBMED: 27763912] [DOI] [PubMed] [Google Scholar]
Helmerhorst 2017b
- Helmerhorst HJF, Schouten LRA, Wagenaar GTM, Juffermans NP, Roelofs JJTH, Schultz MJ, et al. Hyperoxia provokes a time‐ and dose‐dependent inflammatory response in mechanically ventilated mice, irrespective of tidal volumes. Intensive Care Medicine Experimental 2017;5(1):27. [PUBMED: 28550659] [DOI] [PMC free article] [PubMed] [Google Scholar]
Higgins 2002
- Higgins JP, Spiegelhalter DJ. Being sceptical about meta‐analyses: a Bayesian perspective on magnesium trials in myocardial infarction. International Journal of Epidemiology 2002;31(1):96‐104. [PUBMED: 11914302] [DOI] [PubMed] [Google Scholar]
Higgins 2003
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [PUBMED: 12958120] [DOI] [PMC free article] [PubMed] [Google Scholar]
Higgins 2011a
- Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins 2011b
- Higgins JP, Whitehead A, Simmonds M. Sequential methods for random‐effects meta‐analysis. Statistics in Medicine 2011;30(9):903‐21. [PUBMED: 21472757] [DOI] [PMC free article] [PubMed] [Google Scholar]
Hrobjartsson 2014
- Hrobjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub‐studies. International Journal of Epidemiology 2014;43(4):1272‐83. [PUBMED: 24881045] [DOI] [PMC free article] [PubMed] [Google Scholar]
ICH‐GCP 1997
- International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. International Digest of Health Legislation 1997;48(2):231‐4. [PUBMED: 11656783] [PubMed] [Google Scholar]
Imberger 2015
- Imberger G, Gluud C, Boylan J, Wetterslev J. Systematic reviews of anesthesiologic interventions reported as statistically significant: problems with power, precision, and type 1 error protection. Anesthesia and Analgesia 2015;121(6):1611‐22. [PUBMED: 26579662] [DOI] [PubMed] [Google Scholar]
Imberger 2016
- Imberger G, Thorlund K, Gluud C, Wetterslev J. False‐positive findings in Cochrane meta‐analyses with and without application of trial sequential analysis: an empirical review. BMJ Open 2016;6(8):e011890. [PUBMED: 27519923] [DOI] [PMC free article] [PubMed] [Google Scholar]
IRCT201212199647N2
- IRCT201212199647N2. Effect of high percent oxygen therapy in compared without oxygen therapy on rehabilitation in the first 12 hours of admission in patients with stroke: a randomized clinical trial. en.irct.ir/trial/10208 (first received 3 November 2013).
Itagaki 2015
- Itagaki T, Nakano Y, Okuda N, Izawa M, Onodera M, Imanaka H, et al. Hyperoxemia in mechanically ventilated, critically ill subjects: incidence and related factors. Respiratory Care 2015;60(3):335‐40. [PUBMED: 25389354] [DOI] [PubMed] [Google Scholar]
Jakobsen 2013
- Jakobsen JC, Gluud C. The necessity of randomized clinical trials. British Journal of Medicine and Medical Research 2013;3(4):1453‐68. [DOI: 10.9734/BJMMR/2013/3208] [DOI] [Google Scholar]
Jakobsen 2014a
- Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta‐analytic methods. BMC Medical Research Methodology 2014;14:120. [PUBMED: 25416419] [DOI] [PMC free article] [PubMed] [Google Scholar]
Jakobsen 2014b
- Jakobsen JC, Gluud C, Winkel P, Lange T, Wetterslev J. The thresholds for statistical and clinical significance – a five‐step procedure for evaluation of intervention effects in randomised clinical trials. BMC Medical Research Methodology 2014;14:34. [DOI: 10.1186/1471-2288-14-34] [DOI] [PMC free article] [PubMed] [Google Scholar]
Jakobsen 2016
- Jakobsen JC, Wetterslev J, Lange T, Gluud C. Viewpoint: taking into account risks of random errors when analysing multiple outcomes in systematic reviews [editorial]. www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000111/full 18 March 2016. [DOI: 10.1002/14651858.ED000111; PUBMED: 27030037] [DOI] [PMC free article] [PubMed]
Kahn 2010
- Kahn JM, Benson NM, Appleby D, Carson SS, Iwashyna TJ. Long‐term acute care hospital utilization after critical illness. JAMA 2010;303(22):2253‐9. [PUBMED: 20530778] [DOI] [PMC free article] [PubMed] [Google Scholar]
Kallet 2013
- Kallet RH, Matthay MA. Hyperoxic acute lung injury. Respiratory Care 2013;58(1):123‐41. [PUBMED: 23271823] [DOI] [PMC free article] [PubMed] [Google Scholar]
Kenmure 1971
- Kenmure AC, Beatson JM, Cameron AJ, Horton PW. Effects of oxygen on myocardial blood flow and metabolism. Cardiovascular Research 1971;5(4):483‐9. [PUBMED: 5160452] [DOI] [PubMed] [Google Scholar]
Kent 2011
- Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. International Journal of COPD 2011;6:199‐208. [PUBMED: 21660297] [DOI] [PMC free article] [PubMed] [Google Scholar]
Kilgannon 2010
- Kilgannon JH, Jones AE, Shapiro NI, Angelos MG, Milcarek B, Hunter K, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in‐hospital mortality. JAMA 2010;303(21):2165‐71. [PUBMED: 20516417] [DOI] [PubMed] [Google Scholar]
Kraft 2018
- Kraft F, Andel H, Gamper J, Markstaller K, Ullrich R, Klein KU. Incidence of hyperoxia and related in‐hospital mortality in critically ill patients: a retrospective data analysis. Acta Anaesthesiologica Scandinavica 2018;62(3):347‐56. [PUBMED: 29210062] [DOI] [PubMed] [Google Scholar]
Kratz 2004
- Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. New England Journal of Medicine 2004;351(15):1548‐63. [PUBMED: 15470219] [DOI] [PubMed] [Google Scholar]
Kulinskaya 2014
- Kulinskaya E, Wood E. Trial sequential methods for meta‐analysis. Research Synthesis Methods 2014;5(3):212‐20. [PUBMED: 26052847] [DOI] [PubMed] [Google Scholar]
MAGIC 2002
- Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high‐risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002;360(9341):1189‐96. [PUBMED: 12401244] [DOI] [PubMed] [Google Scholar]
Mantel 1959
- Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719‐48. [PUBMED: 13655060] [PubMed] [Google Scholar]
Mascha 2015
- Mascha EJ. Alpha, beta, meta: guidelines for assessing power and type I error in meta‐analyses. Anesthesia and Analgesia 2015;121(6):1430‐3. [DOI: 10.1213/ANE.0000000000000993; PUBMED: 26579648] [DOI] [PubMed] [Google Scholar]
Metnitz 2009
- Metnitz PG, Metnitz B, Moreno RP, Bauer P, Sorbo L, Hoermann C, et al. Epidemiology of mechanical ventilation: analysis of the SAPS 3 database. Intensive Care Medicine 2009;35(5):816‐25. [PUBMED: 19288079] [DOI] [PubMed] [Google Scholar]
Meyhoff 2012
- Meyhoff CS, Jorgensen LN, Wetterslev J, Christensen KB, Rasmussen LS, PROXI Trial Group. Increased long‐term mortality after a high perioperative inspiratory oxygen fraction during abdominal surgery: follow‐up of a randomized clinical trial. Anesthesia and Analgesia 2012;115(4):849‐54. [PUBMED: 22798533] [DOI] [PubMed] [Google Scholar]
NCT01201291
- NCT01201291. Impact of Inspired Oxygen Fraction on Outcome in Patients With Traumatic Brain Injury (BRAINOXY). clinicaltrials.gov/ct2/show/NCT01201291 (first received 14 September 2010).
NCT01319643
- NCT01319643. Normal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU) (OXYGEN‐ICU). clinicaltrials.gov/ct2/show/NCT01319643 (first received 22 March 2011).
NCT01722422
- NCT01722422. Hyperoxia and Hypertonic Saline in Septic Shock (Hyper2S). clinicaltrials.gov/ct2/show/study/NCT01722422 (first received 6 November 2012).
NCT02698917
- NCT02698917. Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation (COMACARE). https://clinicaltrials.gov/ct2/show/NCT02698917 (first received 4 March 2016).
O'Driscoll 2017
- O'Driscoll BR, Howard LS, Earis J, Mak V, British Thoracic Society Emergency Oxygen Guideline Group, BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax 2017;72(Suppl 1):ii1‐90. [PUBMED: 28507176] [DOI] [PubMed] [Google Scholar]
Pannu 2016
- Pannu SR, Dziadzko MA, Gajic O. How much oxygen? Oxygen titration goals during mechanical ventilation. American Journal of Respiratory and Critical Care Medicine 2016;193(1):4‐5. [DOI: 10.1164/rccm.201509-1810ED; PUBMED: 26720783] [DOI] [PubMed] [Google Scholar]
Panwar 2013
- Panwar R, Capellier G, Schmutz N, Davies A, Cooper DJ, Bailey M, et al. Current oxygenation practice in ventilated patients ‐ an observational cohort study. Anaesthesia and Intensive Care 2013;41(4):505‐14. [PUBMED: 23808511] [DOI] [PubMed] [Google Scholar]
Panwar 2015
- Panwar R, Hardie M, Bellomo R, Barrot L, Eastwood GM, Young PJ, et al. Conservative versus liberal oxygenation targets for mechanically ventilated patients. A pilot multicenter randomized controlled trial. American Journal of Respiratory and Critical Care Medicine 2016;193(1):43‐51. [PUBMED: 26334785] [DOI] [PubMed] [Google Scholar]
Petersson 2014
- Petersson J, Glenny RW. Gas exchange and ventilation‐perfusion relationships in the lung. European Respiratory Journal 2014;44(4):1023‐41. [PUBMED: 25063240] [DOI] [PubMed] [Google Scholar]
Pocock 2015
- Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials: part 3 of a 4‐part series on statistics for clinical trials. Journal of the American College of Cardiology 2015;66(24):2757‐66. [PUBMED: 26700838] [DOI] [PubMed] [Google Scholar]
Pogue 1997
- Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta‐analysis. Controlled Clinical Trials 1997;18(6):580‐93. [PUBMED: 9408720] [DOI] [PubMed] [Google Scholar]
Rachmale 2012
- Rachmale S, Li G, Wilson G, Malinchoc M, Gajic O. Practice of excessive F(IO(2)) and effect on pulmonary outcomes in mechanically ventilated patients with acute lung injury. Respiratory Care 2012;57(11):1887‐93. [PUBMED: 22613692] [DOI] [PubMed] [Google Scholar]
Raj 2013
- Raj R, Bendel S, Reinikainen M, Kivisaari R, Siironen J, Lång M, et al. Hyperoxemia and long‐term outcome after traumatic brain injury. Critical Care 2013;17(4):R177. [PUBMED: 23958227] [DOI] [PMC free article] [PubMed] [Google Scholar]
Raoof 2010
- Raoof S, Goulet K, Esan A, Hess DR, Sessler CN. Severe hypoxemic respiratory failure: part 2 ‐ nonventilatory strategies. Chest 2010;137(6):1437‐48. [PUBMED: 20525656] [DOI] [PubMed] [Google Scholar]
Rasmussen 2018
- Rasmussen BS, Perner A, Wetterslev J, Meyhoff CS, Schjørring OL. Oxygenation targets in acutely ill patients: still a matter of debate. Lancet 2018;392(10163):2436‐7. [PUBMED: 30527413] [DOI] [PubMed] [Google Scholar]
Review Manager 2014 [Computer program]
- Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rodríguez‐Roisin 2005
- Rodríguez‐Roisin R, Roca J. Mechanisms of hypoxemia. Intensive Care Medicine 2005;31(8):1017‐9. [PUBMED: 16052273] [DOI] [PubMed] [Google Scholar]
Rothen 1995a
- Rothen HU, Sporre B, Engberg G, Wegenius G, Högman M, Hedenstierna G. Influence of gas composition on recurrence of atelectasis after a reexpansion maneuver during general anesthesia. Anesthesiology 1995;82(4):832‐42. [PUBMED: 7717553] [DOI] [PubMed] [Google Scholar]
Rothen 1995b
- Rothen HU, Sporre B, Engberg G, Wegenius G, Reber A, Hedenstierna G. Prevention of atelectasis during general anaesthesia. Lancet 1995;345(8962):1387‐91. [PUBMED: 7760608] [DOI] [PubMed] [Google Scholar]
Roussos 2003
- Roussos C, Koutsoukou A. Respiratory failure. European Respiratory Journal 2003;47:3S‐14S. [PUBMED: 14621112] [DOI] [PubMed] [Google Scholar]
Sacco 2013
- Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44(7):2064‐89. [PUBMED: 23652265] [DOI] [PMC free article] [PubMed] [Google Scholar]
Savovic 2018
- Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association between risk‐of‐bias assessments and results of randomized trials in Cochrane Reviews: the ROBES meta‐epidemiologic study. American Journal of Epidemiology 2018;187(5):1113‐22. [PUBMED: 29126260] [DOI] [PMC free article] [PubMed] [Google Scholar]
Schjørring 2018
- Schjørring OL, Toft‐Petersen AP, Kusk KH, Mouncey P, Sørensen EE, Berezowicz P, et al. Intensive care doctors' preferences for arterial oxygen tension levels in mechanically ventilated patients. Acta Anaesthesiologica Scandinavica 2018;62(10):1443‐51. [PUBMED: 29926908] [DOI] [PubMed] [Google Scholar]
Sepehrvand 2018
- Sepehrvand N, James SK, Stub D, Khoshnood A, Ezekowitz JA, Hofmann R. Effects of supplemental oxygen therapy in patients with suspected acute myocardial infarction: a meta‐analysis of randomised clinical trials. Heart 2018;104(20):1694‐8. [PUBMED: 29599378] [DOI] [PubMed] [Google Scholar]
Siemieniuk 2018
- Siemieniuk RAC, Chu DK, Kim LH, Güell‐Rous MR, Alhazzani W, Soccal PM, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ 2018;363:k4169. [PUBMED: 30355567] [DOI] [PubMed] [Google Scholar]
Sinclair 2004
- Sinclair SE, Altemeier WA, Matute‐Bello G, Chi EY. Augmented lung injury due to interaction between hyperoxia and mechanical ventilation. Critical Care Medicine 2004;32(12):2496‐501. [PUBMED: 15599157] [DOI] [PubMed] [Google Scholar]
Sjöberg 2013
- Sjöberg F, Singer M. The medical use of oxygen: a time for critical reappraisal. Journal of Internal Medicine 2013;274(6):505‐28. [DOI: 10.1111/joim.12139; PUBMED: 24206183] [DOI] [PubMed] [Google Scholar]
Suzuki 2013
- Suzuki S, Eastwood GM, Peck L, Glassford NJ, Bellomo R. Current oxygen management in mechanically ventilated patients: a prospective observational cohort study. Journal of Critical Care 2013;28(5):647‐54. [PUBMED: 23683560] [DOI] [PubMed] [Google Scholar]
Tan 2014
- Tan HL, Wijeweera O. Oxygen in critical care. Trends in Anaesthesia and Critical Care 2014;4:102‐8. [DOI: 10.1016/j.tacc.2014.05.001] [DOI] [Google Scholar]
Terkawi 2016
- Terkawi AS, Mavridis D, Flood P, Wetterslev J, Terkawi RS, Bin Abdulhak AA, et al. Does ondansetron modify sympathectomy due to subarachnoid anesthesia?: meta‐analysis, meta‐regression, and trial sequential analysis. Anesthesiology 2016;124(4):846‐69. [DOI: 10.1097/ALN.0000000000001039; PUBMED: 26835645] [DOI] [PubMed] [Google Scholar]
Thorlund 2009
- Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38(1):276‐86. [PUBMED: 18824467] [DOI] [PubMed] [Google Scholar]
Thygesen 2012
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012;126(16):2020‐35. [PUBMED: 22923432] [DOI] [PubMed] [Google Scholar]
TSA 2011 [Computer program]
- Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. Version 0.9 Beta. Copenhagen: Copenhagen Trial Unit, 2011.
Turner 2013
- Turner RM, Bird SM, Higgins JP. The impact of study size on meta‐analyses: examination of underpowered studies in Cochrane reviews. PLOS ONE 2013;8(3):e59202. [PUBMED: 23544056] [DOI] [PMC free article] [PubMed] [Google Scholar]
Wagner 1977
- Wagner PD, Dantzker DR, Dueck R, Clausen JL, West JB. Ventilation‐perfusion inequality in chronic obstructive pulmonary disease. Journal of Clinical Investigation 1977;59(2):203‐16. [PUBMED: 833271] [DOI] [PMC free article] [PubMed] [Google Scholar]
Watson 2000
- Watson NA, Beards SC, Altaf N, Kassner A, Jackson A. The effect of hyperoxia on cerebral blood flow: a study in healthy volunteers using magnetic resonance phase‐contrast angiography. European Journal of Anaesthesiology 2000;17(3):152‐9. [PUBMED: 10758463] [DOI] [PubMed] [Google Scholar]
Wetterslev 2008
- Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75. [PUBMED: 18083463] [DOI] [PubMed] [Google Scholar]
Wetterslev 2009
- Wetterslev J, Thorlund K, Brok J, Gluud C. Estimating required information size by quantifying diversity in random‐effects model meta‐analyses. BMC Medical Research Methodology 2009;9:86. [PUBMED: 20042080] [DOI] [PMC free article] [PubMed] [Google Scholar]
Wetterslev 2015
- Wetterslev J, Meyhoff CS, Jørgensen LN, Gluud C, Lindschou J, Rasmussen LS. The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD008884.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]
Whitehead 2002
- Whitehead T, Slutsky AS. The pulmonary physician in critical care ᛫ 7: ventilator induced lung injury. Thorax 2002;57(7):635‐42. [PUBMED: 12096209] [DOI] [PMC free article] [PubMed] [Google Scholar]
Woods 2002
- Woods KL, Abrams K. The importance of effect mechanism in the design and interpretation of clinical trials: the role of magnesium in acute myocardial infarction. Progress in Cardiovascular Diseases 2002;44(4):267‐74. [PUBMED: 12007082] [DOI] [PubMed] [Google Scholar]
Wunsch 2010
- Wunsch H, Linde‐Zwirble WT, Angus DC, Hartman ME, Milbrandt EB, Kahn JM. The epidemiology of mechanical ventilation use in the United States. Critical Care Medicine 2010;38(10):1947‐53. [PUBMED: 20639743] [DOI] [PubMed] [Google Scholar]
You 2018
- You J, Fan X, Bi X, Xian Y, Xie D, Fan M, et al. Association between arterial hyperoxia and mortality in critically ill patients: a systematic review and meta‐analysis. Journal of Critical Care 2018;47:260‐8. [PUBMED: 30077082] [DOI] [PubMed] [Google Scholar]
Young 2012
- Young P, Beasley R, Bailey M, Bellomo R, Eastwood GM, Nichol A, et al. The association between early arterial oxygenation and mortality in ventilated patients with acute ischaemic stroke. Critical Care and Resuscitation 2012;14(1):14‐9. [PUBMED: 22404056] [PubMed] [Google Scholar]
Zaher 2007
- Zaher TE, Miller EJ, Morrow DM, Javdan M, Mantell LL. Hyperoxia‐induced signal transduction pathways in pulmonary epithelial cells. Free Radical Biology and Medicine 2007;42(7):897‐908. [PUBMED: 17349918] [DOI] [PMC free article] [PubMed] [Google Scholar]
Zhang 2016
- Zhang Z, Ji X. Quadratic function between arterial partial oxygen pressure and mortality risk in sepsis patients: an interaction with simplified acute physiology score. Scientific Reports 2016;6:35133. [PUBMED: 27734905] [DOI] [PMC free article] [PubMed] [Google Scholar]
References to other published versions of this review
Barbateskovic 2017
- Barbateskovic M, Schjørring OL, Jakobsen JC, Meyhoff CS, Dahl RM, Rasmussen BS, et al. Higher versus lower inspiratory oxygen fraction or targets of arterial oxygenation for adult intensive care patients. Cochrane Database of Systematic Reviews 2017, Issue 4. [DOI: 10.1002/14651858.CD012631] [DOI] [Google Scholar]